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Abstract
This thesis investigates the use of atrophy patterns from structural brain imaging to
distinguish different dementia pathologies, including Alzheimer’s disease, dementia
with Lewy bodies and frontotemporal dementia pathologies. Using gold standard
histopathology to stratify groups, analysis is based on 3D-T1-weighted imaging ac-
quired during life in patients who attended clinic in one of three European centres. As
well as comparison of disease groups with healthy controls, more clinically relevant
comparisons between disease groups are performed to identify features that may be
useful for differential diagnosis.
The image analysis techniques used in this thesis range from simple visual assessment
to more advanced machine learning. Visual rating scales were found to be reliable,
quick to perform, and when used in combination, could achieve diagnostic accuracy
equal to unstructured visual assessment by dementia experts. Voxel based morphom-
etry, used to provide a comprehensive estimate of global patterns of atrophy in patho-
logically distinct dementias, confirmed findings in the literature based on clinical data,
and identified novel regions of interest for further study. A fully automated diagnos-
tic approach using multi-atlas segmentation propagation and support vector classifiers,
revealed brain volume differences between pathologically distinct groups, yet with sev-
eral technical limitations to address.
Since histopathological diagnosis is rare in such a large, pathologically diverse cohort,
this thesis also considers opportunities to develop the dataset into a shared resource for
the dementia research community. To this end, a web application was developed to
allow the data to be shared between collaborating centres, with plans to adapt this into
a teaching resource.
In summary, this thesis uses a variety of analysis techniques to identify imaging fea-
tures that may be useful for the differential diagnosis of dementia pathologies. Various
opportunities are explored to maximise the value that can be derived from this unique
and valuable dataset.
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Thesis Aims
Distinguishing between the different neurodegenerative causes of dementia is vitally
important to allow affected individuals and their families to access appropriate treat-
ment, support and care [1], and this requirement will be even more pressing as/when
disease-modifying therapies become available. Accurate diagnosis during life can
be challenging as distinct underlying pathologies can result in overlapping clinical
symptoms [2], and with the exception of rare autosomal dominant forms of demen-
tia, histopathological diagnosis currently remains the gold standard [3]. However, in
the context of thorough clinical examination certain patterns of atrophy, evident on
structural MRI, have some predictive value in the differential diagnosis of neurodegen-
erative dementias. The evidence base is however limited in many cases, and relatively
few studies have assessed atrophy patterns in the knowledge of underlying pathology.
Therefore, using MR imaging acquired during life in a large multi-centre cohort of
pathologically proven dementias, the aims of this thesis were:
1. To distil characteristic imaging features reported in the literature into a clinically
useful algorithm that can be used to interrogate structural imaging, and to test its
accuracy against pathological diagnosis.
2. To investigate the diagnostic value of visual rating scales widely used in dementia
research, and the feasibility of applying them in a clinical setting.
3. To provide a comprehensive voxel-wise estimate of the global patterns of atrophy
associated with different dementia pathologies, and to critically evaluate differen-
tial patterns that may help to guide visual assessment tools and region of interest
analysis.
4. To assess regional differences in brain volume that can help to distinguish be-
tween different dementia pathologies.
5. To determine the additional diagnostic value of combining standard measures of
assessment in an automated multivariate classifier.
6. To develop methods to share this unique and valuable dataset with the wider
dementia research community.
Chapter 1
Introduction
Dementia is an umbrella term that describes progressive cognitive deficits, sufficient to
impact on daily living, and is associated with a number of neurodegenerative disease
processes, with Alzheimer’s disease being the most common. In addition to the impact
on the affected individual, these devastating diseases place a huge emotional and phys-
ical burden on caregivers, which intensifies as symptoms progress to include a loss of
mobility, communication, and self care. Median survival is estimated to be around four
and a half years, although may be ten years or more if disease onset occurs before 70
years of age [4].
Dementia is a global health problem. Current estimates suggest 5-8% of people over
60 are affected, equating to 47.5 million people worldwide, with this figure predicted
to triple by 2050 to 135.5 million as the world’s population ages [5]. In the UK alone,
dementia is thought to affect 670,000 people (6.5% of the population) [6], costing the
economy around £23 billion a year, with the majority of these costs currently absorbed
by people with dementia and their families [7]. The potential socioeconomic impact
of these diseases is, therefore, profound. In recognition of this fact, many of govern-
ments around the world have adopted long-term national dementia strategies [8–10]
and international efforts have been consolidated through the launch of the Global Ac-
tion Against Dementia programme, and the formation of the World Dementia Council
at the G8 Dementia Summit, held in the UK in December 2013.
Now represented internationally at the governmental level, there are opportunities to
influence global research spending and policy for the benefit of dementia research.
Using this leverage should smooth the way for greater scientific discovery into the
mechanisms driving these complex neurodegenerative diseases and ultimately lead to
the discovery of disease modifying therapies. Even with such a breakthrough, however,
it will remain important to help people live well with dementia, a process that starts with
early and accurate diagnosis [11].
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In this chapter, the diagnosis of dementia is discussed in terms of pathology, genet-
ics and clinical features. Focussing on the three major neurodegenerative forms of
dementia studied in this thesis, namely Alzheimer’s disease, dementia with Lewy bod-
ies (DLB) and frontotemporal lobar degeneration (FTLD), the challenges of accurate
diagnosis are discussed in relation to the clinical tools currently available to extract
diagnostically useful features.
1.1 Diagnosis of Dementia
Pathologically, the degenerative dementias are linked by protein misfolding in the brain,
with the primary abnormal protein and its pattern of deposition currently used to define
each neurodegenerative disease. Clinically, the dementias are less well defined, with
distinct underlying pathology often producing overlapping clinical symptoms, and this
is further complicated by the possibility of multiple comorbidities affecting the brain
that are increasingly prevalent with advancing age. In this section, the current consen-
sus guidelines for pathological diagnosis are reviewed, with reference to genetic causes
and risks, followed by the associated criteria for clinical diagnosis during life. A list of
all current diagnostic guidelines are included in Table 1.1.
1.1.1 Alzheimer’s Disease
Pathology
Intraneuronal fibrils of primarily abnormal tau (neurofibrillary tangles (NFTs)), and ex-
tracellular deposits of β-amyloid (Aβ) peptides (senile plaques) are essential for a neu-
ropathological diagnosis of Alzheimer’s disease [12]. The mechanism which triggers
these abnormal accumulations is widely speculated [13–17] but remains unproven, as
indeed does the normal function and/or clearance of these proteins in the healthy brain
[18–20]. The distinct progression of the accumulation of Aβ-plaques and NFTs across
brain regions is, however, undisputed and continues to be used for staging the severity
of disease [12, 21].
Based on the latest National Institute on Ageing and the Alzheimer’s Association (NIA-
AA) criteria, assessment of Alzheimer’s disease neuropathologic change should incor-
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porate:
A Thal phases of Aβ-plaque accumulation, which start in the neocortex, progressing to
the hippocampal region, the diencephalon and striatum, brainstem and then the
cerebellum [22].
B. Braak and Braak staging of NFTs, which progresses from transentorhinal involve-
ment, to include limbic regions and extension into the neocortex [23, 24].
C. Scoring of neuritic plaques (a subset of senile plaques) according to the Consortium
to Establish a Registry for Alzheimer’s disease (CERAD) protocol, which is pri-
marily based on frequency (sparse, moderate, frequent) rather than distribution
[25].
To improve inter-rater reliability Aβ and NFTs scoring are reduced to four stages (see
Figure 1.2). Based on the assessment of all three scoring systems, Alzheimer’s disease
neuropathologic change is classified as "Not", "Low", "Intermediate" or "High", with
"Intermediate" or "High" considered a sufficient underlying cause of dementia (see
Figure 1.2).
While Alzheimer’s disease neuropathologic changes can exist in a pure form, co-
morbidities are increasingly prevalent with advancing age [27]. The NIA-AA, there-
fore, also recommends assessment of the most common of these co-morbidities during
post mortem examination, which include: Lewy body disease (included in Figure 1.2),
vascular brain injury, hippocampal sclerosis, argyrophilic grain disease and transactive
response DNA binding protein 43 kDa (TDP43) inclusions [12, 21]. These patholo-
gies, which may also occur in a pure form, are discussed as such in subsequent sec-
tions.
Genetics
Fully penetrant, autosomal dominant mutations associated with Alzheimer’s disease
occur on one of three genes: the amyloid precursor protein (APP) gene [28], the Prese-
nilin 1 (PSEN1) gene [29] or the Presenilin 2 (PSEN2) gene [30]. Pathogenic mutations
in the APP gene result in increased production of Aβ and/or alteration in the ratio of
specific Aβ peptides, and are associated with cerebral amyloid angiopathy (CAA) as
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A
Score
Thal phase for
Aβ-plaques
B
Score
Braak and Braak
NFT stages
C
Score
CERAD neuritic
plaque score
0 None 0 None 0 None
1 1 or 2 1 1 or 2 1 Sparse
2 3 2 3 or 4 2 Moderate
3 4 or 5 3 5 or 6 3 Frequent
Figure 1.1: NIA-AA scoring of Alzheimer’s disease neuropathologic change. Three
established pathology rating scales (Thal phases, Braak and Braak and
CERAD) are mapped onto three four-point scales (A, B, C respectively).
CERAD=Consortium to Establish a Registry for Alzheimer’s Disease,
NFTs=Neurofibrillary tangles.
A C B0 or B1 B2 B3 Lewybodies
0 0 Not 1 Not1 Not 1 None
1
0 or 1 Low Low Low2 Brainstem
2 or 33 Low Int. AD Int. AD2
2 Any C Low AD
4
(High DLB)
Int. AD
(Int. DLB) Int. AD
2 Limbic
3
0 or 1 Low AD
4
(High DLB)
Int. AD
(High DLB)
Int. AD2
(Int. DLB) Neocortical
2 or 3 Low AD
4
(High DLB)
Int. AD
(High DLB)
High AD
(Int. DLB)
Figure 1.2: NIA-AA Criteria for Alzheimer’s disease neuropathologic change based on
the ABC scores outlined in Figure 1.1 (adjusted for additional Lewy body
disease inclusions (see Section 1.1.2)). Liklihood of pathological Lewy body
disease is assessed in relation to Braak and Braak staging of neurofibril-
lary tangles according the McKeith criteria [26]. AD=Alzheimer’s disease,
DLB=dementia with Lewy bodies, Int.=Intermediate, NIA-AA=National In-
stitute on Ageing and the Alzheimer’s Association
1. Medial temporal lobe NFTs in the absence of significant Aβ or neuritic plaques
occurs in older people and may be seen in individuals without cognitive impair-
ment, with mild impairment, or with cognitive impairment from causes other
than Alzheimer’s disease.
2. Widespread NFTs with some Aβ/amyloid plaques but limited neuritic plaques is
relatively infrequent and when it occurs, other diseases, particularly tauopathies,
should be considered.
3. High levels of neuritic plaques in setting of low Thal phase is a rare occurrence
and should prompt reconsideration of neuritic versus diffuse plaques, and the
possible contribution of other diseases to cognitive impairment or dementia.
4. Higher levels of Aβ or neuritic plaques with low Braak stage should prompt con-
sideration of contribution by co-morbidities like vascular brain injury, Lewy body
disease, or hippocampal sclerosis.
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well as Alzheimer’s disease [31]. The proteins encoded by the PSEN1 and PSEN2
genes are directly involved in the processing of APP, and mutations in these genes
also lead to an increase in Aβ production [31]. PSEN1 mutations are the most com-
mon cause of familial Alzheimer’s disease, while PSEN2 mutations are very rare. Fa-
milial Alzheimer’s disease accounts for around 0.5% of all Alzheimer’s disease cases
(http://www.molgen.ua.ac.be/ADMutations/).
The more common "sporadic" form of Alzheimer’s disease is influenced by a number
of risk factor genes. To date, the APOE ε4 allele confers the greatest risk from a sin-
gle gene, and is known to be dose dependent, with increased risk associated with ε4
homozygotes [32]. More recently, a TREM2 (triggering receptor expressed on myeloid
cells 2) heterozygous mutation was also identified as a moderate risk for Alzheimer’s
disease [33], while advances in sequencing technologies have revealed several addi-
tional genetic risk factors, each conveying a relatively small risk for developing the
disease [31, 34]. Importantly, the identification of these genes continues to shed light
on the biological pathways of the disease and provides opportunities to investigate al-
ternative therapeutic approaches [35].
Clinical Presentation
There is an increasing interest in identifying presymptomatic forms of Alzheimer’s dis-
ease [36, 37], and patients with mild cognitive problems due to Alzheimer’s disease,
termed "mild cognitive impairment" [37, 38]. For most patients, however, a clinical
diagnosis of Alzheimer’s disease starts with evidence of dementia, to include cognitive
and behavioural symptoms that 1) interfere with the ability to function in daily life,
2) represent a decline from previous levels of functioning, and 3) are not explained
by delirium or a major psychiatric disorder [39]. According to the most recent NIA-
AA guidelines, assessment should subsequently include testing for a number of clin-
ical features and biomarkers (discussed in Section 1.2) that add a degree of certainty
to the diagnosis, i.e. possible or probable Alzheimer’s disease [39]. In addition to
the typical amnestic presentation of Alzheimer’s disease, the guidelines acknowledge
atypical variants of Alzheimer’s disease, which include logopaenic aphasia (language
variant), posterior cortical atrophy (visual variant), and a frontal, dysexecutive variant.
These atypical classifications are also included in the most recent recommendations
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Figure 1.3: Spectrum of clinical symptoms associated with Lewy body disease.
PD=Parkinson’s disease, PD-MCI=Parkinson’s disease - mild cognitive im-
pairment, PDD=Parkinson’s disease dementia, DLB=Dementia with Lewy
bodies
from the International Working Group (IWG-2) research criteria for the diagnosis of
Alzheimer’s disease [37].
1.1.2 Dementia with Lewy Bodies
Pathology
Lewy bodies and Lewy neurites are pathological aggregates containing α-synuclein,
and are the core features required for the histopathological diagnosis of a range of Lewy
body diseases, which includes Parkinson’s disease and DLB [26]. Lewy body disease
produces a spectrum of clinical symptoms, from primary motor features (pure Parkin-
son’s disease) to primary cognitive impairment (pure DLB) (see Figure 1.3)[40]. Phe-
notypic manifestations within this spectrum (i.e. motor to cognitive) has been shown
to correlate with the distribution of α-synuclein, from brainstem nuclei, to limbic, and
neocortical regions [41, 42], although this is not true in all cases and the disease mech-
anisms that lead to dementia are likely to be complex [43]. Lewy body disease is
however, frequently found in the presence of Alzheimer’s disease neuropathological
change, therefore, at the cognitive end of the spectrum, a pathological diagnosis of
DLB requires both evidence of Lewy body pathology and a relative absence of coexist-
ing Alzheimer’s disease pathology (see Figure 1.2) [21, 26].
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Genetics
Very few cases of familial DLB have been described, a causal gene has not been iden-
tified, and DLB is generally considered a sporadic disease [44]. There are however,
known genetic risk factors for DLB (e.g. GBA) [45], some of which are shared with
Alzheimer’s disease (e.g. APOE ε4) and Parkinson’s disease (e.g. SNCA, SCARB2)
[46].
Clinical Presentation
Whilst milder forms of α-synuclein related cognitive impairment are recognised, de-
mentia is a core feature essential for the diagnosis of DLB. A typical presentation in-
cludes deficits in attention, executive function and visuospatial ability, with relatively
preserved memory early in the disease course [26]. Additional features including fluc-
tuating cognition, recurrent visual hallucinations and spontaneous features of parkin-
sonism, add further support to the diagnosis (see consensus criteria for details [26]).
The temporal sequence of symptoms is also important for the diagnosis of DLB and its
differentiation from Parkinson’s disease dementia. DLB is diagnosed when dementia
occurs before or concurrently with parkinsonism (within one year), while Parkinson’s
disease dementia should be diagnosed if dementia develops in the context of estab-
lished Parkinson’s disease [26]. Biomarker techniques used for the diagnosis of DLB
are discussed in Section 1.2.
1.1.3 Frontotemporal Lobar Degeneration
Pathology
Whilst there is considerable clinical overlap, four major pathological proteinopathies
underlie FTLD. FTLD-Tau and FTLD-TDP43 account for the majority of FTLD
pathology (~40% respectively) [47], while around 10-15% are immunoreactive for
fused in sarcoma protein (FUS) [48]. A rare fourth class, only detectable with im-
munohistochemistry against proteins of the ubiquitin proteasome system (FTLD-UPS),
is used to describe the pathology associated with rare CHMP2B mutations [48] (see
Figure 1.4).
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Figure 1.4: FTLD pathology stratified by molecular class [48]. Genetic mutations associated with these pathologies are listed in the dashed boxes.
Associated clinical phenotypes are listed in the tables below [50, 56, 57]. FTLD-UPS is used to describe the pathology associated with rare
CHMP2B mutations.
Glossary: 3R: 3 repeat tau, 4R: 4 repeat tau, AGD: Agyrophilic grain disease, aFTLD-U: Atypical FTLD with ubiquitin inclusions, BIBID:
Basophilic inclusion body disease, bvFTD: behavioral variant FTD, C9ORF72: Chromosome 9 open reading frame 72, CBD: Corticobasal
degeneration, CBS: Corticobasal syndrome, FUS: Fused in sarcoma protein, GGT: Globular glial tauopathies, NIFID: Neuronal intermediate
filament inclusion disease, MND: Motor neuron disease, Picks: Pick’s disease, PNFA: Progressive non-fluent aphasia, PSP: Progressive
supranuclear palsy, PSPS: Progressive supranuclear palsy syndrome, SD: Semantic dementia, TARDBP: TAR DNA-binding protein 43
(mutation), VCP: Valosin-containing protein.
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FTLD-Tau is characterised by lesions containing insoluble tau protein, which can be
further classified by assessment of the predominant isoforms of tau present in these
lesions (for more info see Appendix A) and their regional distribution within the brain
[49]. Unlike the NFTs found in Alzheimer’s disease which contain all six isoforms of
tau, the majority of lesions associated with FTLD-Tau primarily contain either 3-repeat
or 4-repeat tau [49].
TDP43 binds to both DNA and RNA and is integral to the production of many pro-
teins, particularly those involved with neuronal development [50]. The pathogene-
sis of FTLD-TDP43 proteinopathies is therefore, complex, with evidence to suggest
that toxic gains and/or functional losses may be associated with TDP43 dysregulation
[51]. However, as a consistent pathological feature of several different genetic forms
of FTLD (see below), dysregulation of TDP43 may be a downstream mechanism com-
mon to several disease pathways [50], including motor neuron disease (MND) and to
a lesser extent Alzheimer’s disease and DLB [52–54]. FTLD-TDP43 pathology can
be further classified into types A, B, C and D based on the morphology and regional
distribution of TDP43 inclusions, with ordering determined by the relative frequency
of this pathology within the population (type A being the most common) [55].
FUS belongs to the FET (previously TET) protein family, which function in several
aspects of cell growth control and therefore, like TDP43, its role in neurodegenera-
tion is not yet fully understood [50]. However, the accumulation of FUS protein is the
most prominent molecular pathology shared by the distinct clinicopathological enti-
ties grouped under FTLD-FUS, namely atypical FTLD with ubiquitin inclusions, neu-
ronal intermediate filament inclusion disease and basophilic inclusion body disease
[48].
Genetics
FTLD has a strong genetic component, with evidence of family history in around 40%
of cases, typically with an autosomal dominant pattern of inheritance [58]. The fre-
quency of occurrence varies by geography but the most common mutations occur on
the microtubule associated protein tau (MAPT), the progranulin (GRN), and in the re-
gion of the chromosome 9 open reading frame 72 (C9ORF72), with the latter also a
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major genetic cause of MND. Less common mutations include the valosin-containing
protein (VCP), charged multivesicular body protein 2B gene (CHMP2B), FUS (also
associated with MND), and TDP43 (or TARDP).
Clinical Presentation
Frontotemporal dementia is the term used to describe the heterogeneous clinical syn-
dromes that manifest in patients with underlying FTLD pathology. The most com-
mon clinical presentations are behavioural variant frontotemporal dementia (bvFTD)
and language variant frontotemporal dementia, known as primary progressive apha-
sia. However, the FTLD spectrum is wide, encompassing cross-over with MND and
parkinsonism. There is rarely a one-to-one mapping between frontotemporal dementia
phenotypes and molecular pathology (or genetic mutation); however, some syndromes
are found to be more frequently associated with certain pathologies as shown in Fig-
ure 1.4.
Criteria for bvFTD [59] requires progressive deterioration of behaviour and/or cogni-
tion with at least three of the following symptoms within three years of disease onset:
behavioural disinhibition; apathy; loss of sympathy or empathy, preservative, stereo-
typed or compulsive/ritualistic behaviour; hyperorality and dietary changes; and a neu-
ropsychological profile exhibiting executive deficits with relative sparing of memory
and visuospatial functions. Additional evidence of significant functional decline and
corroboration from brain imaging (discussed in Section 1.2) adds greater certainty to
the diagnosis, from possible to probable bvFTD.
Primary progressive aphasia can be further subdivided into three specific categories
with specific diagnostic criteria: the non-fluent variant, the semantic variant, and the
logopaenic variant, however, the later is typically associated with Alzheimer’s disease
pathological changes [60]. More details on the clinical features associated with these
categories is provided by Gorno-Tempini et al [60]. Warren et al also provide a simple
algorithm for bedside clinical assessment [61].
Parkinsonian syndromes with primary motor features, such as corticobasal syndrome
(CBS) and progressive supranuclear palsy (PSP), which are the result of accumulation
of abnormal 4-repeat-tau, may also exhibit frontal executive impairment or non-fluent
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aphasia, and cognitive impairment is considered a supportive feature in their diagnostic
criteria [62, 63]. MND-type motor disfunction with frontotemporal dementia features
(FTD-MND) is also a recognised clinical phenotype associated with TDP43 or FUS
pathology. Indeed, due to the extent of the overlap between MND and frontotemporal
dementia at the clinical, pathological and genetic levels it has been proposed that these
are not distinct disorders and should be considered two ends of a disease continuum
[64].
1.2 Diagnostic Tools
With the exception of rare autosomal dominant forms of dementia, definitive biomark-
ers of neurodegenerative pathology are lacking, and accurate diagnosis during life relies
on the interpretation and synthesis of evidence from multiple sources. In this section
the diagnostic tools available to extract this evidence are reviewed.
1.2.1 Clinical Assessment
The foundation of an accurate diagnosis is a detailed clinical examination, and any
additional biomarkers should only be interpreted in the context of these findings. In-
vestigation starts with history taking from the patient and a knowledgeable informant,
to include family history, vascular risk factors, and a review of medication. This initial
investigation is perhaps the most important and an experienced clinician can determine
a great deal from this initial interview. An objective cognitive assessment follows and
typically includes tests of orientation, attention, memory, language, executive function,
praxis and visuospatial skills, taking into account prior level of functioning and attain-
ment. In cases of mild or uncertain dementia, formal neuropsychological testing can
be useful to further probe cognitive deficits. Physical examination of the neurological
system is used to detect sensory, motor and coordination deficits that may support neu-
rodegenerative dementia or indicate other rarer and possibly treatable causes. Blood
should be tested to exclude partially treatable causes of dementia, these include test of
thyroid function, vitamin B12 levels, and infection if clinically indicated [65–67].
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1.2.2 Neuroimaging
Neuroimaging can provide valuable diagnostic information about both the structure and
function of the brain, which can be used to exclude certain non-degenerative patholo-
gies or provide evidence to support subtype dementia diagnosis (see Figure 1.5). Ta-
ble 1.1 provides a summary of imaging recommendations included in current diagnos-
tic guidelines and commonly available imaging techniques are reviewed in this section,
while molecular imaging is discussed in the following (Section 1.2.3).
Structural Brain Imaging
CT and MRI are the primary imaging modalities available for assessing brain structure.
While much can be determined about brain structure from CT, MRI produces non-
ionising radiation, allows for multiple aspects of brain tissue pathology to be explored,
and is the structural imaging modality of choice in the assessment of dementia. 3D
T1-weighted sequences provide good spatial resolution, high contrast between grey and
white matter, and can be reformatted in three planes for thorough assessment of cere-
bral atrophy or the detection of other lesions that could be contributing to the patient’s
symptoms [68]. The diagnostic value of patterns of atrophy, detected on T1-weighted
imaging, is the focus of this thesis. Methods to detect and interrogate these patterns
are discussed in detail in Chapter 2, while characteristic imaging features previously
described in the literature are discussed in Chapter 3.
T2-weighted and fluid attenuation inversion recovery (FLAIR) are used to detect vascu-
lar damage, but can also indicate inflammatory, metabolic, toxic or infective processes
that could be contributing to cognitive deficits [69]. T2*-weighted imaging (or prefer-
ably susceptibility weighted imaging [70]) is used to detect cerebral microbleeds often
associated with CAA, which may be important in the aetiology of Alzheimer’s disease
[71]. Diffusion weighted imaging provides a volume-averaged measure of the diffusion
of water molecules within brain tissue, which is altered in various pathological states
and is particularly useful for detecting recent infarct [72], or spongiform change asso-
ciated with rare cases of Creutzfeldt Jakob disease [73]. For completeness, vascular
features are also discussed in more detail in Chapter 3, however, they do not feature in
the experimental work of this thesis.
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Pathology Guidelines Clinical Guidelines Imaging Recommendations
AD NIA-AA: Hyman et al (2012)
(Montine et al (2012))
NIA-AA: McKhann et al (2011)
IWG-2: Dubois et al (2014)
- Extensive infarcts or WMHs for a diagnosis
of mixed-AD
- Abnormal dopamine transporter PET scan
for a diagnosis of mixed-AD
- Decreased 18F-FDG uptake or dispropor-
tionate atrophy in temporoparietal regions
- Extensive infarcts or WMHs for a diagnosis
of AD/atypical AD
DLB DLB-C: McKeith et al (2005) DLB-C: McKeith et al (2005)
- Low striatal DAT uptake on SPECT/PET
- Relative preservation of MTL on CT/MRI
- Generalised low uptake on SPECT/PET
perfusion scan with reduced occipital activity
- CVD evident on brain imaging
FTLD
FTLD-C: Cairns et al (2007)
Updates:
Mackenzie et al (2009): TDP43
Mackenzie et al (2010): FUS
Mackenzie et al (2011): TDP[ABCD]
bvFTD-C: Rascovsky et al (2011)
Hypo-perfusion/metabolism or atrophy in
frontal and/or anterior temporal lobe regions
PPA-C: Gorno-Tempini et al (2011)
Hypo-perfusion/metabolism or atrophy in the:
- left posterior fronto-insular region (PNFA)
- anterior temporal lobe region (SD)
- left posterior perisylvian or parietal (LPA)
CBD-C: Armstrong et al (2013) Structural lesion suggestive of focal cause
NINDS-SPSP: Litvan et al (1996)
NNIPPS: Bensimon et al (2009)
Relevant structural abnormality (i.e. basal
ganglia/brainstem infarcts, lobar atrophy)
Table 1.1: Current guidelines for pathological diagnosis and clinical diagnosis with imaging recommendations. Imaging recommendations are coloured
based on the type of evidence they provide - Core feature, Supportive feature, Exclusion criterion. AD=Alzheimer’s disease, DLB=de-
mentia with Lewy bodies, FTLD=frontotemporal lobar degeneration, bvFTD=behavioural variant FTD, PPA=primary progressive aphasia,
CBD=corticobasal degeneration, NIA-AA=National Institute on Ageing and the Alzheimer’s Association, NINDS-SPSP=Neurological Dis-
orders and Stroke and Society for Progressive Supranuclear Palsy, NNIPPS=Neuroprotection and Natural History in Parkinson Plus Syn-
dromes
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A basic MRI protocol consisting of standard sequences required for thorough assess-
ment of relevant imaging features is presented in Figure 1.6. While thinner slices,
and where possible 3D rather than 2D acquisitions, provide better spatial resolution to
detect smaller lesions, there is a compromise to be made between the level of detail
available for assessment and the time taken to acquire the image.
Functional Brain Imaging
Cerebral perfusion imaging with 99mTc-HMPAO single photon emission computed to-
mography (SPECT) is an established technique often used in the diagnosis of dementia.
99mTc-HMPAO is a lipophilic compound which passes through the blood brain barrier
and undergoes hydrophilic conversion, quickly trapping the radiotracer in brain tissue
(stabilising 10-15 minutes post injection) [74]. SPECT imaging provides an estimate
of relative regional flow differences and the detection of regions of hypoperfusion asso-
ciated with reduced neuronal activity [74]. 18F-FDG is a glucose analog and therfore,
provides a more direct measure of neuronal activity than 99mTc-HMPAO. Comparisons
between perfusion imaging (SPECT) and metabolic imaging (positron emission to-
mography (PET)) suggest that while there may be equivalence in detecting people with
dementia from controls, PET is superior in the differential diagnosis of Alzheimer’s
disease and DLB [75].
Different aspects of the pre-synaptic dopamine system, implicated in Parkinson’s dis-
ease and other parkinsonian disorders (DLB, PSP, corticobasal degeneration (CBD),
multiple system atrophy), can also be imaged in vivo using 123I-FP-CIT SPECT or
18F-FDOPA PET. While 123I-FP-CIT labels dopamine transporters (see Figure 1.5),
18F-FDOPA reflects the synthesis and storage of L-DOPA (a precursor of dopamine) in
pre-synaptic vesicles. Direct comparison of both tracers has demonstrated equal sen-
sitivity [76], however, there is some evidence to suggest a compensatory mechanism
in the dopamine system causes upregulation of L-DOPA synthesis in the early stages
of disease, potentially reducing the sensitivity of 18F-FDOPA as an early biomarker
[77].
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Figure 1.5: Neuroimaging in the diagnosis of dementia. MRI images are from patholog-
ically confirmed cases. FDG PET images fromKoeppe et al [78]. FPCIT im-
ages from Morgan et al [79] with pathological confirmation of Alzheimer’s
disease and DLB pathology. Only the DLB image is abnormal. Florbetaben
images are overlaid on MRI images from Villemagne et al [80]. Nonspecific
binding is shown in white matter in controls and FTLD, specific binding is
shown in cortical areas of Alzheimer’s disease and DLB patients.
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Figure 1.6: Basic MRI protocol required for the clinical assessment of cognitive impairment. GE = gradient echo.
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1.2.3 Molecular Biomarkers
Biomarkers of amyloid and tau pathology are now available, with the ability to identify
some aspects of Alzheimer’s disease pathology in earlier stages of the disease. Due to
the technical requirements of these techniques they are not yet widely available. Their
current use is discussed briefly below.
Cerebrospinal Fluid
cerebrospinal fluid (CSF) obtained by lumbar puncture provides a means of measuring
biochemical changes that occur in the brain’s extracellular space. Basic CSF biomark-
ers, such as cell counts, serum albumin and oligoclonal bands, can be be used to exclude
infections, damage to the blood brain barrier, and inflammatory disorders which may
mimic or contribute to dementia [81]. More recently, however, CSF biomarker tech-
niques have been developed to measure core Alzheimer’s disease pathology such as
Aβ1−42, phosphorylated tau (pTau) and total tau (tTau). In Alzheimer’s disease Aβ1−42
is low, while tTau (a more general marker of neuronal degeneration) and pTau (thought
to be more specific for Alzheimer’s disease) are both high. Current evidence suggests
a combination of low Aβ1−42 and high pTau or tTau provides optimal diagnostic speci-
ficity [82]. Establishing reference ranges and cut-points for these measures is chal-
lenging in the absence of confirmed pathology, and further complicated by a lack of
standardisation in CSF collection and analysis [83, 84]. However, work is under way
to address these issues and CSF analysis has recently been included in the research
diagnostic guidelines for Alzheimer’s disease [37].
Amyloid PET Imaging
While CSF provides a measurement of soluble Aβ1−42, PET ligands, with their design
based on histopathological stains such as congo red and thioflavin-T, provide a measure
of aggregated fibrillar Aβ [85]. Studies have demonstrated that both measures are well
correlated [86], however, imaging provides the additional benefit of being able to lo-
calise amyloid deposition within brain tissue. Like CSF, standardisation of quantitative
image analysis is still ongoing [87], however, simple visual reads of amyloid ’pos-
itive’ or ’negative’ are recommended for diagnostic use [37] and have been validated
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against post mortem assessment of Alzheimer’s disease pathology [88] (see Figure 1.5).
There are currently four 18F amyloid PET tracers licensed for use in the diagnosis of
Alzheimer’s disease: 18F-Florbetapir/AMYViD (Avid) [89], 18F-Flutemetamol/Viza-
myl (GE) [90], 18F-Florbetaben/Neuraceq (BV Cyclotron VU) [91], 18F-Flutafuranol
(AstraZeneca/Navidea) [92]. Despite different grey matter and white matter retention
characteristics, preliminary studies suggest there is no clear advantage to using one
over the other [93].
Tau Imaging
Tau imaging is the next major diagnostic milestone in dementia and has the potential to
provide greater insights into the development and treatment of major tauopathies, such
as Alzheimer’s disease and some variants of FTLD [94]. In Alzheimer’s disease re-
search in particular, it may help to answer some long standing questions relating to the
role of tau pathology in the degenerative process and its relation to Aβ deposition [94,
95]. Due to the complexities of tau aggregation and the requirements for tracer design
(for a review see Villemagne et al [95]), the development and validation of tau tracers
is complex and still ongoing. Significant advances have been made, moving from non-
selective tau tracers, which also bind to extracellular Aβ plaques [96, 97], to tracers
with more selective binding affinity for tau pathology (reviewed by Villemagne et al
[95]), however, questions still remain over tracer kinetics and some unexplained focal
retention inconsistent with neuropathological reports [95]. Tau imaging is still in the
development and testing stage and is a long way from being used for clinical diagnosis,
however, it has great potential to advance current understanding of neurodegenerative
disease processes and evaluate prospective therapies.
1.3 Conclusion
The neurodegenerative dementias are complex diseases and our understanding of their
aetiology is limited. Histopathology allows for the stratification of disease by primary
abnormal molecular component but in many cases it remains unclear if these are the
downstream effects of a more complex disease pathway. Genetics continues to provide
the greatest insights into underlying disease mechanisms and increased understanding
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of genetic risk factors and environmental interactions may hold the ultimate key to
therapeutics and improved diagnostics.
In-depth study of early cognitive features and symptom progression have led to greater
appreciation of distinct clinical phenotypes and this information has been incorporated
into the latest diagnostic guidelines. While there is currently no one-to-one mapping
between the clinical features appearing during life and the pathology evident at post
mortem, in many cases these features are more indicative of certain pathologies and
their identification increases the probability of accurate clinical diagnosis.
Biomarkers continue to evolve, helping to further refine clinical phenotypes in some
cases and provide direct evidence for aspects of the underlying pathology. However,
many of these techniques are highly complex, expensive and remain unavailable outside
of specialist centres. In the absence of disease modifying therapies, this is unlikely to
change as healthcare systems struggle financially to cope with the demands of an ageing
population. In the meantime, the existing international commitment to help people live
well with dementia requires optimising the use of the diagnostic techniques that are
more widely available, such as MRI.
Structural brain imaging, particularly MRI, is not only widely available, it is also multi-
purpose, and continues to be recommended for use in all diagnostic guidelines. Firstly,
it can be used to exclude surgically treatable mass-effect lesions that, due to their size
and or location within the brain, could be the source of cognitive impairment. Secondly,
it can be used to characterise and determine the extent of vascular lesions, which are
increasingly recognised as an important contributor to cognitive decline. Although the
role of vascular disease is not fully understood, vitally for patients it can be managed
and treated, and its assessment is recommended in all diagnostic guidelines, forming
part of the exclusion criteria for pure Alzheimer’s disease and DLB (see Table 1.1).
Finally, MRI can also be used to detect patterns of cerebral volume loss with predic-
tive value for underlying dementia pathology. While no pattern is 100% sensitive or
specific, certain characteristic features (described in Chapter 3) can provide good sup-
porting evidence for the diagnosis of specific dementia subtypes.
Cerebral volume loss is recognised as a downstream effect of several neurodegenerative
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disease processes [98], yet changes can be detected in early [99] and even presymp-
tomatic [100] stages of disease. It is well established as an outcome measure in clinical
trials [101], and is included as a core or supporting feature in most diagnostic guidelines
[36, 38, 39, 59, 60, 65]. While there is an extensive evidence base to support the use
of cerebral volume loss in the diagnosis of dementia, much of this evidence is derived
from the study of clinically diagnosed dementias, which even in specialist centres, may
be inaccurate in around 30% of cases [3]. Identifying patterns of volume loss that help
to separate pathological processes from normal ageing, and from one another, based on
gold standard histopathology diagnosis, may help to translate these imaging findings
from the research domain to routine clinic practice. This thesis aims to address this
issue using a rarely-available, large, pathologically-proven dataset with standard 3D
T1-weighted imaging acquired in patients with the three primary neurodegenerative
dementias (Alzheimer’s disease, DLB and FTLD). Using a variety of image analysis
techniques from basic visual assessment to more computationally advanced classifi-
cation techniques, this thesis investigates the opportunities to maximise the value of
routine structural MRI in the diagnosis of dementia.
Chapter 2
Techniques for Extracting Diagnostic
Value from Structural MRI
2.1 Introduction
As discussed in Chapter 1, structural MRI is widely available and routinely acquired in
the assessment of cognitive impairment. Characteristic patterns of atrophy, discussed
in detail in Chapter 3, are known to have predictive value in the diagnosis of dementia
but accurate and reliable methods of quantifying and extracting this information are
required in order to make use of it for clinical or research purposes. In this chapter, a
variety of analysis techniques based on the assessment of atrophy are discussed, from
simple visual assessment to more complex automated analysis. Current evidence for
their use in neurodegenerative dementia is discussed in Chapter 3. As the focus of this
thesis is on the diagnostic value of structural MRI, discussion will centre around cross-
sectional imaging techniques, however, longitudinal imaging also provides valuable
insights into disease progression [102, 103] and is often used as an outcome measure
in clinical trials [104, 105].
2.2 Qualitative Assessment
Qualitative assessment of structural imaging does not require any specialist software or
computing capabilities, and can be performed on any standard radiology workstation,
making it suitable for implementation into clinical practice. It does, however, require
expert knowledge of an array of imaging features and patterns of atrophy associated
with the neurodegenerative dementias. In this section, we briefly discuss some of the
features that can be detected from basic visual assessment (a more in depth discussion
of these features can be found in Chapter 3) as well as the tools available to help struc-
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ture image analysis, making the diagnostic information it contains more accessible to a
wider clinical audience.
2.2.1 Basic Visual Assessment
Unstructured visual assessment of brain imaging in the diagnosis of dementia is the
primary means of analysis in clinical settings. Assessment varies between reviewers
but in broad terms three primary components are typically considered: 1) exclusion of
potentially treatable causes of dementia (e.g. mass-effect lesions, infection); 2) deter-
mining the extent of vascular disease; and 3) assessment of the degree and focality of
cerebral atrophy. The first two of these components are not unique to the diagnosis
of dementia and will be familiar to neuroradiologists. The third component, however,
requires dementia expertise which is not readily available in every clinical setting. As a
result, reports of cerebral atrophy can often be vague, without reference to many of the
features with diagnostic value. Discussion of specific features associated with different
neurodegenerative dementias is included in Chapter 3 but in broad terms, there are four
key questions that can are commonly used to help define the cause of an individual’s
dementia:
Are the brain appearances appropriate for age? Typical ageing often results in a va-
riety of brain changes without any discernible effect on cognitive function. These may
include vascular changes, such as enlarged perivascular spaces and white matter hyper-
intensities [106], and/or cerebral atrophy often taking the form of enlarged ventricles,
sulcal widening, or a degree medial temporal lobe atrophy [107, 108]. The assessment
of brain imaging should, therefore, always take the person’s age into consideration to
determine if changes are likely to be pathological or just part of the typical ageing
process.
Is there evidence of asymmetry? An asymmetric pattern of atrophy, either globally or
locally (e.g. medial temporal lobe), is typically associated with FTLD pathology, and
evidence of this should be reported to help guide clinical diagnosis [109, 110].
Is there an atrophy gradient? Evidence of an atrophy gradient, with greater atrophy in
anterior rather than posterior brain regions is also an indication of an underlying FTLD
pathology [109, 110]. Conversely, a posterior greater than anterior atrophy gradient is
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more frequently associated with young-onset Alzheimer’s disease [111]. Atrophy gra-
dients may also be localised to within brain structures, such as the hippocampus, where
greater atrophy anteriorly has also been reported in association with FTLD pathology
[112].
Is there focal atrophy? Atrophy localised to within a particular lobe or brain region
may also have positive predictive value for underlying pathology and evidence of dis-
proportionate atrophy in particular brain regions should be included in the report [109,
110]. Specific features with positive predictive value for dementia diagnosis are dis-
cussed in Section 3.4.
2.2.2 Visual Rating Scales
Quantification of imaging features can enhance the diagnostic value of structural imag-
ing but in most cases this requires specialist software and expertise so it is seldom used
in clinical practice. By contrast, visual rating scales can be applied directly to clinically
acquired images without the use of additional software, and with suitable training, can
be used as an adjunct to standard clinical reads. Visual rating scales used to assess both
subcortical signal changes and cerebral atrophy are discussed below. However, greater
attention is paid to the cerebral atrophy scales as these are applied in practice to the
work of this thesis.
Subcortical Signal Changes
The exact significance of white matter abnormalities demonstrated on T2-weighted or
FLAIRMRI is not yet fully understood [113, 114] but by quantifying and localising the
extent of these abnormalities in a standardised way, it is possible to look for correlations
with demographic and clinical variables that may help to explain their contribution to
cognitive decline. Visual rating scales have been designed with this purpose in mind,
although since some include deep grey matter and brainstem regions, they are collec-
tively referred to as subcortical signal change scales following STandards for Report-
Ing Vascular changes on nEuroimaging (STRIVE) guidance [115]. subcortical signal
change scales are broadly divided into two categories. The first category includes scales
designed (or adapted) to provide a general global assessment of vascular burden, and
the second includes those designed to provide more fine grained assessment of specific
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brain regions. The more general scales, such as the Fazekas [116] or Manolio [117]
scales, focus on periventricular changes, appearing as "caps" and "bands" of high signal
around the ventricles, and supratentorial white matter changes, ranging from punctate
foci to large confluent areas. Of the more detailed scales, the Scheltens scale [118]
and the Age Related White Matter Changes (ARWMC) scale [119] are widely used for
research purposes. The Scheltens scale is the most complex, with a six-point scale ap-
plied in supratentorial, basal ganglia, and infratentorial regions, each of which are then
subdivided into four smaller regions. The scale accounts for lesion size and frequency,
and there is an additional three-point scale used to assess periventricular abnormalities
[118]. The ARWMC scale is used to rate similar regions (minus the periventricular
region) but using a simplified four-point scale, with the left and right hemispheres rated
separately. The ARWMC scale was designed for use with both CT and MRI scans,
however, inter-rater reliability was shown to be higher based on MRI scoring, and MRI
was better able to detect smaller lesions [119]. The use of subcortical signal change
scales is recommended in the latest STRIVE guidance [115]. A summary of the most
commonly used rating scales discussed here is provided in Table 2.1.
Cerebral Atrophy
Visual rating scales have been developed specifically to rate several brain regions sen-
sitive to atrophy in dementia, and can be used to provide quick, semiquantitative mea-
sures of the degree of atrophy in these regions [120]. They encourage structured image
reporting and provide radiologists and non-radiology clinicians with a framework for
interpreting imaging findings, making visual assessment more consistent and poten-
tially more sensitive. Visual rating scales have been used extensively in research, and
a review is provided in Table 2.2. A selection of these scales are discussed in detail
below. More information on the design, methodology and validation of visual rating
scales is included in Appendix B.
Global cortical atrophy: The global cortical atrophy scale by Pasquier et alwas devel-
oped to evaluate atrophy on axial slices in 13 brain regions, including frontal, parieto-
occipital, and temporal regions, and dilation of the ventricles [121]. Regions were as-
sessed separately in each hemisphere and the final score was the sum of all scores in the
thirteen regions. With such extensive coverage, the reliability of the original thirteen-
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Region Fazekas et al (1987) [116] Scheltens et al (1993) [118] Manolio et al (1994) [117] Wahlund et al (2001) [119](ARWMC)
Peri-
ventricular
0=absence
1=’caps’ or pencil-thin lining
2=smooth ’halo’
3=Extension into WM
0=none
1=smooth halo (≤1-5mm)
2=large confluent (5-10mm)
Image-based references:
0=none
1=barely detectable
..
8=extensive confluence
9=complete coverge
Not included
WMH
0=absence
1=punctate foci
2=beginning confluence
3=large confluent areas
0=none
1=<4mm; n≤ 5
2=<4mm; n>5
3=4-10mm; n≤ 5
4=4-10mm; n> 5
5=>10mm; n≥ 1
6=confluent
0=none
1=focal lesions
2=beginning confluence
3=complete diffuse involvement
Basal
ganglia
Not included Not included
0=none
1=1 focal lesion (≥5mm)
2=>1 focal lesion
3=confluent lesions
Infra-
tentorial
Not included Not included
0=none
1=focal lesions
2=beginning confluence
3=complete diffuse involvement
No. of
citations
987 487 311 681
Table 2.1: Definitions for the most widely used subcortical signal change scales. The scales are designed to be performed on axial T2-weighted or
FLAIR images. The number of times each scale has been cited is included as an indication of its impact. ARWMC=Age Related White
Matter Changes, WM=white matter, WMH=white matter hyperintensities.
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point scale was low and was further confounded by the inclusion of regions susceptible
to partial volume effects. Subsequent simplification of the scale to a four point-scale
based on a more global (not regional specific) impression of atrophy resulted in in-
creased uptake among the scientific community (see Table 2.2), although the scale has
been primarily used as a component part of larger diagnostic assessments [122]. Due
to the large brain area assessed by global cortical atrophy scales, they are likely to be
more severely confounded by age than other atrophy rating scales, although there is
evidence to suggest this could be improved by using age-specific cut-offs [123].
Frontotemporal atrophy: Frontotemporal atrophy scales may be useful in the dif-
ferential diagnosis of frontotemporal dementia syndromes, and the scales developed
around these regions have been designed and validated specifically for this purpose.
The most successful of these scales stemmed from a postmortem staging scheme used
to rate atrophy in brains with FTLD pathology, which has been iteratively refined sev-
eral times since [124]. The five-point scale was first devised by Davies et al [125] and
rating was performed at the level of the anterior temporal lobe and the lateral genicu-
late nucleus. Kipps et al extended this scale further to include rating of the posterior
temporal lobe, while also describing slice selection in greater detail, which resulted in
improved reliability [126]. Finally, Ambikairajah et al refined the scale for use with
patients of the MND-FTD continuum, which included rating of the orbito-frontal cor-
tex, the anterior cingulate cortex and the motor cortex [127]. While references images
were provided for each iteration of the scale, on close examination the spectrum of
atrophy represented is not always uniformly distributed between scale increments. In
some cases, such as the anterior temporal region, the scales may therefore benefit by
being condensed to four points rather than five.
Medial temporal lobe atrophy: medial temporal lobe rating scales were first devel-
oped for use with CT imaging [128] but in the last twenty years they have been predom-
inantly designed for use with MRI (see Table 2.2), as it became the imaging modality
of choice in the diagnosis of dementia. The Scheltens scale [129] has had the biggest
impact on the field, and has formed the basis of many subsequent scales [130–133],
although none of them has had the impact of the original. The Scheltens scale fo-
cuses on three key features of medial temporal lobe atrophy, namely: the width of the
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choroid fissure, the width of the temporal horn and the height of the hippocampus. The
degree of atrophy in each of these regions is combined to produce a score reflecting
overall medial temporal lobe atrophy. Both sides of the medial temporal lobe are as-
sessed separately and in the case of asymmetry the highest score is reported. In order
to assess sensitivity and specificity, the scale is dichotomised, with scores of 0–1 indi-
cating the absence of Alzheimer’s disease, and scores of 2–4 indicating the presence
of Alzheimer’s disease. Since it was introduced, the Scheltens scale has been used in
over 100 studies (see Table 2.2). The reliability of the scale has been reported to be
robust to the clinical experience of the rater [134] but increases as the rater gains more
experience with the scale itself [135]. Better understanding of the pathological phe-
nomenon measured by the scale has led to modification of the dichotomised scale to
account for atrophy due to ageing [136, 137], which has also helped to improve perfor-
mance. The Scheltens scale has been included in the research criteria for the diagnosis
of Alzheimer’s disease [138].
Posterior atrophy: There is currently only a single scale for the assessment of posterior
atrophy, which was developed by Koedam [139] and Lehmann [111]. The scale focuses
on the posterior cingulate sulcus, precuneus, parieto-occipital sulcus and the cortex
of the parietal lobes. The left and right hemispheres are assessed separately and a
separate score is given in each imaging plane (axial, sagittal, coronal). In the case of
different scores in different planes, the highest score is taken. The scale is useful for the
identification of young onset Alzheimer’s disease, which often presents with posterior
atrophy and relatively preserved medial temporal lobes. Combining both the medial
temporal lobe scale and the posterior atrophy scale has been shown to have improved
diagnostic accuracy for Alzheimer’s disease [111].
2.3 Quantitative Assessment
A number of sophisticated analysis methods are available to quantify global and re-
gional atrophy from MRI and they are used extensively in research, including clinical
trials. Due to special hardware requirements, computational demands and dependency
on specific acquisition techniques, relatively little progress has been made to date to
integrate these into clinical work streams. This is likely to change in the near future
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Reliability Applications
Scale Brain region Scalepoints
Imaging
plane
MR
contrast InterRater IntraRater Citations Research Trials
Pasquier [121] Global cortical 4 Axial T2-W >0.6 (Cwκ) >0.7 (Cwκ) 44 35 Y
O’Donovan [144] Ventricles 4 Axial T1-W 0.9 (ICC) 0.92 (ICC) 1 0 N
Davies/Kipps [125, 126]
Frontotemporal
5 Coronal T1-W 0.62-0.71 (Cκ) 0.79-0.83 (Cκ) 90/60 9 N
Davies [145] 5 Coronal T1-W 0.7 (Cwκ) 0.75 (Cwκ) 31 3 N
Ambikairajah [127] 5 Coronal T1-W 0.9 (Uκ) Not reported 0 0 N
Chow [146] 5 3-plane T1-W 0.06-0.2 (Kw) Not reported 0 0 N
De Leon [128, 147]
Medial temporal
4 Axial T1-W 0.72 (Uκ) Not reported 213 0 N
Scheltens [129] 5 Coronal T1-W 0.72-0.84 (Cwκ) 0.83-0.94 (Cwκ) 350 100+ Y
Galton [130] 4 Coronal T1-W 0.36-0.49 (Fκ) 0.8 (Cκ) 100 13 N
Urs/Duara [131, 132] 5 Coronal T1-W 0.75-0.94 (Uκ) 0.84-0.93 (Uκ) 21/59 12 Y
Kaneko [148] 4 Coronal STIR 0.68 (Uκ) 0.79 (Uκ) 0 0 N
Kim [133] 5 Axial T1-W 0.64 (Uκ) 0.62/0.95 (Uκ) 1 1 N
Koedam [139] Posterior 4 3-plane
T1-W
FLAIR
0.65-0.84 (Cwκ) 0.93/0.95 (Cwκ) 19 5 N
Table 2.2: Atrophy visual rating scales developed or adapted for application to imaging in dementia. As an indication of the impact of each scale,
the number of published studies that have applied them is provided, as well an indication of their inclusion in clinical trials. Highest
reported reliability values are listed - the citation is listed if not taken from the original paper. Search carried out April 2014. Abbreviations:
Cwκ=Cohen’s weighted κ , Cκ=Cohen’s κ , Fκ=Fleiss’ κ , ICC=intraclass correlation coefficient, KW=Kendall’s W, Uκ=Unspecified κ ,
STIR=Short T1 Inversion Recovery, T1-W=T1-weighted, N=no, Y=yes
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and there is already work under way to integrate some of these techniques directly with
hospital picture archiving and communications systems (PACS). In this section some
of the key steps for quantitative image assessment are discussed, in part to help inform
the analysis decisions taken in relation to the work of this thesis.
2.3.1 Correcting Intensity Non-Uniformity
intensity non-uniformity (INU), or ’bias’, is a common artefact in MR images that re-
sults in a smooth intensity variation within an image. While this has limited effect
on visual assessment it can impact significantly on image registration and segmenta-
tion algorithms, which often assume that a single tissue type is represented by similar
voxel intensity [140]. The artefact can be caused by multiple factors related to scanner
hardware, pulse sequence or the object being imaged (reviewed in [141]).
Both prospective and retrospective correction techniques are available. Prospective
techniques focus on correcting factors related to the acquisition process by acquiring
images with a uniform phantom, multiple coils, or special pulse sequences [142]. Ret-
rospective correction is based directly on the intensity information extracted from the
acquired image, which in some cases is integrated with a priori spatial and/or intensity
probability information about the imaged anatomy [142]. Unlike the prospective tech-
niques, these techniques are also able to correct INU due to the object being imaged
(i.e. the head) and are more frequently used in neuroimaging studies [143].
2.3.2 Image Registration
Image registration is a crucial first step in the quantitative assessment of medical im-
ages, where the extraction of valuable information is based on more than one image.
Examples include the fusion of multi-modality images to enhance diagnostic value,
assessing change between multiple timepoints for disease monitoring, determining dif-
ferences at a group level to identify distinguishing features, and the construction and
utilisation of atlas based techniques for volume extraction [149]. Mathematically, im-
age registration is an iterative process that involves the alignment of two or more images
based on a geometric transformation, a subsequent measure of how well the images are
aligned, and a means of optimising the process to achieve a good solution.
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Image transformations can be categorised as affine or non-rigid based on the extent
of image distortion used to align the image with a target. Affine registrations in 3D
space have a maximum of twelve degrees-of-freedom (DF) to allow translations, ro-
tations, scaling and skews, whilst preserving all parallel lines in the image. A special
case of affine registration is rigid registration, which includes only translations and ro-
tations (six DF), and preserves all distances in the image [149]. Affine registrations
are particularly useful for aligning bone and in neuroimaging are often used to pro-
vide approximate alignment. To account adequately for the degree of variation in brain
tissue, however, more complicated deformations are often required. non-rigid registra-
tion transformations can provide polynomial mapping between the coordinates in the
original image and the target image, and many more degrees of freedom to allow more
flexible distortion of the image. non-rigid registration algorithms may be based on the
alignment of image landmarks or the matching of image intensity [149].
The extent of image deformation should be constrained to ensure a biologically plau-
sible solution. This is typically achieved by implementing a cost function which com-
bines a post-transformation similarity measure with a regularisation term, modelled
on a physical process such as fluid flow, that penalises unlikely transformations such
as folding or high local stretching or bending [149]. Additional constraints include a
trade-off between computation time and accuracy, which is influenced by factors such
as the DF and the number of iterations. Image pre-processing, such as bias correction
(discussed above) and constraining the algorithm to a masked region, can also improve
the quality of the registration.
2.3.3 Image Segmentation
Image segmentation is used to simplify the representation of an image into anatomically
relevant classes to allow meaningful analysis of brain tissue. Segmentation methods
assign a label to each voxel such that voxels with the same label are assumed to share
anatomical or physiological characteristics. A selection of the methods used for image
segmentation are reviewed in this section.
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Manual Delineation
Manual delineation of brain structures is considered the gold standard in image seg-
mentation as a human operator is better able to adapt to variations in image quality
and/or anatomy that can potentially confound automated algorithms based on pre-
defined rules. Manual operators, however, are not without error and a degree of both
inter- and intra-operator variation does exist, introducing uncertainty into the result-
ing volume estimates [150]. Segmentation protocols for various different brain regions
have been developed to help standardise the process and minimise measurement er-
ror, however, with multiple published protocols used for different studies, considerable
variation still exists [150, 151]. To address this issue for hippocampal segmentation,
which is often outcome measure in clinical trials, the European Alzheimers disease
consortium (EADC) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) are
currently developing a harmonised segmentation protocol based on the most highly
cited protocols in the literature [152].
Despite advantages in segmentation accuracy, manual delineation is time-consuming,
labour-intensive and expensive, and unlikely to be adapted into routine clinical use.
It does, however, continue to be used to validate automated segmentation techniques
[153].
Automated Techniques
Pre-Processing Steps
Asmentioned briefly above, there are several undesirable yet often unavoidable features
of an image that can confound automated segmentation algorithms, such as artefacts,
scan orientation, and anatomical variation (exacerbated by disease pathology). Image
pre-processing is, therefore, essential to ensure a good starting point for the algorithm.
Key image pre-processing steps includes INU correction (as discussed above in Sec-
tion 2.3.1), image registration (as discussed above in Section 2.3.2), and removal of
non-brain tissue.
Image registration prior to segmentation is typically to a standard template, such as the
International Consortium for Brain Mapping 152 (ICBMI152) template [154], which is
the average of 152 T1-weighted images acquired in healthy adult brains approximately
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transformed to Talairach space [155] (for more details on its evolution see [156, 157]).
This aligns images in a standard coordinate space, providing approximate voxel-wise
correspondence, to allow subsequent mathematical operations to be applied between
images and comparisons to be drawn between results.
Non-brain tissue such as the eyes, dura and skull have signal intensities similar to brain
tissue, therefore, their extraction reduces the segmentation to a simplified anatomical
region [158]. Techniques to remove non-brain tissue produce either a new image con-
taining only brain voxels or a binary mask (1 for brain voxels, 0 for non-brain tissues),
which can be incorporated into the segmentation process.
Segmentation Methods
Various segmentation methods have been implemented to answer a diverse range of
clinical questions with medical imaging. These methods can be classified into four
categories discussed below.
Intensity-based methods classify each voxel based on its signal intensity. These meth-
ods include thresholding, which uses the intensity histogram to determine the opti-
mal threshold to best separate specific tissue classes; or region growing, which starts
from a seed point and extends to include all voxels with similar intensities. Intensity-
based methods are generally suitable for the classification of grey matter, white matter
and CSF, but unsuitable for segmenting smaller brain structures that have substantial
overlap in intensity. These techniques are particularly sensitive to noise in the image
[153].
Atlas-based methods use (often manually) segmented brain images as a template for
segmenting new images. In this context an individual brain atlas typically consists of an
intensity image (e.g. T1-weighted image) and a corresponding segmented or labelled
image. Atlases are based on a single subject thought to represent average anatomy and
signal intensity, or on a population average thought to be more representative of natural
anatomical variability. The image to be segmented is typically aligned to the atlas in
a two stage process. Firstly an affine registration is used to achieve global alignment
at a low computational cost. Secondly a non-rigid registration is used to achieve local
alignment of specific anatomy at a much higher computational cost. Accurate registra-
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tion is vital to allow the spatial information to be transferred directly from the atlas to
the image, allowing multiple brain structures to be segmented at once, which is a major
advantage of this technique. Anatomical variation due to disease pathology introduce
additional challenges, however, and ideally the atlas used should be representative of
the population under study. Currently most available atlases are based on a healthy
control population [159].
Surface-based methods attempt to fit a parameterised surface (or mesh) to a region
of interest whilst maintaining certain shape characteristics. These techniques combine
rules from geometry, to represent shape, and physics, to define how the shape deforms.
These methods are commonly used to determine cortical thickness, where an initial
mesh is generated from whole brain segmentation and evolved to fit the cortex, with
constraints applied based on prior anatomical knowledge [160].
Hybrid methods combine elements of the other segmentation methods discussed, to
achieve an optimal solution. There is no ideal segmentation solution for all tasks, or
even for any one task, however, the benefit of a hybrid approach is that it can use a com-
bination of methods to compensate for the disadvantages of any one technique. Most
state-of-the-art techniques now developed for neuroimaging are examples of hybrid
techniques [153].
2.3.4 Voxel Based Morphometry
voxel-based morphometry (VBM) is a tool for studying differences in composition of
brain tissue between groups, and can also be used to investigate correlations between
subject characteristics and neuroanatomical patterns. The technique provides a regis-
tration and segmentation pipeline to pre-process brain imaging data in such a way as
to sensitise it to a clinical signal of interest. It then allows the user to specify a lin-
ear combination of features to explain this signal, modelled (using the general linear
model) at the voxel level. These models can then be interrogated statistically to look
for group differences or clinical correlations in the image signal. Although there are
other VBM impementations available (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM),
this technique will be described here in terms of the widely used statistical parametric
mapping (SPM) framework [161].
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Unified Segmentation
Unified Segmentation, the first step in the VBM processing pipeline, is a probabilis-
tic framework, developed by Ashburner and Friston, that allows image registration,
segmentation and bias correction to be combined within the same model [162]. By in-
tegrating these three steps in a single model, the final solution is optimised rather than
the sequential steps. This technique is used to create roughly aligned grey and white
matter segmentations for each image that will be refined in subsequent steps of the pro-
cessing pipeline. The available (user-specified) options to tune the model are described
below.
Bias correction: In SPM, INU (described in Section 2.3.1) is modelled as a linear
combination of smooth basis functions. The bias correction regularisation term in SPM
allows prior information about the degree of INU in the images to be introduced into
the model. Increasing the regularisation term indicates that the image contains less
INU and reduces its influence over the model. An option is also provided to set the full
width at half maximum of the Gaussian smoothing kernel. A large full width at half
maximum should be chosen if there is less INU to prevent loosing the natural intensity
variation between the different tissue types.
Tissue classification is performed by fitting a six component Gaussian mixture model
(representing grey matter, white matter, CSF, bone, soft tissue, air) to each image inten-
sity histogram [162]. Based on a combination of the location (given by the mean), the
spread (given by the variance) and a weighting factor for each Gaussian, a reasonably
accurate model of the data can be obtained. By associating each of the Gaussians with
a different tissue type it is possible to calculate the probability of a particular tissue type
given the image intensity at that voxel. SPM provides the option to extend this model
to fit multiple Gaussians per tissue class, relaxing the assumption that a single tissue
type has a Gaussian intensity distribution, which can help to improve the accuracy of
the model.
Starting Estimates: SPM provides an option to specify a tissue probability map, or
brain atlas (as described in Section 2.3.3 - Atlas-based methods). All images are
roughly aligned to the tissue probability map coordinate system using a twelve DF
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affine transformation to provide an initial starting point for the iterative process of fit-
ting the model. Further regularisation of deformations can be specified to improve
alignment, however, the default sttings are typically used if Diffeomorphic Anatomical
Registration Through Exponentiated Lie Algebra (DARTEL) is included in the VBM
processing pipeline (described below). It is also possibe to set the distance between the
points sampled during model fitting. Smaller values use more of the data and produce
more accurate results but are computationally more expensive and take longer to run
(www.fil.ion.ucl.ac.uk/spm/doc/manual.pdf).
Clean up process: By setting the "cleanup" parameter, misclassified voxels are crudely
accounted for using dilations and erosions of the segmentations. The level of cleanup
specified constrains the extent of the dilations and erosions. Additional removal of mis-
classified voxels is achieved through a few iterations of a simple Markof random field
(MRF) model (http://dbm.neuro.uni-jena.de/vbm/markov-random-fields/). The tech-
nique compares the classification of the central voxel in a neighbourhood of voxels
(in this case a 3x3x3 neighbourhood) and, based on the classification of its neighbours,
combined with the prior probability of the class, determines the likelihood of the central
voxel being correctly classified. The prior probability is determined by the strength of
the MRF, a weighting of zero indicates no MRF, while higher weightings can be used
for noisy data. This additional clean up procedure is designed to deal with isolated
voxels or holes in a cluster of connected voxels that are likely to have been misclassi-
fied.
DARTEL
DARTEL is used to estimate the deformations that best align the roughly segmented
grey and white matter segmentations generated by the unified segmentation framework
[163]. By incorporating many more parameters into the representation of brain shape (3
DF per voxel), DARTEL increases the flexibility of the registration process to achieve
more accurate inter-subject alignment.
Starting with the roughly aligned segmentations generated by the unified segmenta-
tion process, group average templates are generated by simultaneously aligning grey
matter with grey metter and white matter with white matter. As DARTEL enforces a
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one-to-one mapping between the forward and backward deformations, this initial group
template is iteratively refined by computing the deformations from the template to each
of the individual images and averaging the inverse transformations applied to each im-
age [163]. With each iteration an increasingly crisp template image is generated. Flow
field images representing the direction of the deformation of each image to the final
template are also generated.
Final Segmentations
The final group template generated by DARTEL is affinely registered to the specified
tissue probability map. The parameters of this registration are used, along with the
computed flow fields from the DARTEL transformations, to warp the native space grey
and white matter segmentations generated by the unified segmentation model [164].
Signal intensity is modulated based on the degree of deformation in each brain region,
with areas of expansion reduced in intensity to preserve the total amount of signal in the
image [164]. The images are then convolved with a Gaussian smoothing kernel, which
sensitises the analysis to a particular spatial scale of effect determined by the full width
at half maximum of the kernel. The value of the full width at half maximum depends
on the accuracy of the inter-subject registration to the tissue probability map space,
with more smoothing required for less accurate registrations. The optimal value is
likely to vary between brain regions with highly variable cortical regions requiring more
smoothing and less variable subcortical regions requiring less smoothing [164].
Masking
Voxel-wise statistical analysis on the final segmentations should include only voxels
contained within a specified mask to help reduce the number of comparisons, and to re-
duce the number of false positive results. While smaller masks can increase sensitivity
and help clarify interpretation, if the mask is overly restrictive potentially interesting
regions of interest will be excluded from the statistical analysis resulting in an increase
in false negative results.
Ridgway et al developed masking strategies to help generate an optimal mask for use
in studies of neurodegenerative disease; these strategies are now available as an SPM
toolbox (http://www0.cs.ucl.ac.uk/staff/g.ridgway/masking/) [165]. Prior to this work,
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masks were typically generated in SPM by excluding voxels in which any of the images
had intensity values below a certain threshold, with the threshold specified as a constant
value or set as a fraction of each images global value. The intersection of the individual
binary masks was then found to create the group mask. However, patients with neu-
rodegenerative dementia often have overlapping patterns of atrophy, particularly in the
medial temporal lobe, therefore, by adopting this strategy clinically interesting regions
may be excluded from the analysis. The methods developed by Ridgway et al addresses
this issue in two ways. In one method this is achieved by relaxing the criteria that all
subjects are required to have voxel intensity above a certain threshold. Instead voxels
are included in the mask if there is consensus among some percentage of subjects that
their intensity is above the threshold. In the other method, a threshold is applied to the
mean intensity mask created from all subject’s segmentations. The mean intensity mask
is highly likely to contain all relevant regions of interest. A good threshold applied to
this average image should remain highly correlated with the unthresholded original. By
using a function to maximise the Pearson correlation coefficient over pairs of voxels be-
tween the unthresholded mask and a thresholded mask it is possible to maximise the
threshold objectively, independently of the operator. This second strategy is therefore
recommended in the first instance [165].
Statistical Analysis
Using the general linear model, SPM provides a framework for specifying a mixture of
variables to define the processed image data [166]. By using classical statistics to inter-
rogate the derived model it is possible to infer which variables contribute significantly
to any within- or between-subject variance.
Defining the imaging data in terms of the general linear model decomposes the data
into effects and error based on the following equation:
y= Xβ + ε
Where y is the signal intensity in the image data, X is the design matrix containing all
available knowledge about the experimentally controlled factors and the potential con-
founds, β is the weighted estimate of the contribution of the design matrix parameters
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(regression coefficients), and ε is the residual signal that is not explained by the design
matrix. Ideally the estimated parameters should explain the signal as much as possible,
and in doing so minimise the unexplained variability represented by the error term. The
errors are typically assumed to be normally distributed with independent and identical
noise across the images. The parameters are estimated by minimising the squared error
term using ordinary least squares estimation.
EXAMPLE
Consider a VBM experiment to compare grey matter density between AD patients and
controls. The general linear model equation above could be rewritten as:
y=

x1AD x1Controls x1Age x1Gender x1TIV
x2AD x2Controls x2Age x2Gender x2TIV
x3AD x3Controls x3Age x3Gender x3TIV
... ... ... ... ...
xnAD xnControls xnAge xnGender xnTIV


βAD
βControls
βAge
βGender
βTIV

+ ε
Where X_iAD and X_iControls are binary indicator variables denoting group for each
subject (1-n) and signal intensity is corrected for the confounding factors of age, gender
and total intracranial volume (TIV) (discussed in Section 4.4.3) by including them as
covariates in the model [167]. A contrast vector, c, can then be defined by selecting
a linear combination of regression coefficients to investigate the effect of interest, e.g.
are there differences in grey matter density between the Alzheimer’s disease group and
the control group.
cT βˆ =
[
−1 1 0 0 0
]

βAD
βControls
βAge
βGender
βTIV

Or βControls−βAD
The null hypothesis, H0, is therefore specified as:
H0 : cT βˆ = 0
2.3. Quantitative Assessment 52
H0 can then be interrogated using univariate statistics such as the simple t-test, de-
fined as the contrast of estimated parameters divided by the square root of the variance
estimate.
T =
cT βˆ√
var(cT βˆ )
VBM applies such tests at the voxel level and a statistics image is generated over the
entire brain volume. Analysis using a standard structural T1-weighted volumetric scan
will, therefore, result in over 1 million tests at the group level, with every test increas-
ing the likelihood that the groups will differ in some regions by chance alone. Multiple
testing correction methods are available to control the chance of false positive results,
essentially setting a threshold below which an effect is considered noise. family-wise
error rate (FWE) and false discovery rate are commonly used in neuroimaging studies
for this purpose [168, 169]. FWE is the probability of any false positives occurring
in any individual tests, while false discovery rate corrects for a proportion of false
positives among the rejected null hypotheses. FWE is, therefore, the more stringent
method of correcting for multiple tests. These methods are implemented in the con-
text of random field theory due to the spatial correlation between neighbouring voxels
(particularly after smoothing) [166]. This violates the assumption of independent sta-
tistical tests assumed by the more standard Bonferroni correction, and would result in
an overly conservative threshold if this technique was applied [170].
2.3.5 Machine Learning
Machine learning algorithms quantify relationships within existing data and use these
identified patterns to make predictions based on new data [171]. Increasingly, these
algorithms are used to interrogate a vast array of medical data, including imaging data,
to look for patterns previously undetected by more conventional statistical analysis or
the human eye. The basic concepts of machine learning for practical implementation
are discussed below.
Learning Algorithms
Learning algorithms can be separated into two categories, supervised or unsuper-
vised.
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• Supervised learning algorithms are used when the existing data is already la-
belled and the algorithm is required to classify the new data in the same way.
This type of learning problem can be then categorised as a classification prob-
lem, if the data can be separated into discrete classes, or a regression problem,
if the desired output is a continuous variable. Popular supervised learning al-
gorithms include support vector machine (SVM), k nearest neighbour classifiers
and random forests.
• Unsupervised learning algorithms are used to discover clusters within the data
when no target value is available. Popular unsupervised learning algorithms in-
clude k-means, Gaussian mixture model, and heirarchical clustering.
The choice of learning algorithm depends not only on the data available and the ques-
tion to be answered but also on the number of samples available within dataset. Ma-
chine learning algorithms are best suited to large datasets often with several thousand
samples, and in some cases unsuitable for smaller datasets below this order of magni-
tude.
Training and Testing
In order for an algorithm to learn patterns in the data it needs to be trained using a data
sample representative of the complete study population, and tested using a similarly
representative sample. Taking a classification problem as an example, the training and
testing dataset must contain each class defined in the problem, and both should con-
tain the same proportion of classes. A dataset with unbalanced classes will bias the
algorithm towards the larger class, however, if this is unavoidable a weighting factor
is applied to increase the cost of misclassifying the smaller class and reduce this bias.
Both training and testing sets must be mutually exclusive to prevent optimising the al-
gorithm for the study population, which will fail to generalise to the wider population,
a process referred to as over-fitting.
The Classification Problem
Machine learning datasets are typically multivariate, with each sample in the dataset
(i..N) defined by an array, x, of M features. In a classification problem, the solution,
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Figure 2.1: Given only a small sample (left image) either, the linear (solid) or non-linear
(dashed) boundary might be more appropriate. A larger sample (middle and
right image) better reflects the true distribution. If the middle image rep-
resents the true distribution, the linear boundary under-fits the data. If the
image on the right represents the true distribution, the non-linear boundary
over-fits the data. Diagram recreated from Lemm et al [172]
y, can be specified as a function of x, i.e. y = f (x), and each data sample can be
represented as a point in n-dimensional space. Taking a binary classification problem
as an example, the goal of a classifier is to construct a boundary in n-dimensional
space that classifies the samples into two classes. This boundary can either be linear
or non-linear, as shown in Figure 2.1. In some cases a non-linear boundary is more
appropriate, however, as shown in Figure 2.1, a non-linear boundary may over-fit the
data given only a small sample size. The popular linear SVM algorithm, often used
with smaller sample sizes, is described here and used for the work of this thesis.
Support Vector Machine
An SVM can be implemented as a linear classifier to construct a separating hyperplane,
T (n-1 dimensions), that classifies all data into two classes. The goal is to position T
such that the distance (margin) to the closest data points on either side (the support vec-
tors) is maximised. Focusing the solution on the support vectors reduces the influence
of outlier data points and produces better classification accuracy.
Taking the simple case, based on two classes, where x has only two features as an
example, x= (x1,x2), and T is a two dimensional line, the discriminant function can be
described as
f (x) = wT x+b
Where f(x), has a value of zero at T, a value less than zero for class 1, and a value greater
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Figure 2.2: The discriminant function, f(x), has a value of zero on the separating hyper-
plane, T. For data points defined as class 1 (purple dots) f(x)<0, for class
2 (blue dots) f(x)>0. The goal of the SVM is to define T to maximise the
margin between the support vectors in class 1 and class 2. W is the weight
vector perpendicular to T.
than zero for class 2 (see Figure 2.2). W, the weight vector perpendicular to T and b
is the bias term, which dictates whether T goes through the origin of the coordinate
system (b=0 represents an unbiased hyperplane through the origin).
By normalising w such that f(xclass1)=-1 and f(xclass1)=1 the margin is given by
margin=
1
||w|| +
1
||w|| =
2
||w||
Minimising the weight vector will, therefore, maximise the margin and the separability
of the data. Misclassifications are inevitable in most cases and the optimal solution is a
trade off between maximising the margin and minimising the number of misclassifica-
tions.
The extent of this trade off can be mediated using the SVM regularisation parameter, c.
If a wider margin is the preferred outcome (with a risk of under-fitting to the training
data), a smaller c value should be selected, and vice-versa if minimal misclassification
is the preferred outcome (with a risk of over-fitting to the training data). If confident
that the training data is truly representative of the general distribution, higher c values
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may produce better classification accuracy, however, in most cases the optimal choice
of c value is best determined empirically using a technique known as grid-search. Us-
ing this technique a range of c-values are tested for every iteration of training process
and the value that consistently optimises the algorithm for the desired outcome is se-
lected.
As previously mentioned, avoiding over-fitting the algorithm to the training data is a
challenge in machine learning. To reduce this risk the training process can be con-
sidered as a sub-problem of the larger classification problem, where the training data
is further divided into training and testing sets. This technique is known as cross-
validation. A special case of cross validation, known as leave-one-out, trains on N-1
samples and tests with one sample a total of N times.
2.4 Conclusion
Many methods are available to extract clinically valuable and complementary infor-
mation from structural MRI. Simple visual assessment techniques are quick and easy
to apply and are well suited for implementation into clinical practice. More advanced
techniques allow for quantitative measures to be extracted which may help with more
fine-grained analysis. However, these advanced techniques are often complex and re-
quire specialist software, hardware and expertise. As computing capabilities continue
to advance, these more advanced techniques, that have been used extensively in de-
mentia research, will eventually be integrated into clinical workstreams. In this thesis,
several of these techniques, from simple to complex, are investigated for their ability
to characterise and distinguish between imaging data acquired in pathologically proven
dementias, data which is rarely available in dementia research.
Chapter 3
Evidence for the Use of Structural MRI
in the Diagnosis of Dementia
3.1 Introduction
As discussed previously, structural MRI serves multiple purposes in the clinical assess-
ment of cognitive impairment. Firstly, it can be used to exclude potentially treatable
causes of dementia (e.g. mass-effect lesions, infection), secondly to determine the
extent of vascular disease, and thirdly to identify characteristic patterns of cerebral at-
rophy. These three broad categories are included together, or at least in part, in consen-
sus diagnostic guidelines for all neurodegenerative dementias, and make up a general
framework for image assessment (see Figure 3.1). Although the subject of this thesis
is the diagnostic value of cerebral atrophy, the imaging features at each stage of the as-
sessment process are discussed in this chapter due to the important implications of each
in the diagnosis of dementia and the role of structural MRI in their identification.
3.2 Exclusion of Mass Effect Lesions
Brain lesions of a certain size or within a certain location may be sufficient to cause
cognitive impairment. Such lesions are potentially suitable for surgical intervention
and their identification should be the starting point when reviewing structural imaging.
These include tumour (eg, meningioma, glioma), subdural haematoma, arteriovenous
Figure 3.1: A general framework for image assessment in cognitive impairment, previ-
ously proposed by Barkhof et al and Harper et al [69, 173]
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Figure 3.2: Lesions of a certain size, in a certain location may be sufficient to cause cog-
nitive impairment. The subdural haematoma image and the hydrocephalus
image was provided by Radiopaedia.org
malformation and hydrocephalus (see Figure 3.2). Radiology expertise is essential at
this stage, particularly for small or isodense lesions that may be missed by an untrained
eye.
3.3 Assessing Signal Change
Signal intensity within a single tissue type should be reasonably uniform on MRI
and the presence of regions of hyperintensity or hypointensity within a single tissue
type typically reflects pathology. In the context of dementia, MR signal change is
frequently associated with vascular disease; however, it may also indicate inflamma-
tory, metabolic, toxic or infective processes which could be contributing to cognitive
deficits.
Vascular disease and Alzheimer’s disease share many risk factors, including an increas-
ing prevalence with age, and in many patients these pathologies coexist [174, 175]. The
exact interaction between neurodegenerative and vascular pathology is debated but crit-
ically for the patient, it is important that vascular risk factors are managed and treated.
Differentiating the relative contribution of vascular from neurodegenerative pathology
as the cause of a patient’s cognitive problems is a common clinical problem where MRI
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can play a central role.
vascular cognitive impairment or vascular dementia is most frequently associated with
atherosclerosis of the cerebral arteries, cerebral small vessel disease (SVD) and CAA
[176]. These disorders manifest as cerebral infarcts, white matter lesions and haemor-
rhages, which can be visualised on structural MRI and will be discussed below in terms
of small or large vessel involvement.
3.3.1 Large Vessel Disease
Atherosclerosis leads to the accumulation of blood derived lipids and proteins, par-
ticularly cholesterol, within the vessel wall [176]. This causes plaque formation and
calcification, resulting in a reduction in blood flow to brain tissue. Complete or pro-
longed ischaemia causes focal regions of tissue necrosis, i.e. cerebral infarctions, which
typically evolve into fluid filled cavities as interstitial fluid accumulates in and around
the infarction. The altered tissue composition means that these lesions are readily visu-
alised with MRI.
A diagnosis of vascular dementia due to large vessel disease is based on both the topol-
ogy and severity of infarcts evident on T2-weighted or FLAIR images as (operationally)
defined by the NINDS-AIREN (National Institute of Neurological Disorders and Stroke
and Association Internationale pour la Recherche et l’Enseignement en Neurosciences)
criteria for vascular dementia [177, 178]. Infarcts must be located in vascular territories
around the anterior (bilaterally), middle or posterior cerebral artery, or in associated
watershed regions (see Figure 3.3). In terms of severity, infarcts must be present in
the dominant hemisphere or bilaterally, at least meeting the topography criteria in the
non-dominant hemisphere.
There is evidence to suggest that the association between large vessel infarcts and cog-
nitive impairment is weaker than the same association with small vessel infarcts. How-
ever, any previous infarction carries a greater risk of developing dementia [180, 181].
The presence of cerebral atherosclerosis, independent of infarction, and therefore po-
tentially reversible, has also been shown to increase the risk of cognitive impairment
[182, 183].
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Figure 3.3: Vascular territories of the cerebral arteries. Anterior cerebral artery territory
is shown in turquoise, middle cerebral artery in blue and posterior cerebral
artery in magenta. The diagram was adapted from the Radiology Assistant
website (http://www.radiologyassistant.nl) and originated in Savoiardo et al
[179]
3.3.2 Small Vessel Disease
Small vessel disease describes a number of discrete pathological entities that affect the
small vessels of the brain. These are described below in terms of their appearance
on MRI using the suggested categories from the recent STRIVE criteria [115] (see
Figure 3.4).
Lacunes of Presumed Vascular Origin
Arteriosclerosis and lipohyalinosis are common causes of SVD that lead to thickening
of the vessel walls but without the additional calcification that occurs in atherosclerosis
of the larger vessels [184]. Cerebral infarction or haemorrhage often occur as a result,
however, the size and location differ from the larger vessel equivalents as a result of
their vascular origin. Pathological staging of Arteriosclerosis/lipohyalinosis in relation
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Figure 3.4: MRI findings related to small vessel disease - recommendations from
STRIVE [115]. *If the lacune is the result of a haemorrhage.
This table is adapted from [115] with permission from Elsevier.
to cognitive deficits has been proposed to start in arteries of the basal ganglia, expand-
ing into peripheral white matter and leptomeningeal arteries, then into thalamic and
cerebral white matter vessels, and finally into brain stem arteries [22].
Radiologically, these smaller infarcts are referred to as lacunes and defined as small,
round or ovoid, fluid-filled cavities in the region of a perforating arteriole. They
are typically between 3-15mm in diameter with CSF-like intensity on T1-weighted,
T2-weighted and FLAIR images, although they are best visualised on the latter two
sequences. On FLAIR images lacunes often have a hyperintense rim, which helps to
distinguish them from prominent perivascular spaces (see below). Bilateral thalamic
infarcts however, which are sufficient to cause cognitive impairment [178], are better
identified on T2-weighted than FLAIR images [185]. Ideally both sequences should be
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acquired for thorough investigation of small vessel disease.
There is evidence to suggest that not all infarcts evolve in the same way [186, 187] and
in some cases conventional MRI sequences are not sensitive enough to detect recent
infarcts. Diffusion weighted imaging is recommended for the identification of subcor-
tical infarcts occurring within weeks, which appear as hyperintense lesions, potentially
larger than the 15mm upper bound previously defined for lacunes. Improved sensitivity
means there is also no lower size limit given for infarcts detected on diffusion weighted
imaging [115].
Lacunes are associated with an increased risk of stroke, gait impairment, and dementia,
with increasing prevalence in relation to advancing age, hypertension, diabetes and
hypercholesterolemia [180, 188–190].
White Matter Hyperintensities
The pathogenesis of white matter lesions, visible as hyperintensities on MRI, is com-
plex and not yet fully understood [191]. In the context of dementia they are most
frequently associated with small vessel disease and characterised pathologically by de-
mylination, axon loss, astrogliosis and microglia activations [176].
On T2-weighted and FLAIR sequences the severity of white matter hyperintensities
can be visually quantified by application of an established rating scale as discussed
in Section 2.2.2. These scales typically classify lesions by location as periventricular,
deep white matter hyperintensities or deep grey matter (if the latter case is included
the collective term is subcortical hyperintensities [115]), although attempts to clarify
the clinical consequences of each have been contradictory [192, 193]. Confluence of
hyperintensities in at least two brain regions, and the beginning of confluence of hy-
perintensities in a further two regions, is considered to represent the involvement of
at least a quarter of the total white matter and is sufficient for a diagnosis of vascular
dementia due to SVD [178]. However, even in cases of extensive white matter hyper-
intensities, the existence of mixed pathology should be considered, although it may be
difficult to confirm or refute. Less often, multifocal/confluent regions of hyperinten-
sity in a patient with suspected dementia may result from a number of other condi-
tions, including infections, inflammatory demyelinating diseases, leukodystrophies or
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leukoencephalopathies [69, 194].
Extension of confluent hyperintensities into the temporal poles is rare and may indicate
that the pathology is not of conventional vascular origin. If the patient has a posi-
tive family history of dementing illness and is known to have suffered previously from
strokes and/or migraines, cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL) should also be considered and genetic
testing may be appropriate [69, 195]. A range of other single gene disorders can, how-
ever, cause SVD [196].
Perivascular Spaces
perivascular spaces (PVS) are interstitial fluid filled cavities surrounding the cerebral
vessel walls and separating them from cortical tissue. Connected to the meningeal in-
terstitial spaces, they act as a prelymphatic drainage system for removal of substances
that cannot be transported in the blood or catabolised intracellularly [197]. Lacking any
valve mechanisms, the movement of fluid within the PVS channels is reliant on regu-
lar pulsations from the adjacent vessel. It has therefore been speculated that reduced
blood flow due to vascular disease could impair PVS function, causing them to dilate.
Furthermore, prolonged or permanent collection of cellular waste in PVS could lead
to an inflammatory response and contribute to a number brain diseases, including the
neurodegenerative dementias [197].
PVS are typically microscopic and not visible on conventional MRI, however, larger
PVS are visible on T2-weighted and FLAIR sequences. These appear linear when im-
aged parallel to the course of the vessel, and round or ovoid, with a diameter generally
smaller than 3 mm, when imaged perpendicular to the course of the vessel [115]. The
appearance of PVS is increasingly prevalent with age and some studies have demon-
strated a correlation with other SVD features and worsening cognition [198, 199].
However, PVS have been observed at all ages in the healthy population, therefore,
their clinical significance remains uncertain [200]. A new rating scale has recently
been published to help study the implications of PVS systematically and in more de-
tail, reflecting a growing interest in this topic [201].
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Cerebral Microbleeds
Sporadic cerebral amyloid angiopathy is characterised pathologically by the deposition
of Aβ in the walls of cerebral blood vessels. This can lead to vessel wall rupture and
haemorrhage, microbleeds, capillary occlusion, blood flow disturbances and microin-
farcts [176].
When placed in an MRI scanner, the paramagnetic blood break-down products as-
sociated with microbleeds cause distortions in the local magnetic field [202]. This
distortion leads to faster dephasing of the MRI signal in these regions and results in
small, round hypointensities on gradient echo based pulse sequences (T2*-weighted
or susceptibility-weighted if available) [115]. The additional dephasing of peripheral
tissue causes a blooming affect around the lesion, causing it to appear larger on imag-
ing than when measured in tissue. Faster dephasing, or magnetic susceptibility effects,
increase in proportion to the magnetic field strength, therefore, microbleeds may ap-
pear larger at higher field strengths, making them easier to detect [71]. For this reason
size cut-points have not been recommended for the identification of microbleeds [71].
Other acquisition parameters that enhance MB detection are longer echo times and
higher spatial resolution [203, 204].
microbleeds associated with CAA are more commonly found in lobar regions, while
microbleeds associated with hypertension are more frequently found in deep brain re-
gions (basal ganglia, thalamus and brainstem), however, these conditions often coexist
in the elderly population [205]. A conservative estimate from a large population based
study suggests the incidence of microbleeds in the general population is approximately
10% [206]. T2* hypointensities may also result from calcification, iron deposits (from
causes other than microbleeds), haemorrhagic metastasis or diffuse axonal injury. Care
should be taken to exclude these mimics and other MR artefacts such as flow voids
or signals from temporal bones, when reporting the extent of microbleeds in the brain
[204].
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3.3.3 A Structured Approach to Assessing Signal Change
Expanding on the general framework presented in Figure 3.1, current evidence from
the literature and relevant consensus guidelines (discussed above) are synthesised in
Figure 3.5 to provide a practical guide to imaging features sufficient to cause vascular
cognitive impairment. Where signal change does not meet criteria, visual rating scales
are recommended to quantify vascular burden. While radiology expertise is essential
to interpret all possible sources of MR signal change, this algorithm may be useful to
guide interpretation within the context of vascular cognitive impairment as defined by
current consensus criteria.
3.4 Cerebral Atrophy
Atrophy, reflecting neuronal loss, is a downstream effect of several neurodegenerative
processes, and can be assessed in detail with structural MRI. Despite a degree of over-
lap, the pattern of tissue loss broadly relates to clinical phenotype, and in the small
number of cases were pathological or genetic confirmation is available, has also been
shown to have predictive value for underlying molecular pathology. Atrophy is best
identified on T1-weighted images and assessed on a combination of axial, sagittal and
coronal views. As outlined in Section 2.2.1, images should be assessed for asymmetric
patterns of atrophy, an anterior-posterior atrophy gradient, or disproportionate localised
atrophy within particular brain regions, taking into account the patients age. Specific
features are discussed below in terms of brain location.
3.4.1 Frontal Lobe Atrophy
Disproportionate frontal lobe atrophy (see Figure 3.6) is typically associated with be-
havioural changes, or language difficulties if the dominant left hemisphere is affected,
and probable clinical syndromes include bvFTD, PNFA progressive non-fluent aphasia
(PNFA), and less frequently, CBS CBS. There is a high probability of an underlying
FTLD pathology, although on an individual patient basis it may be difficult to pinpoint
the particular molecular signature.
Patients diagnosed with bvFTD have been reported to have symmetrical or asymmetri-
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Figure 3.5: An algorithmic approach to assessing MR signal change. This algorithm is intended to guide interpretation within the context of vascular
cognitive impairment as defined by current consensus criteria. Radiology expertise is essential to rule out all other sources of MR signal
change.
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cal frontal atrophy with or without additional temporal lobe atrophy and these findings
form part of the criteria for bvFTD [59]. Medial frontal regions,the orbitofrontal cor-
tex and the insula in particular, have been consistently reported in association with
bvFTD [145, 207–212]. In patients with PNFA, left-sided posterior frontoinsular at-
rophy, which may be limited to a subtle widening of the left sylvian fissure, has been
frequently reported [213–215] and has also been included in the corresponding diag-
nostic criteria [60].
Both Tau and TDP43 pathologies have been associated with frontal lobe atrophy, how-
ever, relatively few imaging studies have looked at specific subtypes of Tau or TDP43
pathologies. Figure 3.8 demonstrates the studies providing evidence of predominant
frontal atrophy by primary molecular pathology.
Frontal lobe atrophy has been reported in several studies of Tau-CBD [52, 110, 214,
216–223], although there is almost certainly an overlap of cases included in these stud-
ies (more than half were based on the Mayo clinic pathology database [214, 217–220,
222]). Despite a typically asymmetric clinical presentation in patients with CBS, only
two of eleven studies reported an asymmetric pattern of atrophy in the frontal lobes,
with no one hemisphere consistently more affected [216, 219]. However, many pa-
tients with a clinical diagnosis of CBS are found to have pathology other than CBD at
post mortem [218, 220, 224].
While there have been very few studies of Tau-Picks, all have reported predominant
frontal lobe atrophy [110, 221, 222, 225], and three of four have reported asymme-
try, with the left hemisphere typically more severely affected than the right [110, 222,
225].
Frontal lobe atrophy has been reported in six studies of Tau-PSP [52, 214, 217, 219,
220, 226], with two reporting additional brainstem atrophy [52, 226], although brain-
stem atrophy has also been reported in the absence of significant frontal lobe atrophy
(described below).
Prominent and bilateral frontal lobe atrophy is the most common feature reported in
relation to TDP43-A pathology [222, 227–230], however, asymmetry (and extension
into the temporal and parietal lobe) has been noted in cases associated with a progran-
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Figure 3.6: Examples of characteristic frontal lobe atrophy in post mortem confirmed cases. The yellow text to the left of the arrow indicates clinical
diagnosis, followed by the pathological diagnosis to the right. From left to right: 1) an example of a healthy adult brain, 2) atrophy of
the left fronto-insular cortex in a patient with PNFA caused by Tau-Pick’s pathology, 3) symmetrical frontal lobe atrophy with Tau-PSP
pathology, 4) asymmetric (left>right) frontal lobe atrophy due to Tau-Picks, 5) frontal atrophy extending into the temporal lobes due to
TDP43A pathology.
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Figure 3.7: Examples of characteristic temporal lobe atrophy in post mortem confirmed
cases. The yellow text to the left of the arrow indicates clinical diagnosis,
followed by the pathological diagnosis to the right. From left to right: 1) an
example of a healthy adult brain, 2) right greater than left sided atrophy in
a patient with bvFTD due to Tau-Picks pathology, 3) left greater than right
sided atrophy in a patient with semantic dementia and underlying TDP43C
pathology, 4) left-sided temporoparietal atrophy in a patient with LPA due
to AD
ulin mutation [227]. There have been very few studies of TDP43-B pathology [228,
229, 231], with two reporting predominant frontal lobe atrophy [228, 229], and only
one with asymmetry (affecting the left more than the right) [228].
3.4.2 Temporal Lobe Atrophy
Medial temporal lobe atrophy, particularly in the hippocampi, is typically associated
with memory problems, while lateral and anteroposterior atrophy (shown in Figure 3.7)
is more commonly associated with language difficulties and behavioural changes. An
attempt is made to distinguish between predominant medial temporal lobe atrophy, de-
scribed below as focal hippocampal, and lateral and anteroposterior temporal lobe atro-
phy (which may also affect the hippocampi) described in this section. Probable clinical
symptoms of lateral and anteroposterior atrophy include semantic dementia, logopaenic
aphasia and bvFTD, and there is a high probability of underlying FTLD pathology, par-
ticularly if there is an asymmetric appearance, although logopaenic aphasia (described
below) has been associated with underlying Alzheimer’s disease pathology.
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Figure 3.8: Frontal lobe volume loss reported in studies of pathologically confirmed cases. Mean number of cases across all studies is shown by the
dotted line.
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TDP43-C pathology almost always results in a clinical presentation of semantic de-
mentia and left greater than right sided, focal anterior temporal atrophy, particularly af-
fecting the temporal pole, the amygdala and anterior hippocampus, with selective loss
of anterior fusiform gyrus and relative preservation of more posterior structures [112,
208, 227–230, 232]. These imaging characteristics form a core part of the diagnostic
guidelines for semantic dementia [60]. Rarely, it results in a behavioural presentation,
or with right greater than left sided atrophy [232, 233], with one study suggesting this is
linked to additional corticospinal tract degeneration [232]. Imaging studies performed
in TDP43-C pathology cases are summarised in Figure 3.9.
Right greater than left sided temporal lobe atrophy is often associated with bvFTD,
and often with additional features of prosopagnosia and/or topographical memory im-
pairment, has also been reported in clinical imaging studies [234]. Definitive evi-
dence is lacking to confirm the most common underlying pathology associated with
this imaging presentation, however, FTD-MND with behavioural symptoms and un-
derlying TDP43-B pathology has been described in a limited number of cases [231,
235]. While the asymmetry is often striking in semantic dementia and the right tempo-
ral variant of bvFTD, both temporal lobes usually become involved and over time the
pattern of atrophy becomes more symmetrical [59, 208, 236, 237].
logopaenic aphasia is also associated with greater left-sided atrophy in the temporal
lobe although in contrast to semantic dementia the pattern of atrophy extends more
posteriorly, predominantly affecting the posterior perisylvian and temporoparietal areas
(angular gyrus, posterior middle temporal gyrus, superior temporal gyrus and superior
temporal sulcus) [60, 238]. Unlike the majority of clinical syndromes associated with
an asymmetrical pattern of atrophy, logopaenic aphasia is typically due to underlying
Alzheimer’s disease pathology [217, 239–241] (see Figure 3.9).
3.4.3 Focal Hippocampal Atrophy
Hippocampal atrophy, visible with MRI (see Figure 3.10), has been shown to corre-
late with NFTs burden [242–247]. It is the most established imaging biomarker of
Alzheimer’s disease and is incorporated in to diagnostic criteria as a supporting feature
[37, 39]. Relative preservation of the medial temporal lobe is suggested as a means
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Figure 3.9: Temporal lobe volume loss reported in studies of pathologically confirmed
cases. Mean number of cases across all studies is shown by the dotted line.
of distinguishing DLB from Alzheimer’s disease at a group level [244, 248–251] (ev-
idence summarised in Figure 3.11), however, the extent to which this is reliable in
individual cases is uncertain, not least as the two pathologies frequently coexist [26,
252].
Hippocampal atrophy is also a feature of hippocampal sclerosis and certain inflamma-
tory disorders, hyperintensity of the hippocampus on T2 or FLAIR images makes this
diagnosis more likely [253]. Focal (and often severe) atrophy affecting the anterome-
dial temporal lobes has been described in MAPT mutation carriers (see Figure 3.10),
with striking loss of the amygdala, parahippocampus and hippocampal heads bilater-
ally [212, 225, 227, 228, 230, 254–256], although a few studies have also reported left
sided asymmetry [212, 225] (evidence summarised in Figure 3.11). A recent study by
Rohrer et al in presymptomatic mutation carriers suggests that volume changes in these
regions may be detectable up to 15 years before disease onset [256].
3.4.4 Parietal/Occipital Atrophy
Posterior brain atrophy (demonstrated in Figure 3.12), in the region of the parietal and
occipital cortex is typically associated with visuospatial and visuoperceptual problems
and the posterior cortical atrophy clinical phenotype [257]. Less frequently posterior
atrophy has also been demonstrated in patients diagnosed with CBS and DLB [220,
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Figure 3.10: Examples of characteristic hippocampal atrophy in post mortem confirmed
cases. The yellow text to the left of the arrow indicates clinical diagnosis,
followed by the pathological diagnosis to the right. From left to right: 1) an
example of a healthy adult brain, 2) bilateral hippocampal in a patient with
AD, 3) severe bilateral hippocampal atrophy in a MAPT mutation carrier
Figure 3.11: Hippocampal volume loss reported in studies of MAPT mutation carriers
on the left. On the right, studies providing evidence that MTL atrophy is
absent in DLB or less severe than in AD. Mean number of cases across all
studies is shown by the dotted line.
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Figure 3.12: Examples of characteristic posterior brain atrophy in post mortem con-
firmed cases. The yellow text to the left of the arrow indicates clinical
diagnosis, followed by the pathological diagnosis to the right. From top
to bottom: 1) an example of a healthy adult brain, 2) slightly asymmetric
parietal lobe atrophy due to Tau-CBD pathology, 3) severe bilateral parietal
lobe atrophy due to AD
258, 259].
Alzheimer’s disease is the most common underlying pathology associated with dispro-
portionate posterior brain atrophy [52, 218, 260] . In these patients the medial temporal
lobes may be relatively spared, particularly in early-onset cases [111, 139], however,
posterior atrophy with additional medial temporal lobe atrophy improves the sensitivity
and specificity for underlying Alzheimer’s disease pathology [109, 111, 139]. Further-
more, these regions, specifically including the entorhinal cortex, precuneus and poste-
rior cingulate, have also been shown to be affected even in presymptomatic mutation
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carriers [101, 261–264].
Tau-CBD has also been associated with parietal atrophy, although less frequently than
with frontal lobe atrophy, and without asymmetry [220, 221, 223, 265]. Atrophy as-
sociated with GRN mutation carriers is often reported as asymmetric, affecting the
entire hemisphere, including frontotemporal and parietal regions [227, 228, 255]. No
pathologically confirmed imaging studies could be found to verify evidence of atro-
phy in posterior brain regions in DLB, however, occipital posterior parietotemporal
hypometabolism has been reported [266].
3.4.5 Infratentorial Atrophy
Midbrain atrophy is characteristic of Tau-PSP [52, 212, 223, 226, 267, 268], and has
been described in clinical imaging studies as having a hummingbird [269] or ’morning
glory’ [270] appearance in midsagittal slices, with axial slices demonstrating the so
called mickey mouse sign [271] (see Figure 3.13). Simple linear measurements in the
midbrain and pons, and calculation of the midbrain to pons ratio, may be a more reliable
means of identifying Tau-PSP (ratio<0.5), with a sensitivity of 79% and a specificity
of 100% in a sample of cases with pathologically confirmation [268]. Other imaging
features in PSP include dilation of the third ventricle and atrophy of the red nucleus
[223, 272].
Pathologically confirmed DLB has also been reported in association with brainstem
atrophy [267], particularly in the dorsal mesopontine region [244].
3.4.6 A Structured Approach to Assessing Cerebral Atrophy
Current evidence from the literature and relevant consensus guidelines (discussed
above) are synthesised in Figure 3.14 to help guide radiological assessment. Since
no imaging feature is 100% sensitive and specific, this approach is not intended to be
definitive, aiming however, to narrow the differential diagnosis and provide a frame-
work for image assessment and reporting.
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Figure 3.13: Examples of characteristic brainstem atrophy in clinically diagnosed PSP.
The top row demonstrates a normal brainstem appearance on the axial
slice on the left. The slice on the right demonstrates a reduction in
the anterior-posterior diameter of the midbrain resulting in the so-called
’Mickey Mouse’ sign. On the bottom row sagittal slices through the brain-
stem demonstrate a normal appearance (left) followed by an abnormal
’hummingbird’ appearance (middle). The image on the right demonstrates
the midbrain to pons ratio measurements that have proved useful for iden-
tifying Tau-PSP [268]
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Figure 3.14: An algorithmic approach to assessing MR signal change. The grey boxes indicate the most likely underlying pathology based on the current
limited evidence in the literature. The dashed grey and purple boxes represent both the clinical syndrome and underlying pathology.
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3.5 No Imaging Abnormality Demonstrated
Following the general framework presented in Figure 3.1, if all stages fail to reveal any
abnormalities, beyond what is expected for age, the scan is reported as within normal
limits, however, this does not rule out neurodegenerative dementia entirely. If clinical
suspicion persists, a SPECT or PET scan can be helpful to look for changes in cerebral
perfusion/metabolism, or repeat MRI scanning in six to twelve months. If available,
molecular biomarkers such as CSF or amyloid PET scanning are also useful to exclude
the presence of amyloid pathology in these cases.
3.6 Conclusion
Structural MR imaging is recommended in the investigation of all neurodegenerative
dementias. It is widely available and as demonstrated above, can serve multiple pur-
poses, including the exclusion of space occupying lesions, establishing the extent of
vascular disease, and the identification of cerebral atrophy. While each step is equally
important in the diagnostic process, the focus of this thesis is explore opportunities to
enhance the last of these steps.
As described above, focal and general patterns of atrophy can help to narrow the differ-
ential diagnosis, going beyond clinical syndrome to provide an indication of molecular
pathology. Several studies of pre-symptomatic genetic mutation carriers have demon-
strated that despite being a downstream effect of the disease process, atrophy is often
evident before the onset of clinical symptoms. While this has important implications
for patient care, it can also be used as part of the enrichment strategy for clinical trials,
whilst simultaneously providing a surrogate marker of disease progression and a useful
secondary measure to supplement cognitive endpoints.
There is clear motivation to make better use of the valuable, and widely available, diag-
nostic information provided by structural MRI, for both clinical and research purposes.
However, the majority of published studies are conducted in relation to clinically di-
agnosed cases, which may be wrong in around 30% of cases [3], using a variety of
techniques, and often based on small sample sizes. As a result, findings are frequently
inconsistent, making it challenging to operationalise them for wider application.
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Very few imaging studies have been carried out in relation to pathologically confirmed
dementias due to the scarcity of the data. As discussed above, and demonstrated in
various figures, the few that are available tend to be based on very small sample sizes
(mean n =10). In an attempt to overcome these shortcomings, many studies are forced
to pool pathologies together, e.g. as a mixed FTLD group containing both Tau and
TDP43, however, valuable information may be lost by combining the data in this way.
Furthermore, the pool of available pathologically confirmed data may be even smaller
than it appears, as most of it originates from only a few specialist centres. The same
images are, therefore, likely to be used to inform multiple studies, introducing a degree
of circularity.
Imaging-genetics studies such as the Dominantly Inherited Alzheimer’s Network
(DIAN), or the GENetic Frontotemporal dementia Initiative, have recognised that to
achieve meaningful sample sizes, multiple groups must come together to share valuable
resources. However, the same data sharing model has been lacking in terms of patho-
logically confirmed cases (although the ADNI has now started to acquire pathological
confirmation in a few cases). The work presented in this thesis, based on retrospective
data collected in three European centres over a twenty year period, is an attempt to pool
valuable clinical, imaging and pathology data in relation to multiple different neurode-
generative dementias. A variety of techniques are applied in an attempt to gain insight
into the patterns of atrophy associated with various neurodegenrative pathologies, with
an interest in translating this information back into clinical diagnostics. In particular
this thesis aims to tackle the following problems:
1. To distil characteristic imaging features reported in the literature into a clinically
useful algorithm that can be used to interrogate structural imaging, and to test its
efficacy against pathological diagnosis.
2. To investigate the diagnostic value of visual rating scales widely used in dementia
research, and the feasibility of applying them in a clinical setting.
3. To provide a comprehensive estimate of the global patterns of atrophy associated
with different dementia pathologies, and to look for differential patterns that may
help to guide visual assessment tools and region of interest analysis.
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4. To assess regional differences in brain volume that can help to distinguish be-
tween different dementia pathologies.
5. To determine the additional diagnostic value of combining standard measures of
assessment in an automated multivariate classifier.
6. To build a sustainable platform to allow this valuable dataset to grow, and to
look for opportunities to share this unique and valuable dataset with the wider
dementia research community.
Chapter 4
Materials and Methods
4.1 Introduction
Motivated to expand on the existing literature describing cerebral volume loss in typi-
cally small samples of gold standard pathologically proven neurodegenerative demen-
tias (described in Section 3.4), a multi-centre, international collaboration was formed
between specialist cognitive clinics and research facilities in London, Newcastle and
Amsterdam. The work of this thesis has included: the practical set up of this collab-
oration, which included cleaning and collating the data, building an online database
application to provide access, and analysis of the data. This chapter provides a gen-
eral overview of the data gathering process and the materials and methods common to
the experimental analysis, while the following five chapters describe the analysis and
database. Experiment specific details will be provided in the relevant chapters.
4.2 Study Population
All cases included in this study had a diagnosis of dementia during life and post mortem
confirmation of underlying pathology. Ethical approval for the study was obtained from
the National Research Ethics Service Committee London South East.
4.2.1 Data Collection Sites
The patient data used in this thesis was collected from specialist cognitive clinics and
research facilities in London, Newcastle and Amsterdam. All data was transferred to
the UCL Dementia Research Centre for processing and analysis.
The majority of patients attended cognitive clinic at the National Hospital for Neu-
rology and Neurosurgery in London or attended for research at the UCL Dementia Re-
search Centre. Some of the older cases attended clinic at St Mary’s Hospital in London.
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These cases were examined pathologically at the Queen Square Brain Bank for Neuro-
logical Disorders or the MRC London Neurodegenerative Diseases Brain Bank.
In Newcastle, data was donated by the Dementia and Memory Services at the Campus
for Ageing and Vitality, Newcastle University. Pathological assessment was performed
at the Newcastle Brain Tissue Resource (formerly Newcastle Brain Bank).
In Amsterdam, patients attended clinic at the Alzheimer Centre, VUUniversityMedical
Centre (VUmc). Pathological assessment was performed at the VUmc Department of
Pathology.
The UK based pathological assessment centres are part of the UK Brain Banks Net-
work.
4.2.2 Patient Diagnosis
In total the three centres held data on 511 patients with pathological confirmation
of their diagnosis. Of these, imaging data was available for 319 patients, however,
only 233 of these were found to have 3D T1-weighted imaging of sufficiently high
quality to be used for image analysis. Reasons for exclusion included no 3D scan,
gross patient movement, scanner artefact, low tissue contrast, and evidence of other
non-neurodegenerative pathologies. Patients who did not have a primary diagnosis
of Alzheimer’s disease, DLB or FTLD pathology were also excluded (n=49) from
this analysis. Examples of excluded diagnosis included prion disease cases, vascular
disease in the absence of neurodegenerative pathology, multiple system atrophy, and
Parkinson’s disease.
In total therefore, 184 patients were identified with histopathologically confirmed de-
mentia: 101 had a primary pathology diagnosis of Alzheimers disease, 28 with DLB,
and 55 with FTLD (24 tauopathies, 25 TDP43 proteinopathies, 3 with FUS proteins
and 3 with other designations [2 C9ORF72 mutation carriers, 1 FTLD-MND]). 25 pa-
tients also had confirmation of their genetic status: 3 with APP, 9 PSEN1, 5 C9ORF72,
3MAPT, and 5 GRN. Pathological examination of brain tissue was carried out between
1997 and 2013 according to standard histopathological processes and criteria in use at
the time of assessment. The quality of neuropathological assessment may have varied
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Figure 4.1: Primary pathology groups included in this thesis. The number of images
contributed per centre per pathology are listed on each bar above.
over this time however, older FTLD cases from the London sites, previously diagnosed
as ubiquitin-positive, tau-negative, were reassessed with TDP43 or FUS immunohisto-
chemistry after the discovery that many patients could be further characterised by these
molecular pathologies. Data on secondary pathologies was not reliable in every case,
therefore, only primary pathological diagnosis was considered for analysis.
4.2.3 Healthy Controls
73 cognitively normal control participants were also included for analysis, however,
with the exception of one participant, pathological confirmation was not available.
Control data was contributed exclusively by the UCL Dementia Research Centre from
a database of participants who have previously enrolled in research studies. 23 of
these subjects were enrolled through the MIRIAD study, the data from which is
now available online for research purposes (https://www.ucl.ac.uk/drc/research/miriad-
scan-database) [273].
4.3 Structural MRI
The motivation for this thesis was to explore cerebral volume loss in pathologically
proven dementias. All analysis is, therefore, described in relation to 3D T1-weighted
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imaging, however, any and all available imaging was collected for every subject (in-
cluding T2-weighted, FLAIR, proton density and diffusion weighted imaging) and
could be used for subsequent analysis. As patients and controls were recruited over
a twenty year period into various studies, at multiple centres, available imaging was
highly variable between subjects, with 3D T1-weighted the most common.
4.3.1 Acquisition
All individuals had T1-weighted volumetric MR imaging performed during life. As
the data were collected retrospectively from multiple centres, the images were acquired
on scanners from 3 different manufacturers (Philips, GE, Siemens) using a variety of
different imaging protocols. Magnetic field strength varied between 1.0T (n=20 scans),
1.5T (n=205 scans) and 3T (n=32 scans).
4.3.2 Image Pre-processing
Imaging data were available in Digital Imaging and Communications in Medicine (DI-
COM), NIfTI (Neuroimaging Informatics Technology Initiative) or Analyze (devel-
oped by the Biomedical Imaging Resource at the Mayo Foundation) format. DICOM
images were anonymised and converted to NIfTI format using the MRIcron dcm2nii
tool (http://www.mccauslandcenter.sc.edu/mricro/mricron/). Images were converted to
DICOM using the dcmbuild tool developed by Dr Mark White of the UCL Medical
Physics department. Analyze files were transferred to and from NIfTI using the in-
house midas2nii or nii2midas tool. Image files were converted to all three image for-
mats for various tasks:
• DICOM: For integration with the online image viewer included in the database
web application (Chapter 9).
• NIfTI: For VBM analysis and image registration and segmentation using
NiftyReg and NiftySeg packages (Chapter 7 and Chapter 8).
• Analyze: For INU correction (see below), creating a whole brain mask using the
Brain-MAPS algorithm (Chapter 8), and for visual assessment (see below).
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4.4 Image Analysis
Details of experiment specific analysis are provided in individual chapters. The tech-
niques below are common among chapters and are described here to avoid repeti-
tion.
4.4.1 Intensity Non-Uniformity Correction
All images were corrected for INU prior to experimental analysis. INU correction was
performed using the nonparametric nonuniformity normalisation (N3) method [274].
N3 models the INU as a smooth multiplicative field and uses the image intensity his-
togram to iteratively smooth this field whilst maximising the high frequency component
(which is reduced as a result of the image blurring that occurs with INU). N3 does not
require any a priori knowledge about the underlying anatomy and is one of the most
stable and widely used INU correction methods [143]. This technique is fully auto-
mated.
4.4.2 Visual Assessment
The visual assessment and visual rating experiments described in Chapter 5 and Chap-
ter 6 were carried out using the Medical Information Display and Analysis System
(MIDAS) viewer [275]. The viewer allows simultaneous multiplanar display of 3D
imaging data. Image contrast and zoom can also be adjusted. MIDAS was also used
for initial quality control of the images.
4.4.3 Calculating Total Intracranial Volume
Brain volume studies are confounded by the variability in pre-morbid brain volume. In
studies of neurodegenerative disease, failure to correct for this variability in the statisti-
cal model will diminish its power to accurately detect group differences or correlations
between structural volumes and clinical measures. By including an estimate of TIV,
which remains constant over time as the CSF expands to fill the space created by cere-
bral atrophy, this potential problem can be controlled [167].
Manual outlining is considered the gold standard for estimating TIV, however, this is
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not practical in large studies. Ridgway et al compared several automated methods
against manual outlining [276]. In Chapter 6, Chapter 7 and Chapter 8, TIV was cal-
culated based on Jacobian integration of the forward deformation fields generated by
the unified segmentation model. This method was shown to be highly correlated with
manual outlining (Pearson correlation coefficient=0.97) [276].
4.4.4 Voxel Based Morphometry
In Chapter 6 and Chapter 7, VBM pre-processing and analysis (described in Sec-
tion 2.3.4) was performed using SPM12b (Statistical Parametric Mapping, Version
12b revision 5829; http://www.fil.ion.ucl.ac.uk/spm) and Matlab version R2012a
(7.14.0.739 - 64-bit, uk.mathworks.com/products/matlab/). Due to the variability in
scanning parameters an initial rigid registration to the Montreal Neurological Institute
ICBMI152 template was performed using the Reg-Aladin tool from the NiftyReg pack-
age [277, 278] to provide a better starting point for the SPM pre-processing pipeline.
Each registration was then checked and manually adjusted (if necessary) such that the
anterior commissure was within a few millimetres of the origin and the orientation was
within a few degrees of the ICBMI152 template. Grey matter, white matter and CSF
were obtained using the unified segmentation approach [162], which includes bias cor-
rection (regularisation=0.001, full-width at half-maximum (FWHM)=60mm) and rigid
registration to the ICBMI152 template. A group average tissue probability map was
generated through iterative alignment of the initial segmentations to an evolving esti-
mate of their group-wise average using the DARTEL toolbox [163, 164] and affinely
registered to the ICBMI152 template. The initial grey and white matter segmenta-
tions were then warped using the DARTEL transformations and computed flow fields,
modulated to account for local volume changes, then smoothed with a 6mm FWHM
Gaussian kernel.
4.5. Statistical Analysis 87
4.5 Statistical Analysis
4.5.1 Python Programming Language
All (non-imaging) data processing and statistical analysis methods were implemented
in Python version 2.7.6 (64-bit). Python is a general purpose, open-source program-
ming language widely used by the scientific community and increasingly applied in
neuroscientific research [279–281] (recently a dedicated research topic of an issue of
Frontiers in Neuroinformatics). It has an extensive collection of libraries for scientific
and numeric computing. The main libraries used in this thesis are NumPy (version
1.8.1), SciPy (version 0.14.0), Pandas (version 0.14.1), Matplotlib (version 1.4.3) and
Scikit-Learn 0.15.2.
• NumPy [282] and SciPy [283] are core modules for all mathematical and statis-
tical operations.
• Matplotlib is a plotting library and is used to create all of the graphical figures in
this thesis [284].
• Pandas is a powerful tool for efficient data manipulation and analysis [285].
• Scikit-Learn provides a wide range of state-of-the-art machine learning algo-
rithms [286].
One of the many benefits of using Python is that entire data analysis workflows can
be implemented in a single programming language, allowing them to be more easily
managed and replicated.
4.5.2 VBM Analysis
Individual design matrices are discussed in Chapter 6 and Chapter 7, however, in both
experiments analysis was restricted to voxels contained within an explicit mask. The
mask was created, based on the optimal threshold of the group average image, using
the automatic mask creation strategy in the SPM toolbox [165] (see Figure 4.2).
In both experiments, results are overlaid on a group average template. This was created
by affinely registering the final DARTEL template to the ICBMI152 template and using
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Figure 4.2: VBM mask based on the optimal threshold of the group average image.
Group average image based on affinely registering the final DARTEL tem-
plate to the ICBM152 template and using this transformation and the com-
puted flow fields to warp the bias corrected, whole brain images.
this transformation and the computed flow fields to warp the bias corrected, whole brain
images (see Figure 4.2). In this case no modulation or smoothing was applied. The
resulting images were then averaged to produce an image template representative of
both the study population and the pre-processing steps applied.
4.5.3 Support Vector Machine
Linear SVMs were used for binary classification tasks in Chapter 6 and Chapter 8. In
all experiments split half separation of the data was applied, i.e. half of the data was
used for training and half reserved for testing purposes. The training data was scaled to
zero mean and unit variance over subjects, with the same transformation then applied
to the testing data. SVMs were trained using leave-one-out cross-validation on the
training data and class weighting was applied to adjust for unbalanced groups. The
regularisation parameter, c, was optimised using grid-search in the range 1E-5 to 100,
increasing by an order of magnitude with every iteration.
Chapter 5
An Algorithmic Approach to Image
Assessment
5.1 Introduction
As outlined in Chapter 3, signal change and cerebral atrophy visible on structural MRI
can be used to identify diagnostically relevant imaging features, which provide sup-
port for underlying pathology, and help to narrow the differential diagnosis. Currently,
both radiology expertise and thorough knowledge of the neuroimaging literature are
required in order to identify many of these features. Such expertise is however, un-
available in many clinical settings. By incorporating important imaging characteristics
and guidance from relevant consensus criteria in a structured algorithm, it may be pos-
sible to make this information more accessible to a wider clinical audience and provide
a practical guide to scan assessment in neurodegenerative dementia.
In this chapter, the algorithmic approach to identifying cerebral atrophy, presented in
Section 3.4, is tested by five image analysts using imaging acquired during life in pa-
tients with a pathology-confirmed diagnosis of dementia and healthy control subjects.
The aim of this study was to evaluate the reliability with which analysts could agree on
a predominant pattern of atrophy based on unstructured visual assessment of the im-
age; and as an estimate of the utility of visual assessment for differential diagnosis, to
determine the frequency with which each pathology group was assigned to each branch
of the algorithm.
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5.2 Methods
5.2.1 Study Population
The study population is described in Section 4.2. In brief, it consists of 184 patients
with a diagnosis of dementia during life and pathological confirmation of underlying
pathology: 101 had a primary diagnosis of Alzheimer’s disease, 28 with DLB, and 55
with FTLD (24 tauopathies, 28 TDP-43 proteinopathies, 3 fusopathoies). 23 healthy
control subjects previously described in the MIRIAD study were also included in the
analysis [105, 273].
5.2.2 Structural MRI
Image acquisition is described in Section 4.3. All individuals had 3D T1-weighted
volumetric MR imaging acquired during life.
5.2.3 Image Assessment
Assessment of the complete imaging dataset (n=207) was carried out by two analysts
(Lorna Harper and Dr Giorgio Fumagalli), both with over three years experience in
analysing structural MRI scans in dementia. To provide further independent testing,
three additional experienced analysts (Prof. Nick Fox, Prof. John O’Brien and Dr
Jonathan Schott), each with over fifteen years experience in analysing structural MRI
scans in dementia, also assessed 80 scans (20 Alzheimer’s disease, 20 DLB, 20 FTLD
(1 FUS, 7 Tau, 12 TDP43), 20 controls) drawn at random from the total study pop-
ulation. Images were viewed using the in-house MIDAS image viewer (described in
Section 4.3) [275] and displayed in a random sequence in terms of underlying pathol-
ogy. Analysts were asked to follow the algorithm outlined in Figure 3.14 to identify
the most prominent atrophy pattern on each scan and the single most likely clinical
and pathological diagnoses associated with it. Image assessment was carried out blind
to all clinical and pathological information except age at the time of scanning. The
algorithm choices made by each rater were recorded in individual on-line forms (an
example form is included in Appendix C). LH and GF initially performed visual rating
training, applying the protocol described above to a sample of 20 images (5 controls,
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15 with a clinical diagnosis of dementia) from research participants who attended the
Dementia Research Centre, London. Five images were assessed by consensus, then a
further fifteen independently, which were then reviewed by consensus.
5.2.4 Inter-Rater Reliability
Inter-rater reliability was calculated at the level shown in Figure 5.1, i.e. the decision
between the categories no atrophy, generalised atrophy, predominant frontal, temporal,
hippocampal, parietal or infratentorial atrophy. inter-rater reliability was calculated
using Fleiss’ kappa statistic, which is an extension of Cohen’s kappa used to determine
agreement between more than two analysts. Kappa statistics are defined as
κ =
Pa−Pe
1−Pe
Where Pa is the proportion of observations in agreement between analysts and Pe is
the proportion in agreement due to chance. In terms of Fleiss’ kappa, for every scan
i=1,..,n and every category j=1,..,k, Xi j = the number of analysts that assign category j
to scan i, and Pa is defined as
Pa=
1
mn(m−1)
n
∑
i=1
k
∑
j=1
X2i j−mn
Pe is given by
Pe=
1
(mn)2
k
∑
j=1
(
n
∑
i=1
Xi j
)2
inter-rater reliability was calculated independently for the two analysts that assessed
the complete data set. It was also calculated for the three more experienced analysts
based on the subset of scans, and then for all five analysts based on the common subset.
Finally, agreement between all unique analyst pairs was calculated based on the com-
mon subset to determine the maximum level of agreement achieved using this dataset.
In the case of only two analysts, Fleiss’ kappa is equivalent to Cohen’s kappa. Ninety-
five percent confidence interval (CI)s were also calculated for each kappa value (see
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Figure 5.1: Primary decision level used to assess inter-rater reliability is shown by the
purple boxes with white text.
Appendix D for details).
5.2.5 Frequency Distribution of Pathology Groups
The relative frequency distribution of pathology groups to each branch of the algorithm
was determined individually for each analyst and the results plotted side by side for
comparison. The frequency distribution was determined based on the complete dataset
(207 images, 2 analysts), and the random subset (80 images, 3 analysts).
All data processing and analysis, including IRR, were performed using Python libraries
NumPy 1.8.1, SciPy 0.14.0 and Pandas 0.14.1 on Python 2.7.6 64-bit.
5.3 Results
5.3.1 Demographics
Demographic details of the patients and controls included in the complete group are
shown in Table 5.1. The DLB and control groups were significantly older than the
TDP43 group (p<0.05). The control was also older than the Alzheimer’s disease group
(p<0.05). The average age of the small FUS group was notably younger than the other
groups, however, the sample size of this group was too small to perform meaningful
statistical analysis. There were no significant differences in disease duration at the time
of scanning between any of the pathology groups. The number of years between scan
and death was significantly different between the Alzheimer’s disease and DLB group
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(p<0.05), with the Alzheimer’s disease group living slightly longer on average. Mini-
Mental State Examination (MMSE) within six months of scan date was only available
in 116 of the 184 patients (missing data in 37/101 Alzheimer’s disease, 5/28 DLB,
26/55 FTLD). Based on the data available, there was a significant difference in aver-
age MMSE scores between the Alzheimer’s disease and Tau group (p<0.05), with the
Alzheimer’s disease group more affected. Very similar results were found when us-
ing MMSE closest to scan where data was available for 170 patients. The small FUS
group had a notably higher MMSE score than the other groups. Demographic details
of the patients and controls included in the subset group are shown in Table 5.2. This
data broadly reflects the total study population, although the Alzheimer’s disease group
taken as a whole were slightly more affected in the subset group, while the FTLD-Tau
group were slightly older.
5.3.2 Inter-Rater Reliability
Agreement (i.e. the single region with the greatest atrophy) was reached between the
two analysts assessing the complete dataset in 110 of 207 scans (53%), resulting in a κ
value of 0.43 (95% CI: 0.37-0.50). A specific breakdown of agreement based on algo-
rithm branch and pathology is demonstrated in Table 5.3. Agreement was highest in the
assessment of the control group (17 of 23 scans (74%)), followed by the FTLD-TDP43
group (20 of 28 (71%)) and the small FTLD-FUS group (2 of 3 (67%)). Agreement
was lowest among the DLB group (12 of 28 (43%)).
The three experienced analysts reached complete agreement in 32 of 80 scans (40%)
in the subset. Agreement between at least two them was reached in 70 of 80 scans
(88%). Fleiss’ kappa was calculated as κ=0.44 (95% CI: 0.37-0.50). Table 5.4 presents
the breakdown of this agreement. Agreement (between two experienced analysts) was
reached in 100% of the FTLD-TDP43 cases and the single FTLD-FUS case, 90% of
the DLB and control cases, and 80% of the AD cases. The greatest variability was seen
in the FTLD-Tau group.
Based on the five analysts assessing the 80-scan subset, complete agreement was
reached in 25 of 80 scans (31%). Agreement between four analysts was reached in
40 scans (50%), between three analysts in 59 scans (74%), and between at least two an-
5.3.
R
esults
94
Control AD DLB Tau TDP43 FUS
N 23 101 28 24 28 3
Gender (%M) 52 61 75 58 50 100
Age at scan (yrs) 70 (7) 61 (11) 70 (6) 64 (9) 60 (8) 49 (3)
Disease duration at scan (yrs) - 4 (3) 3 (2) 4 (2) 3 (3) 2 (1)
Time from scan until death (yrs) - 6 (3) 4 (2) 5 (3) 6 (3) 4 (1)
MMSE (x/30) - 17 (6) 20 (5) 23 (5) 22 (7) 28 (2)
Table 5.1: Study population demographics. Results are shown as mean (standard deviation). MMSE is within six months of imaging acquisition
Control AD DLB Tau TDP43 FUS
N 20 20 20 7 12 1
Gender (%M) 55 50 70 43 50 100
Age at scan (yrs) 69 (8) 61 (11) 71 (6) 70 (7) 58 (9) 46 (NA)
Disease duration at scan (yrs) - 5 (4) 3 (3) 3 (2) 3 (4) 2 (NA)
Time from scan until death (yrs) - 4 (2) 3 (2) 5 (3) 6 (3) 5 (NA)
MMSE (x/30) - 14 (6) 20 (5) 25 (2) 21 (8) 26 (NA)
Table 5.2: Subset study population demographics. Results are shown as mean (standard deviation). MMSE is within six months of imaging acquisition
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alysts in 80 scans (100%). Fleiss’ kappa was calculated as κ=0.44 (95% CI: 0.41-0.48).
Table 5.5 presents the breakdown of agreement between at least three analysts. Agree-
ment was higher among the FTLD-TDP43 and control scans (92% and 85% respec-
tively). Agreement was lowest for the Alzheimer’s disease and FTLD-Tau groups (55%
and 57% respectively).
Finally, agreement between all unique analyst pairs was calculated. The highest
calculated kappa value was between two of the experienced analysts, κ=0.57 (95%
CI: 0.46-0.67). Lowest agreement between any two analysts was κ=0.34 (95% CI:
0.23-0.45).
5.3.3 Frequency Evaluation at the Individual User Level
The relative frequency with which each pathology group (in the complete dataset) was
assigned to each of the main branches of the decision algorithm (generalised, frontal,
temporal, hippocampal, parietal, infratentorial - see Figure 5.1) is presented in Fig-
ure 5.2. Asymmetry within the frontal and temporal branches is displayed as hatched
regions.
Both analysts classified more than 50% of the Alzheimer’s disease cases as having ei-
ther predominant parietal or hippocampal atrophy, although analyst 2 selected parietal
lobe atrophy more frequently. Analyst 1 also classified around a fifth of cases with
temporal lobe atrophy, while analyst 2 assigned roughly the same proportion to gener-
alised atrophy. Similarly in the DLB cases, analyst 2 interpreted a generalised atrophy
pattern more often, while analyst 1 distributed the cases more evenly among parietal,
generalised and no atrophy, and a slightly higher proportion with temporal predomi-
nant atrophy. Both analysts classified a high proportion (>50%) of FTLD-Tau cases
with predominant frontal or temporal lobe atrophy, and often with left-sided asymme-
try. Left-sided temporal lobe atrophy was also the dominant finding in patients with
FTLD-TDP43 for both analysts. Both analysts also classified a high proportion of con-
trols as having no atrophy.
Figure 5.3 presents the relative frequency with which each pathology group in the imag-
ing subset was assigned to each of the main branches of the decision algorithm by the
experienced analysts. Based on the imaging subset analysed, analyst 1 classified the
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No Atrophy Frontal Temporal Hippocampal Parietal Infratentorial Generalised Total
Controls 16 (70%) - - - 1 (4%) - - 17 (74%)
AD 5 (7%) 1 (1%) 2 (3%) 14 (19%) 21 (29%) - 3 (4%) 46 (63%)
DLB 3 (11%) - - 2 (7%) 3 (11%) - 4 (14%) 12 (43%)
Tau - 8 (33%) 3 (13%) - 2 (8%) - - 13 (54%)
TDP43 - 3 (11%) 13 (46%) 1 (4%) 1 (4%) - 2 (7%) 20 (71%)
FUS - 1 (33%) - 1 (33%) - - - 2 (67%)
Total 24 (12%) 13 (6%) 18 (9%) 18 (9%) 28 (14%) 0 9 (4%) 110 (53%)
Table 5.3: Algorithm agreement for two analysts assessing the full dataset of scans (n=207). Agreement reached in 110 of 207 scans (53%). Values are
shown as count (group proportion)
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No Atrophy Frontal Temporal Hippocampal Parietal Infratentorial Generalised Total
Controls 17 (85%) - - - - - 1 (5%) 18 (90%)
AD 2 (10%) - 1 (5%) 6 (30%) 3 (15%) - 4 (20%) 16 (80%)
DLB 7 (35%) - - 5 (25%) 2 (10%) - 4 (20%) 18 (90%)
Tau - 2 (29%) 2 (29%) - - - 1 (14%) 5 (71%)
TDP43 3 (25%) 1 (8%) 6 (50%) 1 (8%) - - 1 (8%) 12 (100%)
FUS - - 1 (100%) - - - - 1 (100%)
Total 29 (36%) 3 (4%) 10 (13%) 12 (15%) 5 (6%) - 11 (14%) 70 (88%)
Table 5.4: Algorithm agreement among at least two experienced analysts for subset of scans. Agreement was reached in 70 of 80 scans. Complete
agreement (among three) was reached in 32 scans (40%). Values are shown as count (group proportion)
No Atrophy Frontal Temporal Hippocampal Parietal Infratentorial Generalised Total
Controls 15 (75%) - - - 1 (5%) - 1 (5%) 17 (85%)
AD 1 (5%) - 1 (5%) 3 (15%) 3 (15%) - 3 (15%) 11 (55%)
DLB 5 (25%) - - 2 (10%) 2 (10%) - 6 (30%) 15 (75%)
Tau - 1 (14%) 2 (29%) - 1 (14%) - - 4 (57%)
TDP43 2 (17%) 1 (8%) 6 (50%) 1 (8%) - - 1 (8%) 11 (92%)
FUS - - 1 (100%) - - - - -
Total 23 (29%) 2 (3%) 10 (13%) 6 (8%) 7 (9%) - 11 (14%) 59 (74%)
Table 5.5: Algorithm agreement in three or more analysts in a subset of scans (n=80). Agreement was reached in 59 of 80 scans. Complete agreement
(among five analysts) was reached in 25 scans (31%). Values are shown as count (group proportion)
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Figure 5.2: Pathology groups contained in the complete dataset (n=207) distributed by
most prominent atrophic brain region. Asymmetry within the frontal and
temporal branches is displayed as hatched regions.
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majority of Alzheimer’s disease cases with hippocampal atrophy, while analyst 2 clas-
sified almost the same proportion with generalised atrophy. Analyst 3’s choices were
between the other two, splitting cases evenly between hippocampal and generalised at-
rophy, followed by parietal lobe atrophy. In the DLB group, analysts 1 and 3 classified
the highest proportion of patients with no atrophy and 25% with hippocampal atrophy,
while analyst 3 interpreted a more generalised pattern or no atrophy. In the FTLD-Tau
cases, analyst 1 detected predominantly frontal and temporal atrophy with a high de-
gree of asymmetry, analysts 2 and 3 categorised most cases as generalised or temporal.
In the single FUS case, all analysts agreed on temporal lobe atrophy. All experienced
analysts detected a predominantly left-sided asymmetry in the FTLD-TDP43 group and
no atrophy in the majority of control cases.
5.4 Discussion
In this chapter, the ability to guide visual image assessment of cerebral atrophy, by
synthesising guidance from consensus criteria and findings from the literature in a
structured algorithm, was tested against ante mortem imaging acquired in pathologi-
cally proven cases. The findings suggest that while characteristic patterns of atrophy
associated with each pathology typically predominated at the group level, there is con-
siderable variation at the individual patient level. The consistency among analysts in
identifying the brain region exhibiting the most predominant volume loss was moderate
at best, with even the experienced analysts only reaching complete agreement in 40%
of cases.
Based on the Landis and Koch interpretation of kappa values [287], the confidence in-
tervals calculated for both the complete dataset and the subset of images, consistently
straddled the fair to moderate agreement categories. Point estimates of agreement were
around κ =0.44 for the two analysts assessing the complete dataset, and both the ex-
perts and all analysts assessing the 80-image subset, suggesting a consistent level of
variability when applying this technique. The highest measure of agreement κ =0.57
was between two experts who have worked together for a number of years (NF and JS),
suggesting that training and experience may improve reliability.
Assessment of frequency of distribution at the individual analyst level suggests that in
5.4.
D
iscussion
100
Figure 5.3: Pathology groups contained in the data subset (n=80) distributed by most prominent atrophic brain region. Asymmetry within the frontal
and temporal branches is displayed as hatched regions.
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most cases, the characteristic patterns of atrophy associated with underlying pathology
(as described in the literature) predominate at the group level. The highest proportion
of Alzheimer’s disease cases were consistently associated with disproportionate hip-
pocampal or parietal lobe atrophy [37, 39, 109, 111, 139], while the FTLD pathologies
were associated with (often asymmetric) frontal and temporal lobe atrophy [59, 60].
DLB pathology was less well defined with less hippocampal atrophy than was reported
in the Alzheimer’s disease group [244, 248–251]. In this context, one possible explana-
tion for the relatively low inter-rater reliability is that signature patterns of atrophy often
span lobar regions, and it may not be possible to determine which of these regions is
more severely affected based on visual inspection alone. Additionally, distinct regions
may be equally affected, such as the hippocampi and parietal lobes in some patients
with Alzheimer’s disease. Many of the analysts identified a generalised non-specific
pattern of atrophy within the images; however, it is worth noting that the most experi-
enced analyst was more definitive in his choices and less reliant on this category. This
analyst’s choices better reflected the evidence in the literature, suggesting that perhaps
this technique is more suitable for experienced users.
While this approach provides a useful summary of the existing evidence for charac-
teristic patterns of cerebral atrophy associated with neurodegenerative dementia, and
encourages critical evaluation of imaging in these regions, it has a number of limi-
tations. Primarily, it may not provide enough specific anatomical landmarks for less
experienced users, and it may be overly restrictive in forcing a clear decision between
the most affected lobar regions. Often atrophy occurs in the boundary regions between
lobar division, or equally in distinct brain regions, and it may be difficult to make
a definitive choice. Furthermore, less experienced users may find it difficult to even
identify these boundaries. More experienced analysts are more likely to incorporate
this information into their assessment to reach an appropriate diagnosis, however, this
decision making process is difficult to operationalise in a simple algorithm. The al-
gorithm also attempts to separate hippocampal atrophy from temporal lobe atrophy to
better discriminate between Alzheimer’s disease and FTLD pathologies; however, this
may not be practical in later stages of disease as focal atrophy expands to include sur-
rounding brain regions. The primary limitation of this study protocol is the relatively
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small number of images assessed by the experienced analysts, and in particular the
small sample of FTLD-Tau and FTLD-TDP43 cases included.
5.5 Conclusion
Certain characteristic patterns of cerebral atrophy, with predictive value for the neu-
rodegenerative dementias can be identified from unstructured visual assessment of 3D
T1-weighted imaging. However, both skill and experience are required to identify these
patterns consistently and even in experienced hands, there is relatively poor agreement
in identifying the brain regions most affected by atrophy. A more targeted, quanti-
tative approach, introducing specific anatomical landmarks, may improve diagnostic
accuracy and make this information more accessible to a wider clinical audience. In
the following chapters a hierarchy of such techniques, from visual rating to fully auto-
mated segmentation, are investigated for their ability to fill this requirement.
Chapter 6
Evaluation of Visual Rating Scales
6.1 Introduction
Visual scan assessment remains the primary method for extracting diagnostically use-
ful information in clinical settings. However, as demonstrated in the previous chap-
ter, without operational guidelines to identify, report or interpret patterns of atrophy
with diagnostic value in dementia much potentially relevant information may be under-
utilised. Visual rating scales, specifically designed to assess general and focal cerebral
atrophy in patients with cognitive impairment (reviewed in Harper et al [120]), may
provide such a framework, allowing for the reliable identification and interpretation of
imaging findings of value in the differential diagnosis of dementia. Furthermore, since
visual rating scales are both quick and easy to apply, and can be performed on routinely
acquired images, they offer an inexpensive means of extracting this information, ideally
suited for implementation into clinical practice, and may make it easier for clinicians
without neuroradiology expertise to extract diagnostically useful information.
Several visual rating scales have been developed specifically to rate brain regions vul-
nerable to atrophy in a range of different dementias. While some have been used ex-
tensively in both research and in clinical settings, most notably the Scheltens medial
temporal lobe scale [129], many have only been evaluated in small single centre stud-
ies. Few studies have attempted to directly compare or to combine the diagnostic value
of individual scales, fewer still in a large multi-centre setting to determine the real
world generalisability and robustness of such findings, and to our knowledge, no study
has exclusively assessed their diagnostic utility when applied to scans acquired from
individuals with pathologically confirmed dementias.
In this chapter, using structural MR scans from healthy individuals and a large sample
of patients with a histopathological diagnosis of dementia, the aim was to: (1) eval-
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uate the reliability of six different visual rating scales and the time taken to perform
these ratings; (2) explore the relationship between each visual rating scale and pattern
of grey matter volume loss; (3) compare the performance of rating scales to expert
scan assessment in predicting underlying pathology; and (4) determine if a machine
learning (support vector) approach, based on all visual rating scale scores, can improve
prediction accuracy.
6.2 Methods
6.2.1 Study Population
The study population is described in Section 4.2. In brief, it consists of 184 patients
with a diagnosis of dementia during life and pathological confirmation of underlying
pathology: 101 had a primary diagnosis of Alzheimer’s disease, 28 with DLB, and 55
with FTLD (24 tauopathies, 28 TDP43 proteinopathies, 3 fusopathoies). 73 cognitively
normal control subjects were also included in the analysis.
6.2.2 Structural MRI
Image acquisition is described in Section 4.3. All individuals had 3D T1-weighted
volumetric MR imaging acquired during life.
6.2.3 Visual Rating of Cerebral Atrophy
Visual rating of the complete imaging dataset of all patients and controls (n=257) was
performed, blind to all clinical and pathological information, by two trained raters (Dr
Giorgio Fumagalli and Lorna Harper). Three regions were rated based on existing
scales previously described in the literature: the five-point anterior temporal (AT) scale
by Kipps/Davies et al [125, 126]; the five-point medial temporal lobe atrophy (MTA)
scale by Scheltens et al [129] currently recommended in the research guidelines for the
diagnosis of Alzheimers disease [138]; and the four-point posterior atrophy (PA) scale
by Koedam et al [139]. To provide additional, more fine-grained assessment of anterior
atrophy, an adapted and simplified version of a visual rating scale originally devised by
Davies et al [145] was used, as described by Fumagalli et al [288]. In brief, three
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regions orbito-frontal (OF), anterior cingulate (AC) and fronto insula (FI) previously
shown to have potential for differential diagnosis [127, 145, 209] were selected. To
improve usability, each scale was simplified to a 4-point scale, and reference images
were devised. To improve consistency, slice selection was specified, with the OF and
AC regions both rated on the first anterior slice where the corpus callosum becomes
visible, and the fronto-insula rated over three slices, starting on the first anterior slice
where the anterior cingulate becomes visible and moving posteriorly. Images were
rated in native space, in keeping with standard clinical reads. To aid rating consistency,
reference images for each rating scale were provided to the raters (see Appendix E).
Separate scores were recorded for regions in left and right hemispheres.
To provide independent validation of the results from the two primary raters, two vi-
sual rating experts (Frederik Barkhof and Philip Scheltens) also assessed 80 scans (20
Alzheimers disease, 20 DLB, 20 FTLD, 20 controls) drawn at random from the total
study population. GF also re-rated this subset population. The time taken by each rater
to apply the visual rating protocol to each image was automatically recorded to estimate
the feasibility of implementing such a protocol in clinical practice.
6.2.4 Expert Diagnosis
Six clinical dementia experts (FB, NF, JO, PS, JS, GF), each provided what they
thought was the most likely pathology diagnosis for the above-mentioned subset study
population (n=80) based on independent, unstructured visual assessment of each MR
image. Experts were blinded to all clinical and pathological information except the
persons age at the time of scanning. Images were displayed in a random sequence in
terms of underlying pathology.
6.2.5 Voxel Based Morphometry
VBM was used to explore the relationship between each rating scale and its associ-
ated pattern of grey matter volume loss. VBM pre-processing is described in detail
in Section 2.3.4 and Section 4.4.4. In brief, images were segmented into grey matter,
white matter and CSF, spatially normalised using DARTEL, and smoothed (full-width
half-maximum 6mm).
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Figure 6.1: Flowchart demonstrating how the visual assessment data (visual ratings and
expert diagnosis) was generated and combined for further analysis.
6.2.6 Statistical Analysis
Figure 6.1 illustrates how the visual assessment data (visual ratings and expert diagno-
sis) was generated and combined for further analysis.
Inter-rater reliability of each rating scale was determined using the intraclass correlation
coefficient (ICC). As described by Shrout and Fleiss [289] there are several forms of
ICC, with the appropriate form determined by the underlying statistical model and the
intended application of the reliability results. In this study a two-way random, absolute,
single-measures ICC (ICC(2,1)) was used to estimate the reliability of each scale when
applied by a single rater. ICC(2,1) was calculated separately for the subset group (n=80)
based on three raters (FB, GF, PS), and the total study population (n=257) based on two
raters (GF, LH). Average measures ICCs (ICC(2,k)) were also calculated to estimate the
improvement in reliability of each scale when based on average scores from multiple
raters.
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Partial correlation of grey matter volume with mean visual rating scores (based on the
mean scores from four raters (FB, GF, LH, PS) in the subset population and two raters
(GF, LH) in the remainder of the total population) was assessed by applying the general
linear model at the level of each voxel using all images (n=257). Left and right hemi-
sphere scores were averaged for each scale such that grey matter volume was modelled
as a function of the six rating scales (OF, AC, AT, FI, MTA, PA) and adjusted for age,
gender, and TIV by including these variables as covariates in the model (equation given
in Figure 6.2). Six additional models were also created to investigate simple correlation
of each individual scale with grey matter volume, also adjusted for age gender and TIV
(equations given in Figure 6.4). A mask was created, based on the optimal threshold
of the group average image, using the automatic mask creation strategy in the SPM
toolbox [165]. Correction for multiple comparisons was made by using random field
theory to control the family-wise error rate at a significance level of 0.05.
Expert rater diagnosis was assessed for each binary disease group comparison and
reported in terms of sensitivity, specificity, and balanced accuracy (0.5*(sensitiv-
ity+specificity)). The ability of each visual rating scale (averaging left and right scores)
to predict pathology was similarly assessed, with the addition of the area under the
receiver-operator characteristic curve (AUC). support vector classifier (SVC) accuracy
was also determined using balanced accuracy and AUC. Confidence intervals were cal-
culated using the Hanley-McNeil approach evaluated in Newcombe et al [290]. Data
processing and analysis was performed using Python libraries NumPy 1.8.1, SciPy
0.14.0 and Pandas 0.14.1 on Python 2.7.6 64-bit.
Linear SVC were used to predict pathology diagnosis based on mean visual rating
scores calculated for the entire study population. Using mean left and right sided scores
from each of the six visual rating scales resulted in 6 features in total. Twelve SVC clas-
sifiers were used to assess each binary comparison: e.g. the prediction of Alzheimers
disease pathology from the control group; Alzheimers disease from DLB; Alzheimers
disease from FTLD; and Alzheimers disease from DLB+FTLD, etc. Features were
corrected for age at the time of scanning. Split-half separation was used to divide the
data for each classifier into training and testing sets. The training data was scaled to
zero mean and unit variance over subjects, with the same transformation then applied
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to the testing data. SVCs were trained using leave-one-out cross-validation and class
weighting was applied to adjust for unbalanced groups. The regularisation parameter,
C, was optimised using grid-search in the range 1E-5 to 100, increasing by an order of
magnitude each time. The SVC was implemented using the squared-hinge loss func-
tion and L2 regularisation. Classification accuracy is presented as balanced accuracy
and AUC values. Feature weighting for each classifier is discussed as an indication of
each scales contribution to group separation [291]. SVC processing and analysis was
performed using the Python libraries SciPy 0.14.0 and Scikit-Learn 0.15.2 [286] on
Python 2.7.6 64-bit.
6.3 Results
6.3.1 Demographics
Demographic details of the patients and control subjects are shown in Table 6.1. The
subjects were well matched for gender, disease duration and TIV. The DLB subjects
were significantly older (p<0.001), with less time between scan until death (p<0.05)
than the Alzheimers disease and FTLD patients. MMSE within six months of scan
date was only available in 116 of the 184 patients (missing data in 37/101 Alzheimers
disease, 5/28 DLB, 26/55 FTLD). Based on the data available, MMSE was significantly
higher in the FTLD than the Alzheimers disease group (p<0.001). Very similar results
were found when using MMSE closest to scan (n=170/184).
6.3.2 Expert Diagnoses Based on Unstructured Visual Scan
Assessment
The mean sensitivity, specificity and balanced accuracy of the six expert diagnosis
based on standard, unstructured assessments of the images are shown in Table 6.2.
Balanced accuracy was high (~90%) for distinguishing Alzheimers disease and FTLD
from controls, and ~70% for DLB vs controls. For the more clinically relevant head-
to-head disease comparisons balanced accuracy was on the order of 70-80%. Balanced
accuracy for the multiple disease group comparisons was ~60-70%, with specificities
of 69-86%, but sensitivities were more variable, ranging from 34-67%.
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Control AD DLB FTLD
Demographics
N 73 101 28 55
Gender (%M)A 52 61 75 56
Age at scan (yrs) 67 (8) 61 (11) 70 (6) 61 (9)
Disease duration at scan (yrs) - 4 (3) 3 (2) 3 (3)
Time from scan until death (yrs) - 6 (3) 4 (2) 5 (3)
MMSE (x/30) - 18 (6) 20 (5) 23 (6)
TIV (mls) 1501 (159) 1479 (150) 1550 (148) 1498 (149)
Mean visual rating scores
Orbito-frontal 0.9 (0.5) 1.6 (0.8) 1.5 (0.7) 2.3 (0.8)
Anterior cingulate 1.0 (0.5) 1.3 (0.7) 1.3 (0.5) 1.9 (0.8)
Fronto-insula 1.2 (0.5) 1.7 (0.6) 1.6 (0.5) 2.1 (0.6)
Anterior temporal 0.9 (0.5) 1.5 (0.5) 1.3 (0.4) 2.1 (0.9)
Medial temporal 0.6 (0.6) 1.6 (0.9) 1.1 (0.7) 2.2 (0.9)
Posterior 0.9 (0.7) 1.6 (0.9) 1.2 (0.8) 1.3 (0.6)
Table 6.1: Patient demographics and mean visual rating scores for each group. Data
are reported as mean (standard deviation). TIV=Total intracranial volume,
MMSE=Mini mental state examination.
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Classification Task Sensitivity Specificity
Balanced
Accuracy
AD from Controls 92% (7%) 86% (10%) 89% (6%)
DLB from Controls 49% (20%) 92% (6%) 70% (9%)
FTLD from Controls 82% (5%) 99% (3%) 90% (2%)
AD from DLB 84% (9%) 58% (17%) 71% (6%)
AD from FTLD 81% (12%) 74% (11%) 77% (10%)
FTLD from DLB 89% (8%) 75% (26%) 82% (12%)
AD from DLB+FTLD 67% (13%) 69% (4%) 68% (8%)
DLB from AD+FTLD 34% (16%) 86% (6%) 60% (7%)
FTLD from AD+DLB 59% (9%) 80% (11%) 69% (6%)
Table 6.2: Accuracy of expert diagnosis based on visual assessment of structural imag-
ing (n=80, 20 per group). Experts were blinded to all clinical and pathologi-
cal information except the persons age. Data are presented as mean (standard
deviation) based on six dementia experts. AD=Alzheimers disease DLB=de-
mentia with Lewy bodies, FTLD=frontotemporal lobar degeneration.
6.3.3 Time to Perform Visual Rating
Mean time to perform and record all six visual rating scales based on three raters assess-
ing the subset study population (n=80) was 2.9±1.3 minutes. Individual rater means
and standard deviations were 2.7±1.1, 2.4±1.0, and 3.6±1.6 minutes.
6.3.4 Inter-rater Reliability of Visual Rating Scores
Single measure and average measure ICC results for each scale are shown in Table 6.3.
For the single measures ICC values, representing the reliability of each scale at the
level of the individual rater, the MTA scale performed best overall, with very similar
results achieved with two raters assessing all 257 scans, and three raters scoring 80
scans (ICC(2,1) ≥ 0.79). The PA, OF and FI scales also demonstrated good reliability
(ICC(2,1) ≥ 0.71) based on two raters assessing the total study population; reliability
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was slightly reduced when performed by three raters in the subset population (ICC(2,1)
≥ 0.56). Conversely, the reliability of the AT scale based on the subset population
(ICC(2,1) ≥ 0.72) was greater than the reliability based on the total study population
(ICC(2,1) ≥ 0.57). The reliability of the AC scale was lowest overall (ICC(2,1) range:
0.56-0.62). As expected, the reliability based on mean rater scores was consistently
greater for all scales (ICC(2,k)≥ 0.73). There were no material differences in reliability
based on the larger or smaller population samples for any scale with the exception of
the AT scale which was less reliable in the larger population sample.
6.3.5 Correlation of Grey Matter Volume with Visual Rating
Scores
VBM analysis revealed a negative partial correlation of higher visual rating score with
lower grey matter density for all visual rating scales. As shown in Figure 6.2, the pattern
of regional atrophy correlated very closely with the specific brain region each scale was
designed to assess. This regional specificity was highest for the MTA scale, although
even the smaller frontal regions (OF and AC) showed significant correlation with their
visual rating scales. Only the AT scale demonstrated a small region in the left superior
parietal lobule/supramarginal gyrus where visual rating scores were positively corre-
lated with grey matter volume loss (i.e. the reverse contrast, see Figure 6.3). Since
higher AT scores are associated with FTLD pathologies, and in particular TDP43-C
pathology associated with semantic dementia [235], which are less likely to demon-
strate atrophy in posterior brain regions, this result is pathologically plausible. As ex-
pected, analysis of each scale in separate models (without influence of the other scales)
demonstrated a more diffuse pattern of atrophy, although, the most highly correlated
regions were still confined to, or included, the brain region targeted by each scale (see
Figure 6.4).
6.3.6 Pathology Classification Accuracy for Each Visual Rating
Scale
Mean visual rating scores for each of the scales were significantly different between
pathology groups, primarily driven by higher scores in the FTLD group in all but the
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Figure 6.2: Voxel-based morphometry images demonstrating negative partial correla-
tion between grey matter volume and each visual rating scale, adjusted for
the other scales (modelled by the equation above). In all images statistical
significance of correlations was corrected for multiple comparisons (family
wise error rate p<0.05). The corresponding visual rating scale reference im-
ages are displayed adjacent to each statistical parametric map. R indicates
the right hemisphere.
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Figure 6.3: VBM analysis of the anterior temporal scale demonstrated a small region
in the left superior parietal lobule/supramarginal gyrus where visual rating
scores were positively correlated with grey matter atrophy. Statistical sig-
nificance was corrected for multiple comparisons (family wise error rate
p<0.05)
Figure 6.4: Six simple correlations of each scale with grey matter volume, i.e. y =
βACXAC+βAgeXAge+βGenderXGender+β TIVXTIV +µ+ e, etc. In all images
statistical significance of correlations was corrected for multiple compar-
isons (family wise error rate p<0.05). The corresponding visual rating scale
reference images are displayed adjacent to each statistical parametric map.
R indicates the right hemisphere.
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Single-Measures ICC Average-Measures ICC
Scale 3 raters, n=80 2 raters, n=257 3 raters, n=80 2 raters, n=257
LMTA 0.84 (0.77-0.89) 0.84 (0.79-0.87) 0.94 (0.91-0.96) 0.91 (0.89-0.93)
RMTA 0.79 (0.7-0.86) 0.83 (0.79-0.86) 0.92 (0.88-0.95) 0.91 (0.88-0.93)
LPA 0.57 (0.44-0.69) 0.71 (0.65-0.77) 0.80 (0.7-0.87) 0.83 (0.79-0.87)
RPA 0.65 (0.53-0.75) 0.72 (0.66-0.78) 0.85 (0.77-0.9) 0.84 (0.79-0.87)
LAT 0.78 (0.69-0.85) 0.62 (0.53-0.70) 0.91 (0.87-0.94) 0.77 (0.70-0.82)
RAT 0.72 (0.61-0.8) 0.57 (0.48-0.65) 0.88 (0.83-0.92) 0.73 (0.65-0.79)
LOF 0.6 (0.47-0.71) 0.72 (0.65-0.78) 0.82 (0.73-0.88) 0.84 (0.79-0.88)
ROF 0.62 (0.50-0.73) 0.74 (0.68-0.79) 0.83 (0.75-0.89) 0.85 (0.81-0.88)
LAC 0.56 (0.43-0.68) 0.61 (0.51-0.69) 0.79 (0.7-0.87) 0.76 (0.68-0.82)
RAC 0.57 (0.44-0.69) 0.62 (0.53-0.69) 0.80 (0.7-0.87) 0.76 (0.69-0.82)
LFI 0.56 (0.42-0.68) 0.73 (0.67-0.79) 0.79 (0.69-0.87) 0.85 (0.80-0.88)
RFI 0.58 (0.46-0.7) 0.72 (0.65-0.77) 0.81 (0.71-0.87) 0.84 (0.79-0.87)
Table 6.3: Intraclass correlation coefficient (ICC) measures with confidence intervals. Single-measures ICC provide an estimate of the reliability of the
scale when applied by a single rater. The average-measures ICC is an estimate of the reliability of the scale based on an average score derived
from k raters. Abbreviations: L = left, R = right, MTA = medial temporal lobe atrophy, PA = posterior atrophy, AT = anterior temporal, OF
= orbitofrontal, AC = anterior cingulate, FI = fronto insula.
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PA scale (see Table 6.1). The results for the best performing scale (based on AUC score)
for each group comparison are summarised in Table 6.4. The MTA scale was most ef-
fective at accurately identifying Alzheimers disease pathology from the control group
(AUC=0.82) and the DLB group (AUC=0.67). Higher PA scale scores (≥2.5) added
some value in comparisons with the FTLD group, although sensitivity was low (22%).
The OF scale was useful for distinguishing DLB from the control group (AUC=0.74).
All other scales were below chance at detecting DLB from the other disease groups.
The MTA scale was the most effective at identifying FTLD pathology when com-
pared with the control group (AUC=0.92) and the DLB group (AUC=0.81). Higher
OF scale scores (≥2.5) were specific for FTLD pathology (81%) when compared with
the Alzheimers disease group (AUC=0.73).
6.3.7 Support Vector Classification Accuracy for Pathology Based
on Visual Rating Scores
The results for each group comparison using the mean right/left scores (i.e. six fea-
tures) are summarised in Table 6.4B and illustrated in Figure 6.5 and Figure 6.6. For all
comparisons, the balanced accuracy ranged from 61-93%, and AUC 0.67-0.97. SVC
classification accuracy demonstrated a substantial improvement over the best single
score in all cases, equivalent to or better than expert diagnosis. Based on the feature
weighting applied by each SVC, the MTA, PA and AT scales contributed most to the
separation of the Alzheimers disease group from controls, and the OF and AT scales
contributed most to the separation of the DLB group from controls. With the exception
of the PA scale, most scales contributed equally to the separation of the FTLD group
from the controls. The PA (indicating Alzheimers disease), AT and OF scales (indi-
cating FTLD) contributed most to the separation of the Alzheimers disease and FTLD
groups. All scales except the PA scale contributed similarly to the separation of DLB
and FTLD, weighted towards the FTLD group.
6.4 Discussion
This large, multi-centre study of pathologically proven dementias, demonstrates that
visual rating scales from routinely acquired structural MR images can be reliably rated,
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A. Best Single Visual Rating Scale B. SVC Performance Based on All Scales
Classification Task Scale(Cut-off) Sensitivity Specificity
Balanced
Accuracy AUC Sensitivity Specificity
Balanced
Accuracy
AUC
AD from Controls MTA (1.5) 64% (56-72%) 89% (83-93%) 77% (69-83%) 0.82 (0.74-0.87) 94% (86-97%) 89% (80-94%) 92% (83-96%) 0.95 (0.87-0.98)
AD from DLB MTA (1.5) 64% (52-75%) 68% (56-78%) 66% (54-76%) 0.67 (0.55-0.76) 82% (66-91%) 64% (47-78%) 73% (56-85%) 0.75 (0.58-0.86)
AD from FTLD PA (2.5) 22% (15-30%) 98% (94-99%) 60% (50-69%) 0.60 (0.51-0.69) 88% (77-94%) 56% (42-68%) 72% (59-82%) 0.78 (0.65-0.86)
AD from DLB+FTLD PA (2.5) 22% (17-28%) 86% (81-90%) 54% (47-61%) 0.55 (0.48-0.62) 90% (81-95%) 32% (22-44%) 61% (49-72%) 0.67 (0.55-0.77)
DLB from Controls OF (1.5) 57% (45-69%) 84% (73-90%) 70% (58-80%) 0.74 (0.62-0.83) 64% (46-79%) 92% (77-97%) 78% (60-89%) 0.86 (0.69-0.94)
DLB from AD OF (1.5) 57% (45-68%) 48% (36-59%) 52% (41-64%) 0.49 (0.37-0.60) 86% (70-93%) 66% (49-79%) 76% (59-87%) 0.75 (0.58-0.86)
DLB from FTLD PA (3.0) 7% (3-16%) 100% (95-100%) 54% (41-66%) 0.46 (0.33-0.59) 93% (78-98%) 89% (72-96%) 91% (75-97%) 0.92 (0.76-0.97)
DLB from AD+FTLD AC (1.0) 93% (85-97%) 11% (6-19%) 52% (41-63%) 0.43 (0.32-0.54) 79% (63-88%) 72% (55-83%) 75% (59-86%) 0.80 (0.64-0.89)
FTLD from Controls MTA (1.5) 82% (73-88%) 89% (82-94%) 85% (77-91%) 0.92 (0.85-0.96) 89% (77-95%) 97% (89-99%) 93% (83-97%) 0.97 (0.88-0.99)
FTLD from AD OF (2.5) 55% (45-64%) 81% (73-87%) 68% (59-76%) 0.73 (0.64-0.80) 81% (69-89%) 67% (53-78%) 74% (61-84%) 0.78 (0.65-0.86)
FTLD from DLB MTA (2.0) 69% (56-79%) 82% (70-90%) 76% (63-85%) 0.81 (0.69-0.89) 89% (72-96%) 93% (78-98%) 91% (75-97%) 0.92 (0.76-0.97)
FTLD from AD+DLB AT (2.0) 64% (55-71%) 63% (54-71%) 63% (55-71%) 0.67 (0.58-0.74) 85% (74-92%) 62% (49-73%) 73% (61-83%) 0.78 (0.66-0.87)
Table 6.4: A. Performance of visual rating scale that most accurately predicts pathology for each binary group comparison. The optimal cutoff points
should be interpreted as: < cutoff=normal,≥ cutoff=abnormal. Sensitivity and specificity values are selected based on the maximum balanced
accuracy score. B. Support vector classifier (SVC) performance based on mean left/right scores for each of the six visual rating scales. All
values in parts A and B are presented with 95% confidence intervals in brackets. AD=Alzheimers disease DLB=dementia with Lewy bodies,
FTLD=frontotemporal lobar degeneration.
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Figure 6.5: Receiver operator characteristic (ROC) plots of support vector classifier
(SVC) performance for prediction of A. Alzheimers disease (AD), B. de-
mentia with Lewy bodies (DLB) and C. frontotemporal lobar degeneration
(FTLD) pathologies. Area under the curve (AUC) values with 95% confi-
dence intervals are displayed for each classifier.
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Figure 6.6: Distance plots of support vector classifier (SVC) performance for prediction
of dementia pathologies. The points are plotted based on their distance from
the separating hyperplane (represented by the dotted line y=0). Area under
the curve (AUC) values with 95% confidence intervals are displayed for each
classifier.
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and are highly correlated with cerebral atrophy in brain regions vulnerable to dementia
pathology. Although their contribution to differential diagnosis is somewhat limited
when used in isolation, when the scores from all scales are combined in an automated
support vector classifier it is possible to achieve diagnostic accuracy equivalent to, and
in some cases better than, unstructured scan evaluation performed by expert raters. The
rating scales in question are quick and easy to learn and can be applied, in total, in less
than three minutes. Taken together, these results suggests that visual rating scales offer
clinicians without neuroradiology expertise a means of extracting diagnostically useful
information in a time-efficient and inexpensive way, that is ideally suited for integration
into routine clinical practice.
The first aim of this study was to directly compare the inter-rater reliability of visual
rating scales designed to assess cerebral atrophy in regions particularly vulnerable to
the effects of dementia pathology. Although reliability is typically reported in the orig-
inal concept study of each visual rating scale, and occasionally in follow-up studies,
a lack of standardisation in the use and reporting of statistical techniques employed to
calculate this metric make it difficult to make direct comparisons (reviewed in Harper
et al [120]). In this study reliability was investigated using a dataset that is larger and
more representative (through the inclusion of multiple dementia pathologies and real
life scans acquired on multiple different scanners over many years) than is typically
used for this purpose. The MTA scale was consistently highly reliable under all condi-
tions. Of the adapted frontal scales, reliability was higher between the two raters assess-
ing images from the total study population, than in the smaller sample rated by three.
This difference is likely to reflect both the differences in sample sizes, and that the
two raters had more experience with these scales suggesting that training may improve
reliability. The reliability of the AC scale was lower overall, perhaps reflecting the sul-
cal variability in this rostral region, which can make it difficult to consistently identify
the specified region of interest. Of all the scales, the AT scale shows the least linear
distribution of atrophy by scale increment, instead adopting a more step-wise change
from score 1 to 2 and from score 2 to 3. This lack of differentiation between points 0-1
and 3-4 may account for the variability in reliability between rating conditions. The
PA scale, requiring the integration of visual information in three planes in four brain
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regions (parietal lobe, posterior cingulate sulcus, parieto-occipital sulcus, precuneus),
is undoubtedly the most difficult to apply. Despite this, the two raters assessing the to-
tal study population achieved a relatively high degree of reliability, although there was
more variability among the three raters based on the smaller dataset. The consistently
high reliability of the average measures ICC (based on mean scale scores averaged
over raters) perhaps suggests that where possible, the use of mean scores from two or
more raters may be preferable, when practicable. However, raters should also undergo
training to improve reliability and reduce personal biases. Comprehensive documented
instructions may also help to reduce any additional bias from applying multiple rating
scales simultaneously.
Using voxel based morphometry, each of the scales was found to be remarkably well
correlated with the anatomical regions of interest they were designed to assess, illus-
trating their regional specificity. This was particularly true for the MTA scale, which
was highly associated with hippocampal volume loss, but even the more complex PA
scale was well correlated with the posterior pattern of atrophy it was designed to de-
tect. Focal atrophy in the small frontal regions assessed by the OF scale, and to a lesser
extent the AC scale (right side only), was also significantly correlated with their asso-
ciated visual rating scores. Whilst previous studies have investigated the relationship
between rating scales and brain volumes in the region of interest [145, 292], these re-
sults using an unbiased technique provide independent validation that each of the scales
is indeed performing as predicted. The concordance can also be considered as evidence
that voxel-based morphometry (as implemented in SPM12b) is performing well in this
challenging, heterogeneous dataset.
While several studies have estimated the classification accuracy of rating scales in the
diagnosis of various dementias [111, 126, 127, 129, 136, 139, 145, 209, 250, 292]
(reviewed in Harper et al [120]), very few have used histopathological diagnosis as
the gold standard [111, 136, 250], and to our knowledge no study has performed this
analysis in such a large, clinically realistic cohort comprising as wide a range of di-
verse pathologies, and made comparisons with expert scan assessment. There were
significant differences in scores between the three canonical pathologies for all visual
rating scales. Post-hoc tests revealed significant differences between the control group
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and each of the pathology groups (p<0.05 with the exception of the AC and PA scale
for DLB), reflecting the vulnerability in these regions to dementia pathologies, inde-
pendent of the affects of ageing. Significant differences in the adapted frontal scales
between the disease groups were driven by the FTLD group (p<0.001), while the MTA
scale demonstrated independent significant differences between each pathology group
(p<0.001).
As previous studies have shown, the MTA and PA scales were the most useful for pre-
dicting Alzheimers disease pathology [111, 129, 139, 250]. We report a lower MTA
sensitivity than has been reported in previous studies [129, 250], perhaps due to the rel-
atively young age of this cohort, and the typically higher proportion of non-amnestic,
atypical presentations that may be present in younger onset Alzheimers disease [67].
Slightly higher PA score cut-off points (≥2.5), than those reported in previous stud-
ies (≥2 [111, 139]), provided optimal separation of Alzheimers disease from FTLD,
however, sensitivity for Alzheimers disease pathology (22%) was compromised at the
expense of higher specificity (98%), and overall accuracy was slightly lower than pre-
viously reported (AUC=0.60 versus 0.66 in [111]. The MTA scale achieved the high-
est levels of accuracy when distinguishing FTLD pathology from either the control
group (AUC=0.92) or the DLB pathology group (AUC=0.81). In agreement with pre-
vious work by Hornberger et al in a much smaller cohort [209], higher OF scale scores
(≥2.5) were best for predicting FTLD from Alzheimers disease (AUC=0.73). The AT
scale was the most useful for identifying FTLD pathologies from a pooled group of
other dementia pathologies (Alzheimers disease + DLB). The OF scale was reasonably
accurate (AUC=0.74) at distinguishing DLB pathology from the control group images.
To our knowledge this is a novel application of this scale not previously explored in
other studies, but echoes findings in earlier work [293], which found marked and dis-
proportionate frontal atrophy on CT images from autopsy confirmed DLB.
Whilst these results suggest that no single atrophy rating scale can accurately distin-
guish the common forms of dementia from one another, by combining all scores in an
automated classifier it is possible to achieve diagnostic accuracy equivalent to, and in
some cases better than, unstructured scan evaluation performed by dementia experts.
Furthermore, accuracy of classification based on visual rating is also consistent with
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the reported accuracies from a previous study using grey matter volume to distinguish
between pathologically confirmed Alzheimers disease and FTLD cases [222]. Given
the ease and accuracy of applying these ratings this approach provides a potentially
valuable way for non experts to extract valuable diagnostic information from routine
scans.
Whilst there is considerable interest in using molecular biomarker techniques to aid in
the differential diagnosis, particularly of Alzheimers disease [294], it is notable that
the classification accuracy report is comparable to the accuracy of the CSF A1-42 level
as recently reported in a large sample by Ewers et al (balanced accuracy: Alzheimers
disease from DLB = 64%, Alzheimers disease from FTLD = 81%) [295]. Although
these tests are identifying different aspects of the disease process, and noting that only
the primary post-mortem diagnosis excluding co-pathology was used, each tests con-
tribution to an accurate differential diagnosis is similar. Continued optimisation of the
classifier through the inclusion of more data is likely to improve performance beyond
what can be achieved with simple dichotomisation of an individual scale. Recent work
by Ferreira et al [137], and previously by Barkhof et al [136] to include age specific
cut-offs into visual rating scales could more easily be incorporated into an automated
classifier (see also Coupé et al [296]; Koikkalainen et al [297]) without the require-
ment to update manual protocols and retrain raters. While the required level of data
to achieve such classifiers is unlikely to be available within any single centre, pooling
imaging and pathology data between centres and making them accessible online to pre-
dict pathology from rating scores could provide a communal resource that is useful for
both research purposes and as a diagnostic aid in clinic.
This study has a number of strengths including the large overall sample size, use of
multiple scales, post-mortem confirmation of diagnosis, real life acquisition of scans,
and comparisons based on blind assessment, i.e. without the benefit of clinical in-
formation which in practice is likely to improve diagnostic performance. Limitations
include the imbalance in the pathology groups, in particularly the relatively low number
of DLB cases included. Furthermore, disproportionate representation of young-onset
Alzheimers disease cases in this sample may make the results less generalizable to the
average clinical population. To obtain sample sizes sufficient for these analyses, FTLD
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was treated as a single diagnostic group rather than as a collection of different patholo-
gies. Control subjects were not pathologically confirmed, therefore, pre-symptomatic
pathology cannot be ruled out in this group, which would result in an underestima-
tion of specificity. However, this does not affect the more clinically relevant between-
pathology group comparisons. Whilst the sample size is very large in the context of
pathologically confirmed dementias, larger numbers in all groups would improve sta-
tistical certainty, particularly in the SVC experiments where it is necessary to split the
data into training and testing sets. Greater power could also allow for more fine-grained
analysis of subtypes of the canonical dementias, and for an investigation of the role of
mixed or multiple pathologies. In terms of expert scan assessment, classification per-
formance was based on a subset of the total study population and assumed to represent
assessment of the entire dataset. Visual assessment was also performed in native space
to better reflect clinical practice, however, reorientation to standard space would allow
for greater anatomical consistency between scans and may potentially improve inter-
rater reliability and diagnostic accuracy. Variation in image slice thickness could also
prevent optimal slice selection for visual rating, however, the use of 3D rather than 2D
images, as is used in this study (with typical voxels sizes of less than 2mm) should
avoid such issues. Finally, it will be of considerable interest to see if similar results
can be obtained by training individuals without prior experience of scan rating to apply
these rating scales.
6.5 Conclusions
In summary, this study demonstrates the utility of visual rating scales to provide di-
agnostically useful information, which when considered in the context of a detailed
clinical examination may help to improve the accuracy of clinical diagnosis for the de-
generative dementias. Visual rating offers a simple and reliable framework to capitalise
on the structural imaging already acquired in most patients at no extra cost. Until more
advanced image analysis techniques are adapted for use in clinical practice, the incor-
poration of visual rating scales (certainly when combined with an automated classifier)
offers a quick, simple, reliable means of extracting valuable diagnostic information
from structural brain imaging.
Chapter 7
Distinct Patterns of Atrophy in
Pathologically ConfirmedDementias
7.1 Introduction
Voxel based morphometry (described in Section 2.3.4) can be used to provide a com-
prehensive assessment of differences in grey matter volume between predefined groups.
It has been used extensively in the study of neurodegenerative dementia, however, the
vast majority of studies have explored differences between clinical syndromes, or in-
vestigated correlation between grey matter volume and cognition. Very few studies
have looked for distinctive patterns of atrophy in pathologically proven cases.
Figure 7.1 summarises the published VBM studies to date based on imaging acquired in
pathologically or genetically confirmed dementias. Only 35 studies were found in total
after an extensive search of the PubMed database. While around half of these studies
provide some assessment of differences in grey matter atrophy between pathologically
confirmed dementias and healthy control subjects, this was rarely the focus of the study.
Instead, groups are almost always further classified by clinical syndrome to look for
distinct imaging signatures associated with cognitive profiles (e.g. aphasia, corticobasal
syndrome etc.) [214, 216, 218, 220, 232, 245, 265], and post-hoc analysis of these
findings in relation to molecular pathology may not be representative of the group as
a whole. Of the studies that were designed to investigate specific patterns of atrophy
associated with molecular pathology, more than half are based on group sizes of ≤10,
and all but two with < 15 [229, 298]. Even fewer studies have been carried out to look
directly for differential patterns of atrophy between molecular pathology groups [221,
222, 229, 247, 298], although some additional information can be inferred from studies
based on genetic mutation carriers [110, 254, 299].
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Detecting consistent patterns of atrophy in larger samples of pathologically proven de-
mentias may provide opportunities to identify regional atrophy not previously consid-
ered, and improve diagnostic accuracy at the individual patient level. Regional differ-
ences could be used to guide visual image assessment or inform more advanced region
of interest analysis using manual or automated segmentation tools. While overlapping
patterns of atrophy between pathologies is likely, additional or more severe involve-
ment of particular regions may increase the probability of one pathology over another,
and could be used for earlier detection and tracking of disease.
The aim of this chapter, using imaging data from a large sample of pathologically
proven dementias, was to investigate consistent patterns of atrophy that differentiate
the primary neurodegenerative pathology groups (Alzheimer’s disease, DLB, FTLD-
tauopathies, FTLD-TDP43 proteinopathies), from healthy control subjects, and criti-
cally, from one another. At the time of writing, this is thought to be the first study to
include as many molecular pathology groups in the analysis, with larger group sizes
than has previously been available, using the most recent and advanced SPM software.
A single model is also used to describe the entire dataset in an attempt to reproduce the
complexity of the diagnostic challenge often faced in clinic.
7.2 Methods
7.2.1 Study Population
The analysis in this chapter included 181 patients with a diagnosis of dementia dur-
ing life and post-mortem confirmation of underlying pathology, and 73 healthy control
subjects previously described in Chapter 4. Three patients diagnosed with FUSopathies
were excluded from the analysis as there was insufficient data to investigate this pathol-
ogy group.
To allow for more fine grained analysis of dementia subtypes the AD group was subdi-
vided into early-onset (73 early-onset Alzheimer’s disease (EOAD)) (age at onset <65
years) and late-onset (28 Late-onset Alzheimer’s disease (LOAD)) cases. The popula-
tion also consisted of 28 DLB cases, 24 FTLD-tauopathy cases and 28 FTLD-TDP43
proteinopathy cases.
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Figure 7.1: Sample sizes of VBM studies using pathologically or genetically confirmed
cases. The graph represents the combined total for all pathology confirmed
cases included in the study. * indicates between disease comparisons with
pathologically (as opposed to genetically confirmed) cases. Mean number of
cases across all studies is shown by the dotted line. The study described in
this chapter is represented by the dotted bar.
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7.2.2 Structural MRI
Image acquisition is described in Section 4.3. All individuals had T1-weighted volu-
metric MR imaging performed during life.
7.2.3 Voxel Based Morphometry
VBM pre-processing is described in detail in Section 2.3.4 and Section 4.4.4. In brief,
images were segmented into grey matter, white matter and CSF, spatially normalised
using DARTEL, and smoothed (full-width half-maximum 6mm).
7.2.4 Statistical Analysis
Regional differences in grey matter volume between groups was assessed by applying
the general linear model at the level of each voxel using all images (n=254). Grey
matter volume was modelled as a function of group and adjusted for age, gender and
total intracranial volume by including these variables as covariates in the model. As a
retrospective, multicentre study it was not possible to define variables to account for the
full extent of scanner and acquisition parameter differences, however, the main source
of variability in image quality is likely to be magnetic field strength. Covariates were
therefore, also included to account for these differences. Group differences were cal-
culated using one-tailed t-tests (in both directions) between group parameter estimates
for each primary group and sub-group comparison.
As described in Section 4.5.2, a mask was created based on the optimal threshold of
the group average image, using the automatic mask creation strategy in the SPM tool-
box [165]. Unless otherwise stated, correction for multiple comparisons was made
using random field theory to control the family-wise error rate at a significance level of
0.001.
In addition to the thresholded statistical parametric maps, differences in grey matter
volume between groups that did not reach statistical significance are presented on ef-
fect size maps to provide more information about the patterns of cerebral atrophy asso-
ciated with each pathology group. Effect size maps for each comparison were created
by calculating the difference between the estimated beta parameters for each group,
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normalised to the control group.
7.3 Results
7.3.1 Demographics
Demographic details of the patients and control subjects are shown in Table 7.1. There
were no significant differences between the groups in terms of gender, disease dura-
tion and total intracranial volume. The EOAD and TDP43 groups were significantly
younger than the other groups (p<0.05). MMSE within six months of scan date was
only available in 116 of the 184 patients (missing data in 37/101 Alzheimers disease,
5/28 DLB, 26/55 FTLD). Based on the data available, the EOAD had the lowest mean
MMSE, significantly lower than the tau group (p<0.05). Very similar results were found
when using MMSE closest to scan (n=170/184).
7.3.2 Comparison of Disease Groups with Healthy Controls
The effect size maps highlight the fact that all neurodegenerative dementia pathologies
cause global loss of brain tissue, with a reduction in volume demonstrated in almost
all brain regions when compared with healthy control subjects. As demonstrated in
Figure 7.2 and Figure 7.3, these effects extend well beyond those regions that reach
statistical significance.
In the SPM images (see Figure 7.2), the Alzheimer’s disease group taken as a whole
(n=101) demonstrated significant (FWE p<0.001) and extensive volume loss compared
to the healthy control group, predominantly affecting temporoparietal regions, with re-
gions also affected in the frontal and occipital lobes, and the striatum. These changes
were mostly driven by the larger EOAD group (n=73), which demonstrated an almost
identical pattern of loss (FWE p<0.001). Conversely, the LOAD group (n=28) demon-
strated a much more focal atrophy pattern in the medial temporal lobes, centred around
the hippocampus (FWE p<0.001) (see Figure 7.2).
Although the effect size map demonstrated a broadly similar pattern of volume loss in
DLB to the Alzheimer’s disease (see Figure 7.3), these effects were less pronounced
and are shown on a reduced scale. The statistical maps also demonstrated a much more
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NC EOAD LOAD DLB Tau TDP43
N 73 73 28 28 24 28
Gender (%M) 52 59 68 75 58 50
Age (yrs) 67 (8) 56 (8) 75 (6) 70 (6) 64 (9) 60 (8)
Disease duration (yrs) - 4 (3) 3 (3) 3 (2) 4 (2) 3 (3)
Date of death (yrs) - 5 (3) 6 (3) 4 (2) 5 (3) 6 (3)
MMSE (x/30) - 17 (6) 19 (5) 20 (5) 23 (5) 22 (7)
TIV (mls) 1501 (159) 1478 (158) 1482 (132) 1550 (148) 1500 (149) 1474 (151)
Table 7.1: Study population demographics. Results are shown as mean (standard deviation). MMSE is within six months of imaging acquisition
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Figure 7.2: Effect size maps are shown on the left, with statistical parametric maps on the right. SPMs are corrected for multiple comparisons using
random field theory to control the family-wise error rate at a significance level of 0.001. The crosshairs represent the global maximum
difference. The top row represents the AD group taken as a whole (EOAD+LOAD).
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Figure 7.3: Effect size maps are shown on the left, with statistical parametric maps on the right. Additional SPM slices are presented for the more subtle
DLB vs control group comparison. SPMs are corrected for multiple comparisons using random field theory to control the family-wise error
rate at a significance level of 0.001. The crosshairs represent the global maximum difference.
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subtle pattern of grey matter volume loss than the Alzheimer’s disease group, affect-
ing the thalamus, the amygdala, and regions around the fusiform gyrus and posterior
cingulate sulcus, with relative sparing of the hippocampus (see Figure 7.3).
The FTLD pathology groups demonstrated the most marked differences in brain
volume, and the respective effect size maps are shown on a larger scale than the
Alzheimer’s disease and DLB groups (see Figure 7.3). In both the FTLD-Tau and
FTLD-TDP43 groups, significant volume loss was demonstrated in frontal and tempo-
ral lobe regions (FWE p<0.001), however, volume loss in the FTLD-Tau group was
more marked in anterior and superior frontal lobe regions, with extension into the an-
terior temporal lobes, while there was greater extension into the temporal lobes in the
FTLD-TDP43 group. Both groups demonstrated subtle asymmetry with the left hemi-
sphere slightly more affected than the right.
7.3.3 Comparison of AD with DLB
There were very few significant differences detected between the Alzheimer’s disease
and the DLB groups (see Figure 7.4). The Alzheimer’s disease group demonstrated
greater tissue loss in some very small regions in the parietal lobe and around the poste-
rior cingulate that survived multiple comparisons correction (p<0.05 FWE). The DLB
group showed greater volume loss in small regions around the pre- and post-central
gyri, however, they did not survive correction for multiple comparisons. The effect
size map also highlights the pre- and post-central gyri as being more affected in DLB,
with some additional regions in the occipital lobe and the cerebellum. All other brain
regions were more severely affected in patients with DLB pathology.
7.3.4 Comparison of AD with FTLD Pathologies
The FTLD-Tau group had significantly less grey matter volume in frontal lobe regions
than the Alzheimer’s disease group (p<0.001 FWE) (see Figure 7.6). In particular,
grey matter volume was reduced in orbitofrontal regions, the anterior cingulate and the
insula, with the left hemisphere slightly more affected than the right. The reverse con-
trast only demonstrated a very small region in the right parietal lobe where volume loss
was greater in the Alzheimer’s disease group than the FTLD group (p<0.05 FWE). The
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Figure 7.4: The top row demonstrates the regions where volume loss in AD was sig-
nificantly greater than in DLB. The middle row is the effect size map, with
regions in blue more affected in the DLB group, and regions in red more
affected in the AD group. The bottom row demonstrates the regions where
volume loss was significantly greater in DLB. UNC=uncorrected for multi-
ple comparisons.
effect size map, however, demonstrated a clear anterior-posterior separation between
affected areas, with bilateral frontal atrophy in the FTLD-Tau group, and bilateral pari-
etal atrophy in the Alzheimer’s disease group (see Figure 7.6).
There was significant grey matter volume loss in left inferior frontal regions and the
anterior temporal lobe (p<0.001 FWE) in the FTLD-TDP43 group when compared
with the Alzheimer’s disease group (see Figure 7.6). The Alzheimer’s disease group
had greater volume loss in the parietal lobe and around the posterior cingulate sulcus
and the parieto-occipital sulcus, but these regions did not survive correction for multiple
comparisons. The effect size map shows an anterior-posterior separation of volume loss
between the Alzheimer’s disease and FTLD-TDP43 group, however, this is less well
defined than the previous comparison of Alzheimer’s disease with FTLD-Tau, with
volume loss in the FTLD-TDP43 group extending further back into posterior temporal
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lobe regions. Temporal lobe atrophy was also slightly asymmetric, affecting the left
hemisphere more than the right (see Figure 7.6).
7.3.5 Comparison of DLB with FTLD Pathologies
In comparison with the DLB group the FTLD-Tau group demonstrated greater grey
matter volume loss in the frontal lobe, with a very similar distribution to the com-
parison of the Alzheimer’s disease group with FTLD-Tau (p<0.001 FWE) (see Fig-
ure 7.7). Likewise, the FTLD-TDP43 group also demonstrated greater volume loss in
the frontal and anterior temporal lobes (p<0.001 FWE), although with some extension
into the right temporal pole, which was not evident in the previous comparison with
the Alzheimer’s disease group (see Figure 7.7). The DLB group demonstrated signif-
icant volume loss in a very small region in the occipital lobe in comparison with the
FTLD-Tau group (p<0.05 FWE), and in a small region of the cerebellum in compari-
son with the FTLD-TDP43 group, however, this did not survive multiple comparisons
correction. In both effect size maps, greater volume loss in the DLB group was largely
confined to the occipital lobe and cerebellum. The lateral aspects of the pre- and post-
central gyri were also involved, although the difference was more pronounced in the
comparison with the FTLD-TDP43 group.
7.3.6 Comparison of Tau with TDP43
There were no statistically significant differences in grey matter volume between the
FTLD-Tau and the FTLD-TDP43 groups that survived multiple comparisons correc-
tion. Uncorrected differences were observed in the frontal lobe, around the anterior
cingulate, representing greater volume loss in the FTLD-Tau group; while the FTLD-
TDP43 group showed greater volume loss in lateral posterior temporal lobe regions
(see Figure 7.5). The effect size map suggests a differential pattern of atrophy with
taupoathies associated with more tissue loss in frontal lobe regions, while the FTLD-
TDP43 demonstrated greater temporal lobe atrophy, extending towards parietal and
occipital lobe regions.
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Figure 7.5: The top row demonstrates the regions where volume loss in AD was sig-
nificantly greater than in DLB. The middle row is the effect size map, with
regions in blue more affected in the DLB group, and regions in red more
affected in the AD group. The bottom row demonstrates the regions where
volume loss was significantly greater in DLB. UNC=uncorrected for multi-
ple comparisons.
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Figure 7.6: Comparison between the FTLD-Tau and the AD group are shown on the left, with the FTLD-TDP43 group and AD on the right. The top
row demonstrates the regions where volume loss in FTLD groups was significantly greater than in AD. The middle row is the effect size
map, with regions in blue more affected in the AD group, and regions in red more affected in the FTLD group. The bottom row demonstrates
the regions where volume loss was significantly greater in AD group than the FTLD groups. UNC=uncorrected for multiple comparisons.
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Figure 7.7: Comparison between the FTLD-Tau and the DLB group are shown on the left, with the FTLD-TDP43 group and DLB on the right. The top
row demonstrates the regions where volume loss in FTLD groups was significantly greater than in the DLB group. The middle row is the
effect size map, with regions in blue more affected in the FTLD group, and regions in red more affected in the DLB group. The bottom row
demonstrates the regions where volume loss was significantly greater in DLB group than the FTLD groups. UNC=uncorrected for multiple
comparisons.
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7.3.7 Comparison of EOAD with LOAD
Although caused by the same underlying pathology, ante mortem differences in grey
matter volume were investigated in early and late onset Alzheimer’s disease. There
were few statistically significant differences between the two groups, however, the
EOAD group demonstrated more tissue loss around the parieto-occipital lobe border
(p<0.001 FWE) (see Figure 7.8). The effect size map demonstrated greater volume
loss in the LOAD group in the hippocampus, the occipital lobe, and a very small region
around the anterior cingulate gyrus. All other regions were more affected in the EOAD
group Figure 7.8).
7.4 Discussion
This VBM study demonstrates patterns of grey matter volume loss associated with
the major neurodegenerative dementia pathologies. By combining data from multiple
centres it was possible to achieve sample sizes sufficient to estimate consistent patterns
of atrophy, not only between patient groups and healthy controls, but also for direct
comparison between patient groups.
Using effect size maps to provide an overview of differences in grey matter atrophy
between groups highlights the fact that, as well as producing distinct focal patterns
of atrophy, neurodegenerative diseases have a more extensive effect on brain tissue.
This often goes unreported when focussing only on statistically significant differences,
which many studies are underpowered to detect. However, in this study it was also pos-
sible to look at statistical differences between disease groups and healthy controls using
a very strict statistical significance threshold, controlling the family-wise error rate at a
significance level of p<0.001. Using these parameters, the Alzheimer’s disease pathol-
ogy group demonstrated an extensive temporoparietal pattern of atrophy, in-keeping
with results from previous studies [260, 298, 300]. To look at these changes in more
detail, the group was separated into early (≤65 years) and late onset cases, with the
LOAD group demonstrating more focal medial temporal lobe atrophy, while the vol-
ume loss in the parietal lobe atrophy appeared to driven primarily by the larger EOAD
group. Only a small region in the parietal lobe remained significant when comparing
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Figure 7.8: The top row demonstrates the regions where volume loss in the LOAD group
was significantly greater than in EOAD group. The middle row is the effect
size map, with regions in blue more affected in the LOAD group, and regions
in red more affected in the EOAD group. The bottom row demonstrates
the regions where volume loss was significantly greater in EOAD group.
UNC=uncorrected for multiple comparisons.
the groups directly; however, the corresponding effect size map emphasised the medial
temporal and parietal separation. As previously suggested in other studies [109, 111,
139], a combination of both medial temporal lobe and parietal lobe atrophy may help
to improve the sensitivity and specificity of the diagnosis of Alzheimer’s disease.
DLB pathology showed less extensive grey matter loss than the other neurodegenra-
tive pathologies included in this study. Using a very strict statistical threshold, deep
grey matter structures such as the thalamus and amygdala, were particularly affected,
with relative sparing of the hippocampus, as reported previously by other studies [250,
251, 301]. Direct comparison of the DLB group with both the Alzheimer’s disease and
FTLD groups using the effect size maps, however, demonstrated relative reduction of
grey matter volume around the pre- and post-central gyri in the DLB group, which has
also been reported in Parkinson’s disease [302] and may reflect more motor involve-
ment in these conditions than in Alzheimer’s disease. Comparison with the FTLD
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groups also highlighted cerebral atrophy in the occipital lobes, which has previously
only been suggested by evidence of hypometabolism using FDG-PET [266].
While there was considerable overlap in the pattern of frontal lobe atrophy between
the FTLD-Tau group and the FTLD-TDP43 group, anterior temporal lobe regions ap-
peared to be more involved in FTLD-TDP43 pathologies, particularly in the left hemi-
sphere, while FTLD-Tau pathologies affected more anterior-superior frontal lobe re-
gions. These results should be interpreted with caution however, as they may have
been driven by disproportionate representation of TDP43-C pathology in the FTLD-
TDP43 group, which usually manifests clinically as semantic dementia, with extensive
left anterior temporal lobe atrophy. Larger sample sizes are required to perform more
fine-grained analysis between the FTLD-Tau and FTLD-TDP43 subtypes.
While this study benefits from an unprecedented large sample size of ante mortem
imaging acquired in patients with pathological confirmation of their diagnosis, and
analysis using the most advanced SPM software, it has a number of limitations. Includ-
ing data from multiple sites increases the sample size and the power to detect statistical
differences between groups, however, it also introduces potential confounds relating to
the different MRI scanners and pulse sequences used to acquire the images. As the
imaging data was acquired over a twenty year period using multiple study protocols,
it was not possible to correct for scanner differences to this level of detail, However,
an attempt was made to correct for magnetic field strength, which is likely to be the
biggest source of variability [303]. Furthermore, although the samples sizes used here
are larger than those previously used in the literature, they are not large enough to allow
detailed analysis of FTLD-Tau and FTLD-TDP43 pathology subtypes. Similarly, sam-
ple sizes were insufficient to stratify groups further by secondary pathology, which may
have an important influence on developing patterns of cerebral volume loss. Finally, as
with many research studies, there may be selection bias in the patients included in this
cohort. Those patients with memory and language led presentations are more likely
to take part in research, including brain donation, than patients with more challenging
behavioural problems. This may affect the representation of pathologies in this cohort
and reduce how well the results generalise to the wider population.
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7.5 Conclusions
By combining data from multiple specialist centres, this is the largest study of its kind
to attempt to provide comprehensive estimates of volume loss in relation to primary
molecular pathology. These patterns of atrophy identified in ante mortem imaging,
provide validity for some of features described in Chapter 3, such as the anterior/pos-
terior gradient separating Alzheimer’s disease and FTLD; the relative sparing of the
hippocampus in DLB vs Alzheimer’s disease; and greater asymmetry in the temporal
lobe region in FTLD-TDP43 cases compared to FTLD-Tau. In addition, previously
unreported findings, such as relatively more atrophy in the pre- and post-central gyri
in DLB compared to Alzheimer’s disease and FTLD, provide new avenues of investi-
gation for imaging features that could be used to help predict underlying neurodegen-
erative pathologies during life and improve the accuracy of clinical diagnosis. Further
investigation of regional differences using multi-label segmentation propagation will
be performed in the next chapter in an attempt to improve the interpretability of these
results.
Chapter 8
Differences in Brain Substructure
Volumes between Dementia
Pathologies
8.1 Introduction
As demonstrated in Chapter 7, the disease processes associated with neurodegenerative
dementia lead to volume loss in almost all brain regions, however, the relative severity
of tissue loss in certain regions often has predictive value for underlying pathology.
While segmenting whole brain images into substructure volumes is anatomically less
specific than the voxel-wise approach used in the previous chapter, the results are more
easily interpretable and easier to operationalise (e.g. the actual volume of the hip-
pocampus vs the extent of significant voxels in the region) to help distinguish between
different neurodegenerative dementias, or to track disease progression. To date, the
whole brain, ventricles and hippocampi have been the most common brain structures
used for this purpose [111, 249, 251, 304–306]. While other brain regions, such as the
thalami [307] and cerebellum [308] have also been investigated, pathological confirma-
tion of underlying pathology is rarely available in these studies and findings are often
reported in terms of clinical syndromes.
Manual delineation remains the gold standard segmentation technique, however, it is
labour intensive, time consuming and largely impractical for application to multiple
brain regions or in large cohort studies. Automated or semi-automated techniques con-
tinue to evolve to help address this issue, and advances in basic computing technology
may eventually make these a viable option in clinical practice. Multi-atlas segmen-
tation propagation and label fusion may be particularly useful for this purpose due
to their high accuracy and ability to segment multiple brain regions simultaneously.
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Such techniques (introduced in Section 2.3.3 and described in more detail below) use
a library of brain atlases (typically T1-weighted images with corresponding segmenta-
tions) together with non-rigid registration to provide a new image with a set of putative
segmentations that can then be combined.
In this chapter, the diagnostic utility of applying this approach to a clinically realistic
dataset of images is evaluated using a state-of-the-art multi-atlas segmentation propa-
gation and label fusion technique, known as multi-STEPS [309]. The images, acquired
during life in a large cohort of pathologically proven dementias, were segmented into
83 brain regions, and the volumes associated with each region incorporated into a SVC
and used to predict underlying pathology. In addition, segmentation was also performed
using a more detailed multi-label (144 region) atlas library to determine if this increase
in detail could improve classification accuracy.
8.2 Methods
8.2.1 Study Population
This study included 181 patients with a diagnosis of dementia during life and post-
mortem confirmation of underlying pathology, and 73 healthy control subjects previ-
ously described in Chapter 4. Three patients diagnosed with FUSopathies were ex-
cluded from the analysis as there was insufficient data to investigate this pathology
group. The population consisted of 101 Alzheimer’s disease cases, 28 DLB cases, 24
FTLD-tauopathy cases and 28 FTLD-TDP43 proteinopathy cases.
8.2.2 Structural MRI
Image acquisition is described in Section 4.3. All individuals had T1-weighted volu-
metric MR imaging performed during life.
8.2.3 Template Libraries
Multi-atlas segmentation propagation relies on a library of brain atlases, which are
used as templates for segmenting new images. In this study three different template
libraries were used, with the first two used to segment brain substructure volumes,
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while the third was used to segment whole brain volumes, which were subsequently
used to create masks for use in the registration process.
The first template library (known as the Hammers’ Atlas) consists of 83 man-
ually segmented regions from 30 healthy volunteers (available from www.brain-
development.org. Copyright Imperial College of Science, Technology and Medicine
2007) [310, 311]. The volunteer cohort from which the templates were derived had
an equal gender distribution, median age was 31 years, ranging from 20 to 54 years.
All scans were acquired on a 1.5T GE scanner using a T1-weighted inversion recov-
ery prepared fast spoiled gradient recall (IR-FSPGR) sequence. A full list of the seg-
mented brain regions is included in Appendix F. Individual segmented regions were
also combined to calculate frontal, temporal, parietal, and occipital lobe, the insula and
cingulate gyri, central brain structures, ventricles and posterior fossa volumes. A list
of the regions contained within each combined region of interest is included in Ap-
pendix F.
The second template library consisted of 144 manually segmented regions from 20
healthy volunteers, scanned as part of the Open Access Series of Imaging Studies (OA-
SIS) project (http://www.oasis-brains.org/) [312]. Cortical regions were segmented ac-
cording to the brainCOLOR protocol (http://braincolor.mindboggle.info/protocols/in-
dex.html), while subcortical regions were segmented according to the Neuromorpho-
metrics protocol (http://neuromorphometrics.org:8080/Seg/). A list of the segmented
brain regions is included in Appendix G. This cohort included 8 males and 12 females,
with an average age of 23.4 years (ranging from 19 to 34 years). Scans were acquired
on a 1.5T Siemens scanner using a T1-weighted magnetization prepared rapid gradient-
echo (MP-RAGE) sequence.
A third whole brain template library was used to create masks used in the registra-
tion and segmentation steps. This library consisted of 839 semi-automated segmenta-
tions (described in Freeborough et al [275]) of baseline time point T1-weighted im-
ages from the ADNI database (www.loni.ucla.edu/ADNI). 682 images were acquired
at 1.5T (200 controls, 338 mild cognitive impairment and 144 Alzheimer’s disease),
while 157 images were acquired at 3T (53 controls, 74 mild cognitive impairment and
30 Alzheimer’s disease). This cohort included 474 males and 365 females, with an
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average age of 75 years. Additional demographic details are presented in Leung et al
[313].
8.2.4 Multi-Label Segmentation Propagation and Label
Fusion
A brief overview of multi-label segmentation propagation is presented before describ-
ing the specifics of the technique used in this study.
Multi-label segmentation propagation and label fusion can be summarised in three
stages:
1. The T1-weighted images included in the template library are independently reg-
istered to the image under study (the target image).
2. The segmentations associated with the library images are propagated to the target
image using the same transformations.
3. The labelled target images are combined (fused) to obtain the final segmentation.
Since some registrations will be more accurate than others, they are typically ranked
according to some global or local image similarity measure, and only a subset of the
most accurate segmentations are fused into the final segmentation. Label fusion is of-
ten based on a voxel level majority voting scheme, however, this method assumes the
manual segmentations represent a ’ground truth’, error-free segmentation, which is un-
likely. To avoid relying on this assumption Leung et al adapted the Simultaneous Truth
and Performance Level Estimation (STAPLE) algorithm [314] for label fusion, devel-
oping a probabilistic approach to iteratively construct a consensus segmentation as an
estimate of the ground truth, whilst simultaneously comparing this to each transformed
atlas as an estimate of image similarity. This technique, known as multiple-atlas propa-
gation and segmentation (MAPS), was found to be highly accurate for segmentation of
the hippocampus. Cardoso et al later adapted this technique to include local, rather than
global, similarity measures (known as Similarity and Truth Estimation for Propagated
Segmentations, or STEPS), which improved the accuracy of hippocampal segmenta-
tion, and was also adapted for use with multi-label atlases (multi-STEPS). Both the
multi-STEPS algorithm and an extension of the MAPS algorithm are used in this study
8.2. Methods 146
and will be described below.
As previously discussed in Section 2.3.3, accurate registration of the images under
study to the atlases in the template library is essential to allow spatial information
to be transferred from one to the other. In this study, using the NiftyReg package
(http://sourceforge.net/projects/niftyreg/), each of the atlas images (n=30 for the Ham-
mers’ atlas, n=20 for the Neuromorphometrics/BrainCOLOR atlas) was affinely regis-
tered (12 DFs) to each target image using a block matching approach [278], and then
non-rigidly aligned using a fast free-form registration algorithm [277]. The manual
segmentations were then propagated using the previously estimated transformations
and resampled using nearest-neighbour interpolation. Label fusion was performed us-
ing the multi-STEPS algorithm described above. Within the STAPLE framework, lo-
cally normalised cross correlation was applied based on local intensity features, using
a Gaussian window, to estimate registration accuracy and rank the atlas images accord-
ingly. A Markov random field model was also incorporated within the framework to
add spatial consistency and smooth the borders between the best local classifiers.
8.2.5 Masking
To improve the accuracy of image registration, whole brain masks were constructed for
each image in the dataset using the Brain-MAPS technique by Leung et al, which is
an extension of the (hippocampal) MAPS technique described above for whole brain
regions. Image similarity is measured based on the global normalised cross correla-
tion between the target image and the template library of 839 semi-automated segmen-
tations (also described above), and used to rank the registrations from best to worst
match after an initial affine registration. Eleven of the best matched atlases (based on
previous optimisation analysis) were selected and registered to the target image using
affine registration and non-rigid registration based on free form deformation. Label
fusion was then performed based on the STAPLE algorithm. The resultant whole brain
segmentations were then filled and dilated by 1mm to create a binary mask for use in
the registration process.
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8.2.6 Quality Control
Quality control based on visual assessment is challenging for such a large number of
segmentations and typically only gross misclassifications will be detected. In an effort
to make this process slightly more robust, summed regional volumes in eight regions
(frontal, temporal, parietal, occipital lobe, ventricles, insula and cingulate gyri, central
brain structures and posterior fossa - see Appendix F) and the right and left hippocampi
were grouped by primary underlying pathology and plotted against TIV, using the ab-
solute deviation from the median, thresholded at 3.5 times the standard deviation, to
highlight outliers. Images highlighted as outliers in any region were then visually in-
spected in greater detail and excluded if necessary.
8.2.7 Statistical Analysis
Linear SVC were used to predict pathology diagnosis based on segmented brain sub-
structure volumes. Three models were constructed from different feature matrices: the
first was based on the 83 segmented volumes in the Hammers’ atlas; the second from
grouping the 83 features into eight summed regional substructure volumes (frontal,
temporal, parietal, occipital lobe, ventricles, insula and cingulate gyri, central brain
structures and posterior fossa); and the third using the 144 regional volumes included in
the Neuromorphometrics/Brain COLOR atlas. Feature matrices were adjusted for age,
gender, TIV and magnetic field strength using a linear model. Fourteen SVCs were
used to assess each binary comparison: e.g. the discrimination of Alzheimer’s dis-
ease pathology from the control group; Alzheimer’s disease from DLB; Alzheimer’s
disease from FTLD-Tau; Alzheimer’s disease from FTLD-TDP43; and Alzheimer’s
disease from DLB+FTLD, etc. Split-half separation was used to divide the data for
each classifier into training and testing sets. The training data was scaled to zero mean
and unit variance over subjects, with the same transformation then applied to the test-
ing data. SVCs were trained using leave-one-out cross-validation on the testing data
and class weighting was applied to adjust for unbalanced groups. The regularisation
parameter, C, was optimised using grid-search in the range 1E-5 to 100, increasing by
an order of magnitude each time. The SVC was implemented using the squared-hinge
loss function and L2 regularisation. Classification accuracy is presented as AUC val-
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ues. Feature weighting for each classifier is discussed as an indication of each volume’s
contribution to group separation [291]. SVC processing and analysis was performed us-
ing the Python libraries SciPy 0.14.0 and Scikit-Learn 0.15.2 [286] on Python 2.7.6
64-bit.
SVC performance is reported in terms of sensitivity, specificity, balanced accuracy
(0.5*(sensitivity+specificity)) and area under the AUC. Confidence intervals were cal-
culated using the Hanley-McNeil approach evaluated in Newcombe et al [290]. Data
processing and analysis was performed using Python libraries NumPy 1.8.1, SciPy
0.14.0 and Pandas 0.14.1 on Python 2.7.6 64-bit.
8.3 Results
8.3.1 Demographics
Demographic details for the patients and controls are shown in Table 8.1. Ten controls
and four Alzheimer’s disease patients were excluded during the quality control pro-
cess (described below). There were no significant differences between the groups in
terms of gender, disease duration and total intracranial volume. The DLB group was
significantly older at the onset of clinical symptoms, and at the time of scanning, than
the Alzheimer’s disease and FTLD-TDP43 groups (p<0.05). The control group was
also significantly older than the Alzheimer’s disease group (p<0.05). Time between
scan and death was significantly longer for the Alzheimer’s disease group compared to
the DLB group (p<0.05). MMSE within six months of scan date was only available
in 112 of the 177 patients included in the analysis (60 Alzheimer’s disease, 23 DLB,
17 FTLD-Tau, 12 FTLD-TDP43). Based on the data available, the Alzheimer’s dis-
ease group had the lowest mean MMSE, significantly lower than the FTLD-tau group
(p<0.05).
8.3.2 Quality Control
A selection of the quality control plots created for the summed regional volumes and
hippocampi are displayed in Figure 8.1, Figure 8.2 and Figure 8.3. Eleven of the 73
controls were highlighted as outliers based on the absolute deviation from the median
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Control AD DLB Tau TDP43
N 63 97 28 24 28
N at 1.0T 0 7 5 1 7
N at 1.5T 46 83 21 21 18
N at 3.0T 17 7 2 2 3
Gender (%M) 49 60 75 58 50
Age at scan (yrs) 66 (8) 61 (12) 70 (6) 63 (8) 60 (8)
Age at onset (yrs) - 57 (12) 67 (6) 60 (9) 57 (9)
Disease duration at scan (yrs) - 3.7 (3.2) 3.0 (2.4) 3.9 (2.1) 3.0 (3.1)
Time until death (yrs) - 5.6 (3.0) 3.5 (2.3) 5.0 (2.9) 5.6 (3.0)
MMSE (x/30) - 17 (6) 20 (5) 23 (5) 21 (7)
TIV (mls) 1463 (130) 1470 (144) 1550 (148) 1504 (148) 1482 (155)
Table 8.1: Study population demographics. Results are shown as mean (standard deviation). MMSE is within six months of imaging acquisition and
was only available for 112 patients (60 AD, 23 DLB, 17 Tau, 12 TDP43).
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in all regions (thresholded at 3.5 times the standard deviation), however, only ten were
excluded from the analysis after visual inspection. Only two of these scans had obvi-
ously bad segmentations due to white matter disease, while a third had an unusual brain
appearance, with a sizeable portion of tissue missing in the fronto-parietal region, with
otherwise normal scan appearance. The other seven scans were excluded for having
implausibly large hippocampal volumes (>4000mm3), although these errors were not
obvious on visual inspection. Four Alzheimer’s disease patients were also excluded
due to white matter lesions affecting segmentation accuracy.
8.3.3 Comparison of Regional Volumes
Both raw regional brain volumes and volumes as a percentage of TIV were investi-
gated for group differences. In terms of the raw volumes there were no significant
volume differences detected between groups in terms of hippocampi, insula and cingu-
late gyri, or posterior fossa. In the frontal and temporal lobes, the FTLD groups and
the Alzheimer’s disease group had significantly smaller volumes than the control group
(p<0.05). The AD group also had significantly smaller volumes than the DLB group
in both the temporal and parietal lobes, and in central structures, and in the occipital
lobe when compared to controls (p<0.05). Ventricular volume was significantly larger
in all disease groups when compared with healthy controls (p<0.05). Raw volumes are
displayed in Table 8.2.
When considered as a percentage of TIV, left hippocampal volumes were significantly
smaller in the patient groups (Alzheimer’s disease, DLB and FTLD-TDP43) than in the
control subjects (p<0.05). There were no significant differences between groups in the
right hippocampi or the FTLD-Tau group. In the frontal lobe, temporal lobe, occip-
ital lobe, ventricles and central structures all disease groups had significantly smaller
volumes than controls (p<0.05). The FTLD-Tau group also had significantly smaller
frontal lobe volumes than the AD group (p<0.05). In the region of the insula and cingu-
late gyri, the FTLD groups had significantly smaller volumes than the control group and
the Alzheimer’s disease group (p<0.05). In the parietal lobe the Alzheimer’s disease
group had significantly smaller volumes than all groups except FTLD-TDP43 (p<0.05).
In the posterior fossa, the Alzheimer’s disease, DLB and FTLD-Tau groups all had sig-
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Figure 8.1: Summed frontal and temporal lobe volumes plotted against TIV. Outliers specific to each plot are marked with red dots. A red cross
indicates an excluded scan - the outlier status of these scans is not plot specific and may have been flagged by quality control in any of the
eight regions. Outliers were detected based on absolute deviation from the median thresholded at 3.5 standard deviations. FUS volumes are
shown for interest only and were not included in the analysis.
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Figure 8.2: Summed right and left hippocampal volumes plotted against TIV. Outliers specific to each plot are marked with red dots. A red cross
indicates an excluded scan - the outlier status of these scans is not plot specific and may have been flagged by quality control in any of the
eight regions. Outliers were detected based on absolute deviation from the median thresholded at 3.5 standard deviations. FUS volumes are
shown for interest only and were not included in the analysis.
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Figure 8.3: Summed parietal and occipital lobe volumes plotted against TIV. Outliers specific to each plot are marked with red dots. A red cross
indicates an excluded scan - the outlier status of these scans is not plot specific and may have been flagged by quality control in any of the
eight regions. Outliers were detected based on absolute deviation from the median thresholded at 3.5 standard deviations. FUS volumes are
shown for interest only and were not included in the analysis.
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nificantly smaller volumes than controls (p<0.05). Volumes as a percentage of TIV are
displayed in Table 8.3.
8.3.4 Diagnostic Accuracy of Support Vector Classifier Using 83
Volumes
The results for each binary SVC, based on the 83 region template atlas, are presented
in Table 8.4 and Table 8.5. Classification accuracy of all primary dementia patholo-
gies was high when compared to the healthy controls, although relatively lower for
FTLD-TDP43 (AUC=0.84) compared to the other groups (AUC≥0.95). In the head
to head disease group comparisons, the SVCs had good accuracy for discriminating
Alzheimer’s disease from both FTLD pathologies, with slightly higher accuracy in the
comparison with FTLD-TDP43 (AUC=0.86) than FTLD-Tau (AUC=0.8). Accuracy
for discriminating DLB from FTLD-Tau was also good (AUC=0.79). The most chal-
lenging comparisons were between Alzheimer’s disease and DLB pathologies, DLB
and FTLD-TDP43 pathologies (AUC=0.66 in both cases), and FTLD-Tau and FTLD-
TDP43 pathologies (AUC=0.58). Discriminating Alzheimer’s disease, DLB or FTLD-
TDP43 from all other dementias was also reasonably good (AUC ≥0.72). Figure 8.5
and Figure 8.6 present the results of SVC performance in terms of distance plots and
receiver-operator curve plots.
8.3.5 Diagnostic Accuracy of Support Vector Classifier Using
Grouped Volumes
The results for each binary SVC based on the volumes of the eight summed regions are
presented in Table 8.5. Classification accuracy was equal to or lower than the 83 feature
analysis in most comparisons, although slight improvements were made in relation to
FTLD comparisons, e.g. FTLD-Tau vs FTLD-TDP43 (AUC=0.58->0.71).
8.3.6 Comparison of Segmentation with a 144 Region Brain
Atlases
The use of a more detailed atlas library (n=144 regions) produced equivalent classifier
performance as the 83 region atlas library in the comparison of disease groups with
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Figure 8.4: ROC plot of SVC performance based on a feature matrix of 144 brain re-
gions. Accuracy is presented as ROC AUC values with 95% confidence
intervals shown in brackets
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Segmented Volumes (mls) Control AD DLB Tau TDP43
Right hippocampus 2.55 (0.32) 2.53 (0.42) 2.58 (0.33) 2.56 (0.38) 2.46 (0.33)
Left hippocampus 2.52 (0.43) 2.36 (0.39) 2.42 (0.34) 2.38 (0.39) 2.31 (0.39)
Frontal Lobe 408 (43.3) 379 (40.8) 400 (46.1) 370 (43.7) 378 (50.4)
Temporal Lobe 239 (20.4) 212 (22.4) 227 (22.7) 218 (25.7) 208 (26.8)
Parietal Lobe 246 (21.6) 237 (25.5) 259 (23.6) 253 (2.49) 247 (30.3)
Occipital Lobe 150 (16.5) 138 (15.4) 145 (14.7) 146 (13.7) 144 (20.4)
Insula & cingulate gyri 69.5 (6.32) 68.4 (7.32) 71.4 (8.50) 67.2 (8.01) 65.8 (8.45)
Central structures 67.3 (7.69) 62.6 (7.61) 66.9 (6.03) 62.9 (5.29) 62.6 (10.1)
Ventricles 24.3 (0.30) 43.7 (12.7) 47.4 (14.4) 44.4 (10.4) 39.1 (11.2)
Posterior Fossa 182 (15.2) 174 (18.4) 180 (19.4) 176 (16.9) 179 (20.9)
Table 8.2: Raw regional volumes for each pathology group presented as mean (standard deviation)
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% of TIV Control AD DLB Tau TDP43
Right hippocampus 0.17% (0.02%) 0.17% (0.02%) 0.17% (0.02%) 0.17% (0.03%) 0.17% (0.01%)
Left hippocampus 0.17% (0.02%) 0.16% (0.02%) 0.16% (0.02%) 0.16% (0.03%) 0.16% (0.01%)
Frontal Lobe 27.9% (2.2%) 25.8% (1.5%) 25.8% (1.5%) 24.6% (1.8%) 25.5% (1.9%)
Temporal Lobe 16.3% (0.7%) 14.4% (0.8%) 14.6% (0.7%) 14.5% (1.1%) 14.1% (1.3%)
Parietal Lob 16.8% (0.6%) 16.2% (1.0%) 16.8% (1.2%) 16.7% (1.0%) 16.6% (1.0%)
Occipital Lobe 10.3% (0.8%) 9.4% (0.5%) 9.4% (0.7%) 9.7% (0.7%) 9.7% (0.7%)
Insula & cingulate gyri 4.8% (0.1%) 4.7% (0.3%) 4.6% (0.3%) 4.5% (0.3%) 4.4% (0.3%)
Central structures 4.6% (0.4%) 4.3% (0.4%) 4.3% (0.4%) 4.2% (0.3%) 4.2% (0.5%)
Ventricles 1.7% (0.2%) 3.0% (0.8%) 3.0% (0.8%) 3.0% (0.6%) 2.6% (0.7%)
Posterior Fossa 12.5% (0.3%) 11.9% (1.0%) 11.6% (1.0%) 11.7% (0.9%) 12.1% (1.0%)
Table 8.3: Regional brain volumes for each pathology group, as a percentage of TIV, presented as mean (standard deviation)
8.3.
R
esults
158
Sensitivity Specificity Balanced Accuracy
AD vs Control 86% (75%-92%) 94% (85%-97%) 90% (79%-95%)
DLB vs Control 93% (78%-98%) 97% (84%-99%) 95% (81%-99%)
Tau vs Control 92% (75%-97%) 97% (83%-99%) 94% (79%-98%)
TDP43 vs Control 79% (61%-89%) 90% (75%-96%) 84% (67%-93%)
AD vs DLB 67% (49%-80%) 71% (54%-84%) 69% (52%-82%)
AD vs Tau 69% (50%-82%) 83% (66%-92%) 76% (58%-87%)
AD vs TDP43 69% (51%-82%) 86% (70%-93%) 77% (60%-88%)
DLB vs Tau 64% (42%-81%) 100% (84%-100%) 82% (60%-93%)
DLB vs TDP43 79% (57%-90%) 64% (43%-81%) 71% (50%-86%)
Tau vs TDP43 100% (84%-100%) 29% (14%-51%) 64% (42%-81%)
AD vs DLB+FTLD 82% (71%-89%) 59% (47%-69%) 70% (58%-79%)
DLB vs AD+FTLD 57% (41%-72%) 83% (68%-91%) 70% (54%-82%)
Tau vs AD+DLB+TDP43 83% (67%-92%) 49% (32%-65%) 66% (48%-80%)
TDP43 vs AD+DLB+Tau 71% (55%-83%) 79% (63%-89%) 75% (59%-86%)
Table 8.4: SVC accuracy based on the 83 brain substructure volumes in the Hammers’ Atlas. 95% confidence intervals are presented in brackets.
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ROC AUC, V=83
(Hammers)
ROC AUC, V=8
(Hammers Grouped)
ROC AUC, V=144
(Neuromorphometrics)
AD vs Control 0.96 (0.87-0.98) 0.93 (0.84-0.97) 0.94 (0.84-0.97)
DLB vs Control 0.96 (0.83-0.99) 0.96 (0.83-0.99) 0.96 (0.83-0.99)
Tau vs Control 0.95 (0.80-0.99) 0.95 (0.80-0.99) 0.94 (0.79-0.99)
TDP43 vs Control 0.84 (0.67-0.93) 0.87 (0.71-0.95) 0.85 (0.69-0.93)
AD vs DLB 0.66 (0.48-0.79) 0.60 (0.43-0.75) 0.65 (0.48-0.79)
AD vs Tau 0.80 (0.62-0.90) 0.70 (0.52-0.83) 0.79 (0.62-0.90)
AD vs TDP43 0.86 (0.70-0.93) 0.70 (0.52-0.82) 0.82 (0.66-0.91)
DLB vs Tau 0.79 (0.57-0.91) 0.74 (0.52-0.88) 0.73 (0.51-0.87)
DLB vs TDP43 0.66 (0.45-0.82) 0.66 (0.45-0.82) 0.69 (0.47-0.84)
Tau vs TDP43 0.58 (0.36-0.76) 0.71 (0.48-0.86) 0.67 (0.45-0.83)
AD vs DLB+FTLD 0.75 (0.64-0.84) 0.63 (0.51-0.73) 0.59 (0.47-0.70)
DLB vs AD+FTLD 0.72 (0.56-0.84) 0.57 (0.41-0.72) 0.64 (0.47-0.77)
Tau vs AD+DLB+TDP43 0.67 (0.50-0.81) 0.72 (0.54-0.84) 0.64 (0.47-0.78)
TDP43 vs AD+DLB+Tau 0.76 (0.60-0.87) 0.63 (0.47-0.77) 0.76 (0.59-0.86)
Table 8.5: SVC accuracy based on the Hammers’ Atlas (83 volumes). Grouped ROC AUC values are calculated based on the 8 (summed) region SVC
(frontal, temporal, parietal, occipital lobe, ventricles, insula and cingulate gyri, central brain structures and posterior fossa). Neuromorpho-
metrics/BrainCOLOR atlas accuracy is based on 144 volumes. The highest classifier accuracy for each binary comparison is in bold. 95%
confidence intervals are presented in brackets. V = volumes.
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Hammers’ Atlas Neuromorphometrics/BrainCOLOR Atlas
AD vs DLB Right Parahippocampal and ambient gyri Right central operculum
Left Middle and inferior temporal gyrus Left superior frontal gyrus medial segment
Left Postcentral gyrus Left Cerebellum Exterior
AD vs Tau Left Superior temporal gyrus - anterior part Right posterior insula
Right Parahippocampal and ambient gyri Right Ventral DC
Left Medial orbital gyrus Left superior frontal gyrus
AD vs TDP43 Right Substantia nigra Left anterior insula
Left Inferior frontal gyrus Right opercular part of the inferior frontal gyrus
Right Inferiolateral remainder of parietal lobe Right cuneus
DLB vs Tau Right Putamen CSF
Left Putamen Left inferior temporal gyrus
Left Pallidum 5th Ventricle
DLB vs TDP43 Left Superior temporal gyrus - posterior part Right supplementary motor cortex
Right Postcentral gyrus 3rd Ventricle
Left Middle and inferior temporal gyrus Right postcentral gyrus
Tau vs TDP43 Left Superior temporal gyrus - posterior part Left posterior insula
Left Middle and inferior temporal gyrus Right anterior cingulate gyrus
Left Anterior temporal lobe - lateral part Right supplementary motor cortex
Table 8.6: The top three highest weighted features for each classification task, and for each atlas library, are listed as an indication of the regions driving
the class separation
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Figure 8.5: Distance plots and ROC plots of SVM performance based on head to head pathology comparisons. Distance plots represent the distance
of each image (represented by 83 segmented brain regions) from the separating hyperplane (marked as 0). Performance of each SVM is
summarized by the area under the curve (AUC) of the receiver operating characteristic, with 95% confidence intervals (CIs).
8.3.
R
esults
162
Figure 8.6: Distance plots and ROC plots of SVM performance based on disease groups versus controls, and a single disease group versus all other
disease groups combined (AO). Distance plots represent the distance of each image (represented by 83 segmented brain regions) from the
separating hyperplane (marked as 0). Performance of each SVM is summarized by the area under the curve (AUC) of the receiver operating
characteristic, with 95% confidence intervals (CIs).
8.4. Discussion 163
healthy controls Table 8.5. Similarly no clear benefits were seen in the head to head
disease group comparisons, although improvements were noted in the comparison of
DLB vs FTLD-TDP43, and FTLD-Tau vs FTLD-TDP43. Results are presented in Fig-
ure 8.4. Table 8.6 provides details of the top three absolute highest weighted features
based on each atlas, to provide an estimate of the regions driving the class separa-
tion.
8.4 Discussion
In this chapter, the ability to identify underlying neurodegenerative pathology from seg-
mented brain volumes was investigated using a multi-atlas segmentation propagation
and fusion technique, and support vector classifiers. Images were segmented into 83
and 144 brain regions respectively using two unique template libraries, these volumes
were than arranged into two independent features matrices and used in SVC analy-
sis. Regardless of the feature set used, excellent separation was achieved between pa-
tients and healthy controls, while only moderate success was achieved when the disease
groups were compared directly. Examination of the feature weights applied in each bi-
nary classifier were not always equivalent between the different template libraries (Ta-
ble 8.6), however, the regions broadly reflected previous reports in the literature, with
weighting of the Alzheimer’s disease and FTLD-Tau classifier particularly influenced
by temporal and frontal regions, while the Alzheimer’s disease and FTLD-TDP43 clas-
sifier was influenced by frontal and parietal regions. Notably, the post central gyrus,
previously shown to be relatively more affected in DLB in the previous chapter, exerted
a reasonably high degree of influence over the Alzheimer’s disease vs DLB and DLB
vs FTLD-TDP43 classifiers.
The 83 region segmentations were also summed according to regional localisation and
assessed for group differences using univariate statistics. Analysis of the raw volumes
revealed some significant differences, primarily between disease groups and controls,
which were in-keeping with previous reports in the literature, and findings from other
studies within this thesis. However, performing the same analysis based on volumes as
a percentage of TIV produced stronger results, highlighting significant differences be-
tween disease groups and healthy controls in almost all regions, as well as some differ-
8.4. Discussion 164
ences between disease groups. In the frontal lobes for instance, while all disease groups
had significantly smaller volumes than controls, significant differences were also de-
tected between the Alzheimer’s disease group and the most affected FTLD-Tau group.
Both FTLD groups also had significantly smaller volumes than the Alzheimer’s disease
and control groups in the region of the insula and cingulate gyri, which are central to
the salience network thought to be disrupted in FTLD. The Alzheimer’s disease group,
comprised primarily of early-onset cases (n=69/97), had significantly smaller parietal
lobe volumes than all but the FTLD-TDP43 group. The DLB group typically demon-
strated the larger volumes in most brain regions compared with the other pathologies,
however, there were notable exceptions in the posterior fossa and occipital lobe regions,
which have previously been implicated in DLB.
In addition to the larger summed brain regions, hippocampal volumes were also in-
cluded in this analysis. While there were significant differences between patient groups
and controls on the left, there were no differences on the right, and overall the con-
trol group demonstrated a relatively small hippocampal volume when compared with
previous reports in the literature. This may be attributable in part to a degree of age
related atrophy in the control group, who were significantly older than the patients
with Alzheimer’s disease. Furthermore, since the control cases are not pathologically
confirmed pre-symptomatic pathology cannot be excluded. As discussed above, and
demonstrated in Figure 8.2, a few implausibly large hippocampal volumes were pro-
duced in the control group and were subsequently excluded from the analysis. It is,
however, possible that even if they were not as large as predicted by the automated seg-
mentation, they may have been on the large end of the spectrum, and excluding them
may have artificially lowered the hippocampal volume range in this group. In terms
of comparisons between the disease groups, the raw volumes broadly reflected what
might be expected from the literature. For instance, given the disproportionate number
of EOAD cases in this cohort, which often have prominent parietal lobe atrophy with
relatively spared hippocampi, the FTLD-TDP43 group, with the inclusion of TDP43-C
pathology (often severely affecting the left anterior temporal lobe), demonstrated the
smallest hippocampal volumes. By comparison, the DLB group had relatively large
hippocampal volumes. However, none of these differences could be detected when
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considered as a percentage of TIV.
While this study is strengthened by the use of state of the art segmentation techniques
and a large, clinically representative imaging dataset of pathologically proven demen-
tias, it has a number of limitations. Primary among these is the difficulty in applying
robust quality control measures to the segmented volumes. The inclusion of multiple
volumes in the segmentation make accurate visual inspection impractical, if not im-
possible, and while an attempt has been made here to partially address this issue, it
is far from robust. In particular, a large number of healthy control subjects were ex-
cluded on the basis of having abnormally large hippocampi, however, the source of this
anomaly could not be identified on visual inspection. An alternative practical solution
implemented alongside sophisticated segmentation techniques, with the opportunity to
adjust or reject poor segmentations, would help to improve the accuracy of the results
and provide greater confidence in their interpretation. One possible approach could be
the use of one-class SVCs, trained on an existing database of quality controlled scans,
which could then be used to assess the quality of new scans prior to segmentation [315].
Quality control issues are potentially amplified in studies of neurodegenerative demen-
tia by the use of template libraries based on young, healthy volunteers, which fail to
represent the often complex patterns of atrophy associated with diseased brains. While
this issue is beginning to be addressed for hippocampal and whole brain segmentations
(see http://cmictig.cs.ucl.ac.uk/niftyweb/), disease specific multi-label atlases are cur-
rently unavailable. It should be noted that quality control issues are not unique to multi-
atlas segmentation propagation and fusion techniques, and may be underestimated in
many brain parcellation techniques. Additional limitations include the imbalance in the
pathology groups, disproportionate representation of young-onset Alzheimers disease
cases, and failure to take into account secondary pathologies when stratifying the dis-
ease groups. As mentioned above, control subjects were not pathologically confirmed,
therefore, pre-symptomatic pathology cannot be ruled out in this group, however, this
does not affect the more clinically relevant between-pathology group comparisons. An-
other potential confounding factor particular to this retrospectively compiled cohort, is
the variability in image acquisition parameters. While volumes were adjusted for mag-
netic field strength, there are several other related factors that could bias these results
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that it was impossible to correct for. Finally, whilst the sample size is very large in
the context of pathologically confirmed dementias, larger numbers in all groups would
improve statistical certainty, particularly in the SVC experiments where it is necessary
to split the data into training and testing sets.
To date this study is thought to be one of only three studies to apply machine learning
algorithms to pathologically proven cases [301, 316], with all three studies achieving
similar levels of classification accuracy. The technique applied by Vemuri et al [301],
based on 91 brain substructure volumes is particularly interesting, and benefits from a
training set of "pure" post mortem confirmed cases (without secondary pathologies),
whilst also going beyond the binary classification tasks carried out in the other two
studies. However, the authors acknowledge they did not have sufficient data to provide
an independent testing set, unlike in this study, relying instead on leave-one-out testing.
Since pathologically confirmed imaging data is such a rare commodity, only a multi-
centre collaborative approach is likely to provide suitable sample sizes to develop these
techniques further.
8.5 Conclusions
In conclusion, this study demonstrates the multiple segmented brain substructure vol-
umes, produced using a fully-automated approach, can discriminate between neurode-
generative pathologies. However, the complexity and computational effort used to ex-
tract these volumes is not balanced by the level of accuracy achieved in this study,
which is comparable with the accuracy achieved using visual rating scales that take,
on average, less than three minutes to apply. Improvements in quality control analysis,
the availability of disease specific brain atlas templates, and more consistent imaging
acquisition have the potential to improve this accuracy. While sharing valuable patho-
logically proven data between centres would help to achieve sufficient sample sizes for
more robust testing.
Chapter 9
Contributions to Open-Science
9.1 Introduction
Open-science is a movement aimed at bringing freedom and transparency to data col-
lection, experimental methodology and analysis in scientific research. The principles of
open-science encompass the reusability of scientific data (open-data), the accessibility
of scientific communication (open-access), and the sharing of scientific tools (open-
research). There is increasing recognition within the scientific community that adopt-
ing the principles of open-science is both ethically responsible, helping to make better
use of finite resources, and necessary, to accelerate the pace of scientific discovery, and
this is reflected by the current requirement for data sharing and data management plans
by many funding bodies.
The benefits of open-data, in particular, are relevant to the study neurodegenerative
dementia, where long pre-clinical periods, variable disease trajectories, and causation
driven by both genetic and environmental factors, complicates data analysis and typ-
ically requires large sample sizes to reliably detect group differences, or measurable
disease modifying effects. Accordingly, the World Dementia Council (described in
Chapter 1) have adopted open-science as one of five priority areas they will champion
to stimulate innovation and development of life enhancing drugs, treatments and care
for people with, or at risk of dementia [317].
In the absence of definitive biomarkers of neurodegenerative disease pathology, the
data at the centre of this thesis is potentially of significant value. Generating a rea-
sonable sample size to accurately stratify primary dementia pathologies by molecular
signature, and examine associated ante mortem clinical data for unique signatures of
disease, required collaboration and data sharing between three specialist centres. Ac-
knowledging the value of this dataset, the work of this thesis extended to the design and
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implementation of a facility to record and share the data between collaborating centres,
with a view to sharing it more widely with the research community beyond the lifetime
of the project. To raise awareness and engage the general public in dementia research,
a citizen science project based on this data was also developed and piloted. Both con-
tributions will be discussed in this chapter. A more detailed discussion of the benefits
of open-data is included in Appendix H.
9.2 Clinico-Pathological Database
As previously described, this study is an international collaboration between special-
ist centres of neurodegeneration in Amsterdam, London and Newcastle. In the first
instance, the priority was to build a web-based system to allow remote access to the
data from each of the three sites. Initially, an external company (Ixico - http://www.ix-
ico.com/) was contracted to provide this system based on an existing clinical trials
management platform, known as Trial Tracker. However, the constraints built into this
system, allowing it to adhere to clinical trials governance, made it inflexible to the
needs of this project. After eighteen months of negotiation, iteration and testing, the
Trial Tracker system was finally abandoned and the decision was taken to build a be-
spoke application to serve the same purpose. The main steps in this process are outlined
below.
9.2.1 Requirements capture
A number of stakeholders across the collaborating centres were consulted to determine
the requirements for a sustainable database system that would be useful beyond the
scope and lifetime of this project. These included clinicians, psychologists, imaging
scientists and pathologists. A governance expert was also consulted to ensure ethical
and responsible sharing of data. Following these initial consultations the data itself
was interrogated to determine if there was sufficient information available to meet the
proposed requirements. Pathological data was interrogated from hard copies of the
post mortem report, while clinical details where primarily extracted from the patient’s
hospital notes. Imaging data was gathered from several sources, and was not always
available in the original DICOM format, therefore, tools to convert between the various
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formats also had to be sourced as part of the requirements capture process (these tools
are described in Chapter 4). As well as data requirements capture, consideration was
also given to the practicalities of data entry through discussion with the data manager
at the Queen Square Brain Bank.
Based on this initial exercise, the following requirements were formalised:
• Ensure all data is completely annonymised when uploaded to the database. This
includes any data flags contained within the imaging headers.
• Ensure the data is secure and the application is protected against common web
attacks.
• Provide role specific user accounts with the opportunity to restrict access to some
data.
• Avoid the use of free text boxes in data entry forms.
• Provide the opportunity to download data in csv format.
• Provide pre-defined database queries to allow the data to be filtered before down-
load or viewing.
• Allow recording of data from multiple clinical time points, e.g. MMSE, imaging.
• Record first clinical symptom with the opportunity to record all other clinical
symptoms.
• Record Alzheimer’s disease pathological staging scores with the flexibility to
include historical staging schemes.
• Record lifestyle factors with implications for dementia, e.g. smoking, hyperten-
sion, diabetes.
• Specifically request data on potentially relevant diagnostic clinical features, e.g.
history of seizures or motor features.
9.2.2 Implementation Using a Python Framework
To enable flexibility and the sustained use beyond the lifetime of this project, the data
sharing system was implemented using the Django open source web application frame-
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work (https://www.djangoproject.com/). The framework is written in Python and en-
courages component reuse based on modular design. It is, therefore, highly scalable
and well suited to a project such as this whose requirements are likely to evolve over
time. Additionally, it provides comprehensive security features and a user authentica-
tion system to simplify user account management, allowing different levels of access
to be set and greater flexibility in how the system can be deployed.
9.2.3 Database Design
To enable database design the data from the London cohort, which constituted over
50% of the available data for this project, was thoroughly interrogated. Relevant data
was organised into tables and the relationships between these tables mapped to impose
a logical structure on the data (see Figure 9.1). A data dictionary was also created to
describe the contents and format of the data stored in each table.
9.2.4 Web-Based Image Viewer
Since the focus of the project is around the imaging data, one of the primary require-
ments was to allow the scans to be viewed online via a web browser without the need
to download the files first. However, few web-based image viewers are available and
those that are typically require a commercial license. The Trial Tracker system has
a license agreement with an external company to supply web-based imaging viewing
capabilities. Since additional license agreements were already in place between Ixico
and UCL, the decision was taken to integrate the new Django based platform with Trial
Tracker to allow access to the viewer. Clinical and pathological data was stored on the
Django system, while imaging data was stored on the Trial Tracker system. Commu-
nication between the two systems was achieved using the Hypertext Transfer Protocol
(HTTP). From the users perspective, only the Django system was seen. Examples of
the web-based forms and viewer are shown in Figure 9.2 and Figure 9.3.
9.2.5 Testing and Deployment
Final deployment of the Django application was to a UCL server already hosting the
Trial Tracker system for clinical trial data management. For this reason, live test-
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Figure 9.1: UML diagram illustrating the relationship between tables in the clinico-
pathological database. Relationships are specified as 0..n: zero to many,
1..n: one to many, 0..1: zero to one. An additional table (Rating) is included
for future applications (described below)
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Figure 9.2: Image viewer associated with the bespoke clinicopathological database application and the patient index page.
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Figure 9.3: Example data entry forms from the bespoke clinicopathological database application.
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ing on this server was not possible. To get round this issue, Amazon Web Services
(http://aws.amazon.com/) was used to set up a server mirroring the operating system
(CentOS) and web server software (Apache) installed on the UCL server. With this
set up the database system was deployed and tested for data entry, site navigation and
data download. After satisfactory testing the system was successfully transferred to the
UCL server.
9.2.6 Future Work
The bespoke web-based database application described here was developed to store the
clinical, imaging and pathology data available from three specialist centres in neurode-
generation. It was built to be flexible and sustainable beyond the lifetime of this project
and provides a good foundation to expand this collaboration to other centres, allowing
this valuable dataset to be shared among the wider scientific community. Several good
open-source NIfTI viewers are also now available, allowing the database application to
be uncoupled from the Trial Tracker system and eliminating the need for an expensive
license agreement. Sophisticated user account management provides the opportunity
to limit access to the data, allowing the system to be developed for other purposes such
as teaching and training. In the first instance, this application would work well to teach
clinicians or researchers to recognise characteristic patterns of atrophy associated with
neurodegenerative dementia. Furthermore, it could also be used to train people to ap-
ply visual rating scales, and could subsequently be used for refresher training or audit
purposes.
9.3 Citizen Science
Citizen science is defined as scientific work undertaken by members of the general
public, often in collaboration with or under the direction of professional scientists and
scientific institutions. It provides opportunities for scientists to engage with the public,
and allows the public to play a unique role in scientific research. Inspired by the suc-
cesses of Cancer Research UK to harness this approach, the Dementia Innovation Unit,
formed as part of the World Dementia Council, have begun to explore similar ideas in
relation to dementia research.
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Parallel to this, the launch of the Join Dementia Research (JDR) Initiative
(https://www.joindementiaresearch.nihr.ac.uk/), which provides a public facing portal
for recruitment into dementia research, has produced a large community of volunteers
(many of them healthy controls) keen to take part in research. This unique community
are potentially well suited to trial proof-of-principle citizen science studies; while these
studies provide a means of keeping the community engaged until they are recruited in
to more conventional research.
Having been seconded to the Dementia Innovation Unit during my PhD, I was asked
to be part of the World Dementia Council’s citizen science steering committee. As an
extension to this work I was asked by the Office of National Director for Dementia
Research, to develop a proof of principle citizen science project for JDR. This became
a collaborative project with Dr Ferran Prados Carrasco (Translational Imaging Group,
UCL). The development of this project, and the learning points that have arisen so far,
are discussed below.
9.3.1 Project Specifications
As a largely untested approach to public engagement/research in the context of demen-
tia, and given the infancy of the JDR initiative, tight constraints were imposed on this
project. The primary constraints are outlined below.
• To develop an online application to engage the healthy control volunteers already
enrolled in JDR. However, affected JDR volunteers should not be excluded from
the project.
• The application should be stand alone, unconnected to the JDR platform, and
unable to extract any of the volunteer data it contains.
• Minimal personal/demographic data should be collected to prevent overburden-
ing volunteers who have already submitted details to JDR.
• The project should be simple but scalable, with an initial focus on raising aware-
ness/engagement, and gauging the response to this type of approach.
• Citizen scientists should actively generate data through participation, rather than
passively donate data as is typical of more conventional research studies.
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• The project should be delivered within two months to coincide with the national
launch of the JDR initiative.
• Given these time constraints, ethics approval must already be in place for the
planned study.
9.3.2 Concept Development
While project ideas were requested from a number of sources, a simple visual image
assessment application was thought to be the most straightforward to produce based on
the constraints outlined above. After seeking advice from Alzheimer’s Research UK
on public engagement, this motivation was strengthened by their observation that the
public often fail to perceive dementia as a brain disease, and rather as a condition that
is "all in the mind". By allowing the public to actually see images of the brain and the
effects of dementia pathology on brain tissue, alongside images from healthy controls,
it was thought this project could help to alter that perception.
Based on the requirement for existing ethics approval, the imaging dataset collated as
part of this thesis, with blanket coverage to use and share it for any research purpose,
was thought to be the most appropriate. However, consultation with local ethics experts
was also sought to clarify this position.
Looking to other citizen science projects for inspiration (particularly cancer research), it
was initially thought that the citizen science task at the centre of the application should
be "gamified" to make it more appealing. However, after discussion with Prof. Chris
Lintott, co-founder of Galaxy Zoo (one of the most successful citizen science projects
to date), and primary investigator for Zooniverse (the world’s largest citizen science
portal with over one million users), this idea was dropped. Prof. Lintott advised that in
his experience, citizen scientists preferred an authentic experience, reflecting a profes-
sional scientist’s view of the data, than an artificial "gamified" environment.
Based on this advise, and building on the work presented in Chapter 6, the concept for
this citizen science project was based on the well established Scheltens’ medial tem-
poral lobe atrophy scale, described in Chapter 2. Citizen scientists would be presented
with images of the medial temporal lobe, and based on reference images for each scale
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point, asked to apply the MTA scale separately to the left and right hemispheres.
From a scientific perspective, and in line with the conclusions from Chapter 6, the
motivation behind this study was to investigate if completely naive raters could reliably
apply the MTA scale. Proving this to be the case, along with the findings presented in
Chapter 6, could help to encourage greater uptake among medical professionals, and
in turn add diagnostic value to the sometimes vague radiology reports generated in the
investigation of cognitive impairment. However, equally motivating in this initial pilot
study was to gauge how the JDR community would respond to this type of approach.
From the point of view of the citizen scientist, it was hoped that this study would
provide greater understanding of the effects of neurodegenerative disease on the brain,
and a rewarding experience of participating in dementia research.
9.3.3 Seeing Dementia
The "Seeing Dementia" project, as it became known, is based on the 80 image subset
(20 Alzheimer’s disease, 20 DLB, 20 FTLD, 20 controls) rated by the visual rating
experts, outlined in Chapter 6, with the expert ratings used here as a gold standard. As
a measure of reliability, citizen scientists will be compared to the expert ratings, and to
each other. Mean citizen scientist ratings will also be used to train and test a SVC and
iteratively determine the number of raters required to achieve maximum classification
accuracy. The data used to generate the optimal classifier performance could then be
used as a training set against which any new data could be tested.
The application was written in PHP based on a PostgreSQL database, with a few addi-
tional features implemented in JavaScript. Dr Ferran Prados Carrasco was the primary
developer in this respect. I developed site content and "look and feel" using HTML and
CSS within the Bootstrap framework, to provide dynamic layout adjustment between
devices (e.g. desktop, tablet, mobile).
In terms of content, both an introductory video and a tutorial video were created using
the Camtasia software (see Figure 9.4). Informative content relating to dementia, MRI
brain imaging, the hippocampi and the medial temporal lobe scale were all generated
to provide users with additional learning opportunities (see Figure 9.5). In terms of
the main application, a single, optimal, medial temporal lobe slice is displayed to the
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user. Sections of the image can be magnified by hovering over it. Five image buttons
are displayed below, representing the medial temporal lobe scores from 0—4 and the
user is asked to select the button that most closely matches the MTL shown in the
main image (see Figure 9.6). If the right medial temporal lobe (MTL) is shown on the
button, the user should score the right hemisphere, and vice versa. To break up the task
users are promoted in 5 stages from PhD student (after 20 ratings) to professor (if all
160 ratings is complete) (see Figure 9.6). With no requirement for citizen scientists to
rate every scan, images are presented at random to provide a more even distribution of
ratings across the 80-image scan subset. In terms of user information, only gender and
age range are requested, however, the user is asked to provide an email address and
password to allow them to log in and out of the application, and start from the scan
where they left off in the previous session (see Figure 9.4). To allow collection of this
information the project was registered with the UCL Data Controller. Application was
also granted by UCL for a project specific web (http://seeingdementia.ucl.ac.uk) and
email address (seeingdementia@ucl.ac.uk). Google Analytics was embedded within
each page to provide additional details about how users interact with the project.
9.3.4 Initial Results
To date, a pilot study of the Seeing Dementia project has been carried out as part of the
iterative design process. A subset of the JDR community registered in the Yorkshire
area were targeted for feedback. Yorkshire was chosen at random from the regional
areas in the UK with the fewest JDR registered studies at that time. The primary find-
ings from this exercise are described below. Accuracy of citizen scientist ratings is not
reported during this development phase.
User Demographics
547 people were registered with JDR within the Yorkshire area. Based on previous ex-
perience, around 10% of registered users who match to a study will participate. Within
four weeks 94 people (17%) had registered with Seeing Dementia, however, only 51
(9%) of those became active users within that time. Figure 9.7 demonstrates the break-
down of users by age range and gender. 80% of registered users and 82% of active users
were female. The majority of users were middle aged. Users within the 70-79 year old
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Figure 9.4: Screen shots of the home page and registration form.
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Figure 9.5: Examples of the informative content included with Seeing Dementia.
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Figure 9.6: Main rating page shown with magnification. Buttons reflecting the MTA
scale points are shown below the main image. After a predefined number of
ratings, the citizen scientist is promoted. The user is given some feedback
on how they compared to the experts based on the percentage of matched
scores.
9.3. Citizen Science 182
Figure 9.7: Seeing Dementia user demographics. The bars reflect the registered users
while the blue line reflects the active users.
bracket were had the lowest proportion of active users to registered users. One female
user declined to disclose her age. Due to limitations of the JDR system it is currently
not possible to automatically determine how accurately this reflects the Yorkshire co-
hort overall. Finally, Google Analytics also revealed that 82% of users accessed the
site via a laptop or desktop computer, which has implications for web design.
Number of Ratings Performed
51 active users scored 4224 medial temporal lobes. Figure 9.8 presents a breakdown
of the number of scores provided by each user by age range. 60% of the users scored
more than half of the 160 medial temporal lobes in 80 images (left and right side rated
separately). One person in each age band completed all ratings, while only a single
user provided less than 20 ratings. On average, users took 17 seconds to score each
MTL.
Feedback and Learning Points
After running the pilot study for four weeks, users were asked to complete a question-
naire about their experiences, 34 people responded. The survey findings and associated
learning points are discussed below:
• Motivations for taking part: Over 50% of survey respondents were motivated
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Figure 9.8: The number of medial temporal lobe ratings performed by the active users
of Seeing Dementia. Within each age range the data is broken down by the
number of ratings performed, e.g. trainees (plain pink bars) have provided
less than 20 scores, professors (blue starred bars) have rated the left and right
MTL in all images.
to take part in Seeing Dementia, and in dementia research more generally, by a
family member developing dementia. Over 20% were motivated out of general
interest and a desire to help. This has potentially important implications for the
inclusion of informative content, as well as the design of future citizen science
studies. Studies such as this one, with a more authentic scientific view of the data
that is popular among the majority of citizen scientists, may be less appealing to
an audience with a personal connection to the subject matter.
• Understanding of the project: Only 65% of respondents felt they fully under-
stood the aims of the project, with 24% undecided, and 11% failed to understand
the motivation. In terms of understanding the task instructions, 62% felt they un-
derstood the task, with 15% undecided, and 23% unable to understand what was
required. Google Analytics revealed a disproportionately low number of views
of the videos (introductory and tutorial) and informative content, suggesting that
in the majority of cases users went straight into the task without instruction. Al-
though there is a help box on the main rating page this is intended as a reminder
and is probably insufficient in terms of instruction. This suggests that the in-
9.3. Citizen Science 184
troduction of a mandatory training session before accessing the main rating task
may be necessary to ensure users are aware of the task requirements.
• Particular issues to be addressed: Based on feedback in the survey, and emails
received while the study was open, there are several usability issues to resolve.
Firstly, the high proportion of people who registered but then failed to contribute
any ratings needs to be addressed. The application was designed not to log peo-
ple in automatically after registering, allowing them time to read the instructional
materials before launching straight into the task. However, this confused many
people and caused them to try and re-register. This was unforeseen and the under-
lying system logic produced unhelpful error messages, adding to the confusion.
It is thought this was the primary reason for the high proportion inactive regis-
tered users. Secondly, the high proportion of users who were unsure or failed to
understand the visual rating task is also a major issue. This response, coupled
with the low number of views of the videos and informative content, suggests
that the task itself should be presented more clearly, with the a compulsory train-
ing exercise built in. Survey respondents also suggested a preference for written
guidance over video. Additional improvements to usability could be made by
providing the user more regular feedback about how their performance compares
to visual rating experts, or providing more information about the brain displayed
in the image, and the disease processes affecting it. Despite the issues identi-
fied, the survey revealed 70% of respondents would recommend the project to a
friend.
9.3.5 Future Work
This initial pilot study has revealed several interesting findings and opportunities to
improve the Seeing Dementia application, as well as insights into the citizen science
approach more generally. Many of the assumptions made during the design process
appear to be incorrect, such as proportionately more tablet users than desktop users,
and a preference for video rather than text instructions. This perhaps reflects a misun-
derstanding of an older user demographic, however, in such a small sample size it is
uncertain how well these findings generalise to the national level. The issues outlined
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above will all be addressed and retested using the newly formed JDR lay champions
group.
More fundamental questions exist about the opportunities and motivations for applying
citizen science in dementia research more generally. While the benefits in terms of rais-
ing awareness of dementia are unquestionable, it is difficult to strike a balance between
answering valid scientific questions and providing a satisfying user experience. Tradi-
tional models of citizen science may be unsuitable in this context, not least because the
user base is potentially older, with a personal connection to the subject matter. Prof.
Lintott of Zooniverse advised that citizen science based on medical applications tends
to be less popular as users often feel burdened by a responsibility to pick the "right"
answer, which diminishes the user experience. Conversely "gamification" of the task is
very expensive and without enough evidence to guarantee a successful outcome.
Continuing advances in mobile technologies may provide additional opportunities to
better adapt citizen science to dementia research, allowing users to generate novel data
to quantify the effect of dementia on the activities of daily life, or engaging patients
and carers to build up an evidence base for low risk therapeutic interventions, e.g.
approaches to music therapy.
9.4 Conclusions
Patients and carers take time out of their heavily burdened lives to provide researchers
with data in the hope and belief that they will use this data responsibly to help, if
not them, then future generations like them. It is vital to treat each donation with the
respect it deserves and maximise the value that can be derived from it by accurately
recording and sharing the data with the wider scientific community. In an attempt to
meet these responsibilities, a scalable online data repository has been developed to
store and share the data associated with the unique cohort collected in relation to this
thesis. Further development of the application into a teaching and training tool may
enhance the value that can be derived from this data that was generously donated by
patients and their families. Citizen science offers unique opportunities to engage the
general public in scientific research and raise awareness about dementia. The rapid
development of mobile technologies has the potential to stimulate interest in this type
9.4. Conclusions 186
of approach. However, designing a successful citizen science project is non-trivial and
much work is needed to better understand how this can be achieved.
Chapter 10
Thesis Conclusions
10.1 Introduction
Distinguishing between the different neurodegenerative causes of dementia is vitally
important to allow affected individuals and their families to access appropriate treat-
ment, support and care. This requirement will become even more pressing as/when
disease-modifying therapies become available. While pathological biomarkers con-
tinue to evolve, in many cases their complexity and cost prohibit them from being
implemented in routine clinical practice. It is therefore, important to optimising the use
of the diagnostic techniques that are more widely available, such as MRI. The purpose
of this thesis was to establish a large ante mortem imaging dataset of pathologically
proven dementias, and use it to investigate ways of maximising the diagnostic value
that can be extracted from routine T1-weighted imaging.
10.2 Can evidence from the literature be reliably
identified through visual inspection at the
individual patient level?
While there is a large evidence base detailing patterns of cerebral volume loss asso-
ciated with specific neurodegenerative dementias, this information is rarely applied in
routine clinical assessment. The potential reasons for this are threefold: 1) the majority
of research studies are based on imaging acquired in clinically diagnosed dementias
and may not accurately reflect underlying pathology; 2) findings are typically reported
at the group level and their reliability is uncertain at the individual patient level; 3) radi-
ology expertise and thorough knowledge of the neuroimaging literature are required in
order to identify many of these features. To address the last of these issues, a structured
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algorithm was developed to help guide visual assessment based on key findings in the
literature. This was then tested by 5 analysts in an attempt to address the first two is-
sues. The findings from this study suggest that while characteristic patterns of atrophy
associated with each pathology predominated at the group level, there was variation at
the individual patient level. Consistency among analysts in identifying the predomi-
nant pattern of atrophy was at best fair, although there was some indication that this
might improve with experience. While this algorithm provides a useful summary of
the current evidence in the literature relating to patterns of cerebral atrophy in neurode-
generative dementia, and may encourage more detailed reporting of findings among
radiology experts, it is largely unsuitable for clinicians with less radiology experience.
A more targeted, quantitative approach, introducing specific anatomical landmarks, is
needed to make this information more accessible to a wider clinical audience.
10.3 Do visual rating scales improve diagnostic
accuracy?
The results of this study suggest that visual rating scales, specifically designed to assess
focal cerebral atrophy in patients with cognitive impairment, provide a useful frame-
work for the reliable identification and interpretation of imaging findings in the differ-
ential diagnosis of dementia. The six previously described rating scales tested in this
study (covering frontal, temporal and parietal lobe regions) were shown to be fairly re-
liable, but with some evidence, both in this study and in other published work, that this
could be improved with training and experience. The average time taken to apply all six
scales was less than three minutes. Using voxel based morphometry, the scores from
each scale were shown to be highly correlated with the specific brain regions they were
designed to assess, providing support for their regional specificity. Using the scales in-
dividually limited their diagnostic accuracy, however, combining these in an automated
support vector classifier provided diagnostic accuracy equivalent to, and in some cases
better than, unstructured visual assessment by dementia experts. These results suggests
that visual rating scales offer clinicians without neuroradiology expertise a means of
extracting diagnostically useful information in a time-efficient and inexpensive way,
that is well suited for integration into routine clinical practice.
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10.4 What patterns of regional atrophy are associated
with specific molecular pathologies?
Using the latest voxel based morphometry software, this study provides a comprehen-
sive assessment of differences in grey matter volume between pathologically distinct
groups. At the time of writing this is thought to be the largest study of its kind in
terms of sample size. Using effect size maps, this analysis demonstrates that neurode-
generative diseases have a global effect on brain tissue, a fact that is often overlooked
when focussing only on statistically significant differences, which many studies are un-
derpowered to detect. Unusually for studies of this kind, it was also possible to look
at statistical differences between some groups using a very strict significance thresh-
old, which convincingly confirmed previous reports in the literature imaging literature,
including differences in cerebral atrophy between early and late onset Alzheimer’s dis-
ease, and the relative lack of cerebral atrophy associated with DLB compared to other
neurodegenerative pathologies. The patterns of atrophy identified here in ante mortem
imaging of pathologically proven cases, could be used to inform future visual assess-
ment studies, or automated region of interest analysis.
10.5 How accurate is fully automated diagnosis of
dementia pathology?
Reliable fully automated image assessment could offer significant advantages in many
isolated or under resourced healthcare settings. Using a combination of state of the
art segmentation algorithms and support vector classifiers this study investigated the
current diagnostic capabilities of this approach. Although the results of this anal-
ysis demonstrated reasonable diagnostic accuracy, there are several opportunities to
improve on this performance which should be explored. In terms of the multi-atlas
segmentation propagation, a template library more representative of the images under
study may significantly improve segmentation accuracy. Questions also remain over the
optimal level of detail to include in the atlas templates, with these results suggesting a
reduction in classifier performance, both if the regions are larger and more generalised
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or smaller and more fine grained. As previously noted by the Mayo clinic, which are
thought to be the only other group with a comparably large imaging and pathology
dataset, forming larger training and testing sets with more data would also significantly
improve the accuracy of this approach and the reliability of analysis.
10.6 Future Work
The work of this thesis has produced a large imaging dataset of pathologically proven
cases, a means of sharing this data with the wider scientific community, and initial
analysis of the data to investigate opportunities to maximise the use of standard 3D
T1-weighted imaging. There is however, considerable potential to expand the scope of
this work. These opportunities are outlined below:
Pathology: From a practical perspective this study used the primary pathological diag-
nosis from histopathological assessment of brain tissue based on criteria in use at that
time. The investigation of co-pathologies is limited not only by sample size, but also
by potential short comings in historical assessment (compared to modern techniques)
or the level of detail included in older pathology reports. Whilst the work of this thesis
provides a framework to continue to increase the sample size, it would be of consider-
able interest to reclassify the older samples based on modern histopathological stains
and consensus criteria.
Expanding the cohort: The data collated as part of this thesis provides a sizeable
baseline for future study, while the web based data repository provides a framework to
encourage greater collaboration and expansion of this collection to include prospective
collection via clinical services in the sites already involved. This thesis has focused
on T1 volumetric imaging but collection of other sequences and/or modalities could
allow for similar approaches to explore, for example, the detailed pathology of vascular
disease.
Incorporating clinical information: As previously stated, imaging should only be in-
terpreted in the context of detailed clinical assessment. Whilst the clinical information
collected to date is relatively minimal, it would be interesting to see if including this
information in the classifier analysis could improve the utility of automated diagnosis.
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The collection of prospective datasets and the use of age-matched control groups could
help to further these aims.
Visual Rating: As demonstrated in Chapter 6, visual rating scales provide a frame-
work for quickly extracting diagnostically useful information form standard structural
imaging. It would be interesting to extend this analysis to investigate the diagnostic ac-
curacy of visual rating scales in naive raters, and the subsequent effects of training. The
online application described in Chapter 9 could also be adapted for use as an online
visual rating training tool, providing initial/refresher training, and certification; with
trainees validated not only against pathological diagnosis but also gold standard ratings
by experts. From a technical perspective, it would also be worth investigating if initial
registration to standard space improved inter-rater reliability. The decision was taken
not to do this for this initial analysis, in an attempt to better match the research protocol
to clinical conditions, however, the retrospective nature of this dataset, acquired over a
twenty year period at multiple different centres, means there is probably far more vari-
ability in this dataset than is typically seen in one clinic. This may negatively influence
both inter-rater reliability and scoring accuracy.
Novel regions of interest: The VBM and volumetric analysis described in Chapter 7
and Chapter 8 identified some potentially new findings of interest, particularly in rela-
tion to the motor areas differentiating DLB and Alzheimer’s disease, and the brainstem
and cerebellum which were neglected in our initial analysis. To what extent drawing
attention to these regions may provide value on an individual patient basis is an inter-
esting topic to explore further.
Technical advances: There are numerous technical advances that could be trialled
such as developing more robust quality control procedures to accompany the multi-
atlas segmentation propagation technique, and moving from binary to multi-level clas-
sifiers to enhance their utility as an automated diagnostic tool. Additionally, investiga-
tion into applying machine learning algorithms at the voxel level may result in a more
efficient analysis pipeline and improvements in classification accuracy. Incorporating
techniques to deal with vascular lesions (such as a non-local lesion filling strategy) prior
to segmentation may also help to improve the accuracy of volumetric analysis. While
efforts were made to exclude images demonstrating gross vascular pathology based on
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visual inspection, smaller lesions may have had some influence of the results presented
in Chapter 7 and Chapter 8.
10.7 Summary
This project has resulted in the development of the largest pathologically proven
dementia-imaging cohort in Europe. Previously under-utilised retrospective data has
been collated and cleaned, allowing this study and future studies to make better use of
this valuable resource. Using a wide range of image analysis techniques, from simple
visual assessment to more complex machine learning, various aspects of the dataset
have been analysed with a view to maximising the diagnostic value of structural imag-
ing routinely acquired in clinical assessment of dementia. A bespoke web application
has also been developed to provide a means of sharing this dataset with the wider scien-
tific community, both as a repository for post mortem imaging data, and as a radiology
teaching resource.
Publications
The publications based on the results of this thesis, or that I have contributed to during
my PhD are listed below.
Peer-Reviewed Journal Articles
• Harper, L., Barkhof, F., Scheltens, P., Schott, J. M. & Fox, N. C. An algorithmic
approach to structural imaging in dementia. J Neurol Neurosurg Psychiatry 85,
692698 (June 2014).
• Slattery, C. F., Beck J. A., Harper, L et al. R47H TREM2 variant increases
risk of typical early-onset Alzheimer’s disease but not of prion or frontotemporal
dementia. Alzheimers & Dementia 2014 Nov;10(6):602-608.e4 (Nov 2014).
• Harper, L., Barkhof, F., Fox, N. C. & Schott, J. M. Using visual rating to diagnose
dementia: a critical evaluation of MRI atrophy scales. Journal of Neurology,
Neurosurgery, and Psychiatry (Apr. 2015).
• Harper, L., Fumagalli, G. G., Barkhof, F., Scheltens, P., O’Brien, J., Burton, E.
J., Bouwman, F. H., Rohrer, J. D., Fox, N. C., Ridgway, G. R., & Schott, J. M.
Maximising the value of structural MRI in the diagnosis of dementia: evaluation
of visual rating scales in pathology proven cases. Brain (Accepted Dec 2015)
Book Chapters
• Harper, L. & Rossor, M. N. OECD Health Policy Studies Addressing Dementia:
The OECD Response, Chapter 4 - The role of big data in driving global cooper-
ation and innovation in dementia. OECD Publishing, (Mar 2015)
Conference Papers
• Harper, L., Burton, E. J., Bouwman, F. H., Barkhof, F., Scheltens, P., O’Brien,
J., Fox, N. C., Ridgway, G. R., & Schott, J. M. Classification of pathology using
brain substructure volumes in post mortem confirmed dementias. Alzheimer’s &
10.7. Summary 194
Dementia: The Journal of the Alzheimer’s Association , Volume 10 , Issue 4 ,
P32 - P33 (July 2014).
• Fumagalli, G. G., Harper, L., Gordon, E., Lehmann, M., Hyare, H., Warren, J. D.,
& Rohrer, J. D. Development of a visual rating scale for atrophy of the anterior
cingulate, insula and frontal lobes. Am J Neurodegener Dis 3, 1375 (Oct 2014).
• Harper, L., Barkhof, F., Scheltens, P., O’Brien, J., Burton, E. J., Bouwman, F. H.,
Rohrer, J. D., Fox, N. C., Ridgway, G. R., & Schott, J. M. Distinct patterns of
atrophy in post mortem confirmed dementias. Alzheimer’s Association Interna-
tional Conference - oral presentation (July 2015)
• Harper, L., Fumagalli, G. G., Barkhof, F., Scheltens, P., O’Brien, J., Burton,
E. J., Bouwman, F. H., Rohrer, J. D., Fox, N. C., Ridgway, G. R., & Schott,
J. M. Visual assessment in post mortem proven dementias: clinical expertise
versus visual rating. Alzheimer’s Association International Conference - oral
presentation (July 2015)
• Weston, P., Nicholas, J., Harper, L. et al. A cortical signature of familial
Alzheimer’s disease: cross-sectional and longitudinal study of presymptomatic
changes. Alzheimer’s Association International Conference - oral presentation
(July 2015)
• Weston, P., Nicholas, J., Harper, L. et al.Measurement of cortical mean diffusivity
detects early microstructural breakdown of the cerebral cortex in presymptomatic
familial Alzheimer’s disease. Alzheimer’s Association International Conference
- oral presentation (July 2015)
Appendix A
Six Isoforms of Tau
Microtubules, one of three principle components of the cytoskeleton, determine cell
shape and a variety of cell movements [318]. Normally functioning tau proteins regu-
late microtubule assembly in brain cells, influencing their rigidity, length, stability and
ability to interact with other organelles [18]. There are six functionally similar tau pro-
teins (isoforms) in the brain that differ by the presence of either three or four repeat
regions in the carboxy-terminal part of of the molecule and the presence or absence
of one or two inserts in the amino terminal part (see Figure A.1) [18]. Four-repeat
(4R) isoforms are more efficient at promoting microtubule assembly [18], although 4R
and three-repeat (3R) isoforms are typically expressed in a one-to-one ratio in the adult
brain (only the shortest tau isoform (0N3R) is found in the foetal brain) [319]. Micro-
tubule assembly is also influenced by phosphorylation state, with phosphorylated tau
proteins less efficient than their non-phosphorylated counterparts.
Figure A.1: Six isoforms of tau present in the developed brain. Only the shortest iso-
form (0N3R) is present in the foetal brain. Nt = Amino (N) terminal, Ct =
Carboxyl (C) terminal, R1-R4 = repeat regions
Appendix B
Visual Rating Design, Methodology
and Validation
There are a number of factors implicit in the design of visual rating scales that may de-
termine their successful adoption in within the research community, and their potential
for adoption into clinical practice. These factors are discussed below and summarised
in Table B.1.
Defining and displaying ROIs
The brain regions selected for visual rating have the greatest impact on the usefulness
of the scale. Regions should be selected based on established findings from volumetric
image analysis and/or macroscopic pathological assessment of the disease population
of interest. The number of regions to be rated, the number of imaging planes to assess
(axial, sagittal or coronal) and the number of slices used is likely to impact on the reli-
ability of the scale, with reliability decreasing with increasing scale complexity. Speci-
fying landmark identifiable slices for rating helps to ensure consistency between raters.
There is good rationale for including focal regions, such as the MTL, which are typ-
ically preferentially involved in certain conditions, for example, Alzheimer’s disease,
and have been shown to correlate with clinical measures of disease severity such as mini
mental state examination (MMSE) [129]. Choice of MR pulse sequence affects both
the appearance of atrophy and the visible extent of white matter changes and should
also be specified. T1-weighted images offer good grey-white matter and CSF contrast,
with high resolution three-dimensional volume acquisitions (that can be reconstructed
in all three planes) offering the greatest utility for rating atrophy. T2-weighted images
are less reliable, since the amount of CSF can be overestimated if T2-weighting is too
strong. Image quality will also affect the reliability of the scale, with rating less reliable
on scans that are subject to artefacts. Consistent image slice positioning will also help
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Design decisions Methodological considerations Clinical implications
Defining a region
of interest
Is there a good evidence base for atrophy in the region? Dictates utility and interpretation in certain clinical pop-
ulations.
Should the region be rated in >1 imaging plane? Requires three-dimensional or multiple image acquisi-
tions and increases time to perform rating.
Is there an imaging landmark to allow consistent slice
selection?
Improves test-retest reliability
Displaying a
region of interest
Is the MR contrast appropriate and in common clinical
use?
Affects the appearance of atrophy and the sensitivity to
artefacts
Is the appearance of the region badly affected by patient
positioning?
Difficult to rate certain regions or to reliably assess sym-
metry if the head is tilted
Defining scale
increments
How much variation can reliably be captured? Truncated use of the scale may result in decreased diag-
nostic value
Is there a reliable cut-off between normal and abnormal
scan appearance? Affects clinical interpretation
Should the cut-off be adjusted for age?
Providing training
material
How is each scale increment best described?
Provides a useful framework for scoring
Are reference images available?
Are there expert raters available to provide training sets? Provides confidence in ratings and a means of audit
Validating the
scale
What is the inter-rater/intra-rater reliability and how
should it be measured?
Determines suitability for use in clinical practice and
comparison with other scores
Do the scores correlate with clinical measures or other
measures of atrophy?
Validates clinical relevance
Is there a diagnostic gold standard available for compar-
ison?
Provides validation of diagnostic value
Table B.1: Summary of key design decisions, associated methodological considerations and clinical implications associated with visual rating scales
198
to improve the reliability of the scale.
Scale increments
The number of scale increments influences the level of detail captured by the scale. A
balance must be struck between detailed quantification and the degree of change that
can be reliably differentiated by visual inspection. In terms of structural neuroimag-
ing, a four-point or five-point scale is most commonly used. The scale is typically
dichotomised to classify normal and abnormal scan appearance. In both four-point and
five-point scales, scale points 0 and 1 typically represent the degree of variation within
the normal population, with points 2 and above describing more obvious pathological
change. Four-point scales force the rater to make a more definite choice of disease state
(presence or absence), therefore, increasing specificity at the expense of sensitivity.
Five-point scales on the other hand may be more sensitive to earlier stages of disease
but may also increase the number of false-positive results. In terms of the scales devel-
oped for use in the diagnosis of dementia, five-point scales may be particularly sensitive
to the effects of ageing. Using age-specific cut-offs may help to improve scale accuracy
[136, 137, 320].
The effect of training
Training can have a significant affect on the performance of the scale. Reference images
providing examples of each scale point are particularly useful and are likely to impact
positively on the reliability of the scale. Reference images which include delineation
of ROIs, such as those provided by Urs et al could also help to improve reliability, par-
ticularly among less experienced raters or raters without radiology expertise. Detailed
descriptions of the expected appearance for each point on the scale can also be helpful
to guide raters and improve consistency. Training sets representative of the clinical or
study population, pre-rated by expert raters, would help to ensure high observer agree-
ment before implementation into clinical practice or research protocols. Training sets
can also be used to audit rater reliability at defined intervals or after a period of absence
[115].
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Validation
If rating scales are used as a method of measurement to make inferences about disease
state, it is important that both the measurement technique and validation of the tech-
nique is rigorous. Test-retest studies are essential to determine the (inter-rater/intra-
rater) reliability of the scale. Appropriate statistical procedures should be applied and
fully reported to allow clear interpretation of the results and fair comparison with other
studies. However, if used routinely, the affect of training and rater experience is likely
to improve the reliability of the scale. Correlation with clinical measures of cognition
[126, 129, 321] and volumetric measurements [127, 145, 292, 322] are also useful to
help validate the scale. Diagnostic tests should also be validated against an established
gold standard measurement technique. Currently, with the exception of individuals with
genetic mutations, post mortem examination of brain tissue is the only definitive means
of establishing diagnosis in neurodegenerative dementia. In most scales described here,
classification of disease groups, and therefore measures of scale sensitivity and speci-
ficity, are based on clinical diagnosis of the study population.
Appendix C
Visual Assessment Form
Powered by
Atrophy Algorithm Validation
Dr Jonathan Schott
* Required
Patient Number *
1151010199
Cerebral Atrophy?
Is there any cerebral atrophy? *
No - within normal limits
Yes - generalised
Yes - focal lobar
Yes - infratentorial
Yes - focal hippocampal
This content is neither created nor endorsed by Google.
Report Abuse - Terms of Service - Additional Terms
Continue »
Atrophy Algorithm Validation https://docs.google.com/forms/d/1614x-AdKMJne9WiVc27P...
1 of 1 13/09/2015 21:59Figure C.1: First page of the visual assessment form. Patient ID is manually populated,
in sync with the MIDAS image viewer
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Figure C.2: The form progresses based on the answers provided, in accordance with the algorithm.
Appendix D
Fleiss’ Kappa Calculation and 95%
Confidence Intervals
As discussed in Chapter 5, kappa statistics are defined as
κ =
Pa−Pe
1−Pe
Where Pa is the proportion of observations in agreement between analysts and Pe is
the proportion in agreement due to chance. In terms of Fleiss’ kappa, for every scan
i=1,..,n and every category j=1,..,k, Xi j = the number of analysts that assign category j
to scan i, and Pa is defined as
Pa=
1
mn(m−1)
n
∑
i=1
k
∑
j=1
X2i j−mn
Pe is given by
Pe=
k
∑
j=1
q2j where q j =
1
mn
k
∑
j=1
Xi j
Kappa values can also be calculated for every category by
κ j = 1− ∑
k
i=1Xi j(m−Xi j)
mn(m−1)q j(1−q j)
The standard error for each κ j is given by
se j =
√
2
mn(m−1)
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Then the standard error for κ is given by
se= se j
√
[∑ki=1 q j(1−q j)]2−∑ki=1 q j(1−q j)(1−2q j)
∑ki=1 q j(1−q j)
The test statistic z = κ/se can be approximated by the standard normal distribution, al-
lowing a confidence interval to be calculated. 95% confidence intervals were calculated
in Python using the percent point function (ppf) (or the inverse cumulative distribution
function).
95%Con f idence Interval = κ± se∗norm.pp f (0.05/2)
Appendix E
Visual Rating Protocol
Reference guides for the six visual rating scales were provided as follows.
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Orbito'Frontal,Ra.ng,Protocol,,
Slice&Selec'on&
&
a)  Corpus&callosum&not&yet&visible&(pre7
ra'ng&slice)&
b)  Corpus&callosum&just&visible&(rate&
olfactory&sulcus&and&cingulate&sulcus&
on&this&slice)&
c)  Post7ra'ng&slice&
Ra'ng&Guide&
&
0:&Closed&sulcus&
1:&Small&sulcal&slit,&just&revealing&CSF&
2:&Opening&of&the&sulcus,&CSF&clearly&visible&
3:&Severe&widening&of&the&sulcus&&
CC&7&corpus&callosum,&OS&7&olfactory&sulcus,&CS&7&cingulate&sulcus&
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Rostral,Anterior,Cingulate,Ra.ng,Protocol,,
Slice&Selec'on&
&
a)  Corpus&callosum&not&yet&visible&(pre7
ra'ng&slice)&
b)  Corpus&callosum&just&visible&(rate&
olfactory&sulcus&and&cingulate&sulcus&
on&this&slice)&
c)  Post7ra'ng&slice&
Ra'ng&Guide&
&
0:&Closed&sulcus&
1:&Sulcal&opening&(CSF&visible),&although&
narrower&towards&the&peak&
2:&Sulcal&widening&along&the&length&of&the&
sulcus&
3:&Severe&widening&of&the&sulcus&
CC&7&corpus&callosum,&OS&7&olfactory&sulcus,&CS&7&cingulate&sulcus&
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Fronto'Insula,Ra.ng,Protocol,
Slice&Selec'on&
&
a)  Anterior&commissure&(AC)&not&yet&
visible&(pre7ra'ng&slice)&
b)  Anterior&commisure&just&visible&(rate&
this&slice&and&the&2&posterior)&
Ra'ng&Guide&
&
(Average&the&score&over&the&3&slices)&
&
0:&Closed&sulcus&
1:&Sulcal&opening,&CSF&clearly&visible&
2:&Sulcal&widening&and&the&emergence&of&
an&arrow&head&shape&poin'ng&towards&
the&midline&
3:&Severe&widening&along&the&length&of&the&
sulcus&
CIS:&Circular&insular&sulcus,&AC:&Anterior&commissure&
208
Anterior,Temporal,Ra.ng,Protocol,
Slice&Selec'on&
&
a)  Connec'on&between&the&frontal&and&
temporal&lobes&is&s'll&visible&(pre7
ra'ng&slice)&
b)  No&visible&connec'on&between&the&
frontal&and&temporal&lobes&(rate&this&
slice)&
c)  Post7ra'ng&slice&
Ra'ng&Guide&
&
0:&Normal&appearances&
1:&Slight&prominence&of&anterior&temporal&
sulci&
2:&Temporal&sulci&deﬁnitely&widened&
3:&Gyri&severely&atrophic&and&ribbon7like.&
WM&and&GM&cannot&be&dis'nguished&
(normal&temporal&lobe&at&this&level&&is&
less&substan'al&than&the&frontal&lobe,&
ribbon7like&gyri&of&stage&3&temporal&lobe&
are&similar&to&stage&4&frontal&gyri)&&
4:&Temporal&pole&has&a&simple&linear&proﬁle&
or&is&not&seen&at&all&
&
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Medial,Temporal,Ra.ng,Protocol,
Also&take&these&structures&into&account:&&
CF&–&choroid&ﬁssure&
TH&7&temporal&horn&
PHG&7&parahippocampal&gyrus&&
CoS&7&collateral&sulcus&
FS&7&fusiform&sulcus&
0:&Normal,&&
1:&Widened&choroid&ﬁssure&
2:&Increased&widening&of&the&choroid&ﬁssure,&widening&of&the&&
temporal&horn,&opening&of&other&sulci&(i.e.&collateral/fusiform&sulcus)&
3:&Pronounced&volume&loss&of&the&hippocampus,&&
4:&End&stage&atrophy&
Slice&Selec'on&
• &In&the&middle&of&the&hippocampal&body,&in&front&of&the&pons&or&halfway&through&the&pons&depending&on&the&angle&of&the&scan&
• &Scroll&though&the&hippocampus&to&get&an&impression&of&the&atrophy&throughout&
• &Don’t&rate&too&close&to&the&amygdala.&If&the&hippocampus&curls&up,&the&slice&is&too&close&to&the&hippocampal&head.&
• &At&the&origin&of&the&fornix,&the&slice&is&too&close&to&the&tail.&
• &A&score&of&0&can&s'll&be&given&if&there&is&some&opening&of&the&choroid&ﬁssure&on&a&few&slices&through&the&hippocampal&body&if&
the&remainder&are&closed.&
• &A&score&of&1&is&given&if&the&choroid&ﬁssure&is&opened&over&the&en're&length&of&the&hippocampal&body.&
Ra'ng&Guide&
CF&CF&
(References,images,from,h@p://www.radiologyassistant.nl/en/p43dbf6d16f98d/demen.a'role'of'mri.html),,,
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Posterior,Atrophy,Ra.ng,Protocol,
Slice&Selec'on&
&
No&slice&selec'on&–&just&scroll&through&
PAR&7&parietal&lobe&&
PCS&7&posterior&cingulate&sulcus&&
POS&7&parieto7occipital&sulcus&&
PRE&7precuneus&
Ra'ng&Guide&
&
0:&Closed&sulci&of&parietal&lobes&and&cuneus&
1:&Mild&widening&of&posterior&cingulate&and&&
parieto7occipital&sulci&
2:&Substan'al&widening&of&the&sulci&
3:&Extreme&widening&of&the&posterior&cingulate&&
and&parieto7occipital&sulci&
0 
1 
2 
3 
Image&from&Lehmann&et&al,&&
Neurobiol&Aging.&2012&Mar;33(3):627.e1A627.e12.&&
Appendix F
Hammers’ Atlas
Numbers2regions for the Hammers_mith atlas n30r83 
 
 
The region list on the next page translates the (essentially arbitrary) voxel value 
coding for the regions into anatomical names. 
 
The exact region definitions and protocols used for manually delineating the 30x83 
regions can be found in the following papers: 
 
(for regions 1-49): 
Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks 
DJ, Duncan JS. Three-dimensional maximum probability atlas of the human brain, 
with particular reference to the temporal lobe. Hum Brain Mapp 2003, 19: 224-247. 
 
(for regions 50-83): 
Gousias IS, Rueckert D, Heckemann RA, Dyet LE, Boardman JP, Edwards AD, 
Hammers A. Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of 
interest. Neuroimage 2008 Apr 1;40(2):672-684 
and on the associated web page, www.brain-development.org. 
 
IMPORTANT HINT: 
Odd numbers always indicate a region on the right side of the brain; even numbers 
one on the left. This can help when using n30r83 with new software, to check R/L 
orientation is correct after spatial manipulations. 
 
 
 
 
Alexander Hammers, Lyon, 15 December 2011. 
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Number in Atlas Name of Structure 
Temporal Lobe  
1; 2 Hippocampus 
3; 4 Amygdala 
5; 6 Anterior temporal lobe, medial part 
7; 8 Anterior temporal lobe, lateral part 
9; 10 Parahippocampal and ambient gyri 
11; 12 Superior temporal gyrus, posterior part 
13; 14 Middle and inferior temporal gyrus 
15; 16 Fusiform gyrus 
30; 31 Posterior temporal lobe 
82; 83 Superior temporal gyrus, anterior part 
Posterior Fossa  
17; 18 Cerebellum 
19 Brainstem 
Insula and Cingulate gyri 
20; 21 Insula 
24; 25 Cingulate gyrus (gyrus cinguli), anterior part 
26; 27 Cingulate gyurs (gyrus cinguli), posterior part 
Frontal Lobe  
28; 29 Middle frontal gyrus 
50; 51 Precentral gyrus 
52; 53 Straight gyrus 
54; 55 Anterior orbital gyrus 
56; 57 Inferior frontal gyrus 
58; 59 Superior frontal gyrus 
68; 69 Medial orbital gyrus 
70; 71 Lateral orbital gyrus 
72; 73 Posterior orbital gyrus 
76; 77 Subgenual frontal cortex 
78; 79 Subcallosal area 
80; 81 Pre-subgenual frontal cortex 
Occipital Lobe  
64; 65 Lingual gyrus 
66; 67 Cuneus 
22; 23 Lateral remainder of occipital lobe 
Parietal Lobe  
60; 61 Postcentral gyrus 
62; 63 Superior parietal gyrus 
32; 33 Inferiolateral remainder of parietal lobe 
Central Structures  
34; 35 Caudate nucleus 
36; 37 Nucleus accumbens 
38; 39 Putamen 
40; 41 Thalamus 
42; 43 Pallidum 
44 Corpus callosum 
74; 75 Substantia nigra 
Ventricles  
45; 46 Lateral ventricle (excluding temporal horn) 
47; 48 Lateral ventricle, temporal horn 
49 Third ventricle 
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Appendix G
Neuromorphometrics/BrainCOLOR
Atlas
Volume'No. Label
[4] $3rd$Ventricle
[11] $4th$Ventricle
[15] $5th$Ventricle
[23] $Right$Accumbens$Area
[30] $Left$Accumbens$Area
[31] $Right$Amygdala
[32] $Left$Amygdala
[35] $Brain$Stem
[36] $Right$Caudate
[37] $Left$Caudate
[38] $Right$Cerebellum$Exterior
[39] $Left$Cerebellum$Exterior
[40] $Right$Cerebellum$White$Matter
[41] $Left$Cerebellum$White$Matter
[42] $Right$Cerebral$Exterior
[43] $Left$Cerebral$Exterior
[44] $Right$Cerebral$White$Matter
[45] $Left$Cerebral$White$Matter
[46] $CSF
[47] $Right$Hippocampus
[48] $Left$Hippocampus
[49] $Right$Inf$Lat$Vent
[50] $Left$Inf$Lat$Vent
[51] $Right$Lateral$Ventricle
[52] $Left$Lateral$Ventricle
[55] $Right$Pallidum
[56] $Left$Pallidum
[57] $Right$Putamen
[58] $Left$Putamen
[59] $Right$Thalamus$Proper
[60] $Left$Thalamus$Proper
[61] $Right$Ventral$DC
[62] $Left$Ventral$DC
[63] $Right$vessel
[64] $Left$vessel
[65] $Left$Insula
[66] $Right$Insula
[69] $Optic$Chiasm
[71] $Cerebellar$Vermal$Lobules$ITV
[72] $Cerebellar$Vermal$Lobules$VITVII
[73] $Cerebellar$Vermal$Lobules$VIIITX
[74] $Vitamin$E$Tablet
[75] $Left$Basal$Forebrain
[76] $Right$Basal$Forebrain
[100] $Right$ACgG$anterior$cingulate$gyrus
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[101] $Left$ACgG$anterior$cingulate$gyrus
[102] $Right$AIns$anterior$insula
[103] $Left$AIns$anterior$insula
[104] $Right$AOrG$anterior$orbital$gyrus
[105] $Left$AOrG$anterior$orbital$gyrus
[106] $Right$AnG$angular$gyrus
[107] $Left$AnG$angular$gyrus
[108] $Right$Calc$calcarine$cortex
[109] $Left$Calc$calcarine$cortex
[112] $Right$CO$central$operculum
[113] $Left$CO$central$operculum
[114] $Right$Cun$cuneus
[115] $Left$Cun$cuneus
[116] $Right$Ent$entorhinal$area
[117] $Left$Ent$entorhinal$area
[118] $Right$FO$frontal$operculum
[119] $Left$FO$frontal$operculum
[120] $Right$FRP$frontal$pole
[121] $Left$FRP$frontal$pole
[122] $Right$FuG$fusiform$gyrus
[123] $Left$FuG$fusiform$gyrus
[124] $Right$GRe$gyrus$rectus
[125] $Left$GRe$gyrus$rectus
[126] $Right$IFG$inferior$frontal$gyrus
[127] $Left$IFG$inferior$frontal$gyrus
[128] $Right$IOG$inferior$occipital$gyrus
[129] $Left$IOG$inferior$occipital$gyrus
[132] $Right$ITG$inferior$temporal$gyrus
[133] $Left$ITG$inferior$temporal$gyrus
[134] $Right$LiG$lingual$gyrus
[135] $Left$LiG$lingual$gyrus
[136] $Right$LOrG$lateral$orbital$gyrus
[137] $Left$LOrG$lateral$orbital$gyrus
[138] $Right$MCgG$middle$cingulate$gyrus
[139] $Left$MCgG$middle$cingulate$gyrus
[140] $Right$MFC$medial$frontal$cortex
[141] $Left$MFC$medial$frontal$cortex
[142] $Right$MFG$middle$frontal$gyrus
[143] $Left$MFG$middle$frontal$gyrus
[144] $Right$MOG$middle$occipital$gyrus
[145] $Left$MOG$middle$occipital$gyrus
[146] $Right$MOrG$medial$orbital$gyrus
[147] $Left$MOrG$medial$orbital$gyrus
[148] $Right$MPoG$postcentral$gyrus$medial$segment
[149] $Left$MPoG$postcentral$gyrus$medial$segment
[150] $Right$MPrG$precentral$gyrus$medial$segment
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[151] $Left$MPrG$precentral$gyrus$medial$segment
[152] $Right$MSFG$superior$frontal$gyrus$medial$segment
[153] $Left$MSFG$superior$frontal$gyrus$medial$segment
[154] $Right$MTG$middle$temporal$gyrus
[155] $Left$MTG$middle$temporal$gyrus
[156] $Right$OCP$occipital$pole
[157] $Left$OCP$occipital$pole
[160] $Right$OFuG$occipital$fusiform$gyrus
[161] $Left$OFuG$occipital$fusiform$gyrus
[162] $Right$OpIFG$opercular$part$of$the$inferior$frontal$gyrus
[163] $Left$OpIFG$opercular$part$of$the$inferior$frontal$gyrus
[164] $Right$OrIFG$orbital$part$of$the$inferior$frontal$gyrus
[165] $Left$OrIFG$orbital$part$of$the$inferior$frontal$gyrus
[166] $Right$PCgG$posterior$cingulate$gyrus
[167] $Left$PCgG$posterior$cingulate$gyrus
[168] $Right$PCu$precuneus
[169] $Left$PCu$precuneus
[170] $Right$PHG$parahippocampal$gyrus
[171] $Left$PHG$parahippocampal$gyrus
[172] $Right$PIns$posterior$insula
[173] $Left$PIns$posterior$insula
[174] $Right$PO$parietal$operculum
[175] $Left$PO$parietal$operculum
[176] $Right$PoG$postcentral$gyrus
[177] $Left$PoG$postcentral$gyrus
[178] $Right$POrG$posterior$orbital$gyrus
[179] $Left$POrG$posterior$orbital$gyrus
[180] $Right$PP$planum$polare
[181] $Left$PP$planum$polare
[182] $Right$PrG$precentral$gyrus
[183] $Left$PrG$precentral$gyrus
[184] $Right$PT$planum$temporale
[185] $Left$PT$planum$temporale
[186] $Right$SCA$subcallosal$area
[187] $Left$SCA$subcallosal$area
[190] $Right$SFG$superior$frontal$gyrus
[191] $Left$SFG$superior$frontal$gyrus
[192] $Right$SMC$supplementary$motor$cortex
[193] $Left$SMC$supplementary$motor$cortex
[194] $Right$SMG$supramarginal$gyrus
[195] $Left$SMG$supramarginal$gyrus
[196] $Right$SOG$superior$occipital$gyrus
[197] $Left$SOG$superior$occipital$gyrus
[198] $Right$SPL$superior$parietal$lobule
[199] $Left$SPL$superior$parietal$lobule
[200] $Right$STG$superior$temporal$gyrus
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[201] $Left$STG$superior$temporal$gyrus
[202] $Right$TMP$temporal$pole
[203] $Left$TMP$temporal$pole
[204] $Right$TrIFG$triangular$part$of$the$inferior$frontal$gyrus
[205] $Left$TrIFG$triangular$part$of$the$inferior$frontal$gyrus
[206] $Right$TTG$transverse$temporal$gyrus
[207] $Left$TTG$transverse$temporal$gyrus
Appendix H
Open-Data
The following is an extract from OECD Health Policy Studies Addressing Dementia:
The OECD Response, Chapter 4 - The role of big data in driving global cooperation
and innovation in dementia. OECD Publishing, (Mar 2015)
The Internet has not only transformed expectations about knowledge transfer and data
sharing but also the timescales on which they occur. Rapid access to shared resources
has led to extraordinary growth and development in many fields from basic science to
big business, however, with the exception of the great accomplishments in genetics,
medical research has largely failed to capitalise on these opportunities. Instead, the
field has stuck closely to traditional models of research where unique data is the primary
commodity available to generate funding and subsequently publications, and the ability
to sustain this circular economy ultimately determines the success of most labs. To
move forward, it is vital to examine these cultural barriers and look for inspiration
from other fields on how to begin to dismantle them.
At the outset of the Human Genome Project (HGP), realising the societal significance
of the data that would be generated, the genetics community disrupted traditional mod-
els of scientific practice by agreeing on a ground-breaking set of principles [323]. The
Bermuda Principles, as they became known, called for all human genomic sequence
information to be freely available in the public domain and rapidly released, in some
cases automatically and within 24 hours. These principles have subsequently been reaf-
firmed and extended to include data from other large scale community resource projects
in genomics, transcriptomics, proteomics and metabolomics [324–326]. Enabling such
a radical change in practice required compliance from all stakeholders, establishing
clear responsibilities for resource producers, resource users, funding agencies and pub-
lication streams. Omics research has recognised the profound value of making the vast
amounts of data generated quickly and widely available to scientists, to achieve results
beyond what the data producers themselves could produce within the same time pe-
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riod, and often beyond the scope of the original project. Conversely, there is increasing
awareness in dementia research that it is impossible to generate the wealth of data re-
quired to understand the complexities of neurodegeneration without sharing resources
[327], at all levels of investigation, from genomics to clinical research. Moreover, if
we are to discover disease-modifying therapies before dementia overwhelms the re-
sources for care available in our ageing society, we must do this quickly, agreeing on
a similarly bold set of principles to overcome the disincentives to share that are inher-
ent in current research practices. To emulate the Omics model, the dementia research
community must first identify data sources suitable for rapid release that would best
serve the community. A useful starting point may be a publication portal for negative
results. Negative results are seldom disseminated despite having the potential to sig-
nificantly reduce duplication of effort, make better use of valuable resources, and, as
a result, accelerate scientific discovery [328]. The provision of a searchable database
and a straightforward publication template could help to re-evaluate current models of
scientific communication. Additional guidelines for use in terms of both data entry, and
due diligence searching as part of a grant application process, could help ensure such a
provision was used to its full potential.
More challenging models of early access are based on the pre-publication release of
data. The benefits of this approach may be far reaching, not only increasing the rate
of scientific discovery, but also helping to address one of the major problems in sci-
ence; the failure to replicate results [329]. Rapid publication of methods and data could
allow results to be confirmed or refuted by other groups, preventing flawed methods
being carried through to final publication, and producing greater confidence in those
that are. Not only could this idea have a major impact on drug discovery, it would
also provide a novel and more responsible publication route, potentially relieving re-
searchers from the current pressure to publish quickly by offering greater recognition
for due diligence.
In addition, pre-publication could also extend to cohort data from longitudinal stud-
ies. Data release could be scheduled after every timepoint or released in batches based
on acquisition of an agreed number of participants. By encouraging multi-centre col-
laboration and harmonisation of data collection tools this model could be extended to
220
include many more data points, contributing to a larger more useful pool of data and es-
sentially creating new, larger cohorts than have previously been assembled. Moreover,
as dementia research moves towards preclinical trials there is an opportunity to build on
work already started in population based studies and encourage greater collaboration
and integration with social sciences and epidemiological research groups who already
have well-established protocols for data sharing [330].
To move towards greater sharing of resources and faster paced development it would be
prudent to also consider the benefits of sharing analysis tools, software and computing
resources. In the case of wet biomarker data, such as CSF, where lab based analysis can
have a major impact on the reported measure [331], it may be useful to set up centres of
excellence conforming to agreed lab standards, where locally acquired samples can be
sent for analysis and the results subsequently made available to the wider community.
In terms of computational analysis, state of the art algorithms and tools could be made
more widely available by pooling valuable computational resources and harnessing the
power of cloud computing.
As the Omics community have demonstrated, successful and timely data sharing hinges
on a system of quadripartite responsibilities between resource producers, resource
users, funding bodies and publishers. Incentives for change must primarily safeguard
the interests of data generators whilst ensuring the economic benefits of shared re-
sources and the increased pace of discovery are experienced by the entire research
community and, more importantly, by society as a whole. Reasonably straightforward
options include introducing unique publication opportunities around negative results,
the detailed description of the data generation, and the development of best practice
guidelines for data collection and harmonisation of the collection tools currently avail-
able. On a technical level, investment is needed to ensure existing data sharing frame-
works in both commercial and publically funded research are useful, efficient, fully
integrated and suitable for sustained use by the entire research community.
Patients and carers take time out of their heavily burdened lives to provide researchers
with data in the hope and belief that they will use this data responsibly to help, if not
them, then future generations like them. From blood sample, to questionnaire, to brain
donation, it is vital to treat each donation with the respect it deserves and maximise the
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value that can be derived from it by accurately recording and sharing the data with the
wider scientific community. Existing barriers to the timely release of data are largely
cultural and, therefore, with enough leverage and support from within the scientific
community, can be overcome, opening the way for essential progress in the pursuit of
disease modifying therapies.
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